On behalf of the Association of Medical Microbiology and Infectious Disease Canada and the Canadian Association for Clinical Microbiology and Infectious Diseases, we would like to welcome you to Toronto, ON, for our 12th annual conjoint meeting on the prevention, diagnosis, and treatment of infectious diseases. This year we are in Canada’s largest city for what we hope will be an opportunity to share our projects, learn new information, and form new collaborations with our colleagues throughout the country.

The Central and Scientific Planning Committees have put in long hours to produce an exceptional program for attendees. As anticipated, there will be a variety of poster and oral presentations of research done by our students, residents, fellows, and colleagues, with awards for the best abstracts presented at the conference. “The Incubator” competition also returns with more new and innovative approaches to be presented. The state of the art lectures will deal with novel technologies in microbiology, as well as an update on the treatment of hepatitis C. The Scientific Planning Committee has co-developed integrated symposia for delegates to attend and the special lecture will focus on sex and infection — and whether it is better to be a woman.

There are numerous committee meetings during the conference including another open session on the Choosing Wisely Canada campaign dealing with paediatrics. The CCM will host a workshop focusing on global harmonization of antimicrobial susceptibility testing in Canadian laboratories and the Trainees’ Day will provide an insightful and informative afternoon for residents and junior staff. Also, we hope you can participate in the third annual Canadian Foundation for Infectious Diseases Bug Run on Saturday morning.

We would like to acknowledge the generous and continued support from our industry partners, sponsors, and exhibitors, which has allowed us to preserve our high-quality meeting. We encourage you to walk through the exhibit hall, expand your network, and see what’s new and exciting.

The social events planned will also allow you to reconnect with colleagues and friends. The popular welcome reception and dinner will again be hosted in the exhibit hall on Thursday evening. In lieu of a closing dinner this year, attendees will have informal opportunities to spend Saturday evening taking in local sights and sounds at the conclusion of the conference.

AMMI Canada and CACMID are proud of the ongoing collaboration leading to this high-quality annual meeting, for more than ten years. On behalf of the Central and Scientific Planning Committees, we look forward to seeing you in Toronto and providing you with not only an educational event, but also opportunities for you to have fun, network, and socialize with your colleagues.

Au nom de l’Association pour la microbiologie médicale et l’ Infectiologie Canada et de l’ Association canadienne de microbiologie clinique et des maladies infectieuses, nous vous souhaitons la bienvenue à Toronto (Ontario) pour la 12e conférence annuelle conjointe sur la prévention, le diagnostic et le traitement des maladies infectieuses. Cette année, nous sommes dans la plus grande ville du Canada pour, ce que nous espérons, sera une occasion de présenter nos projets, d’obtenir de nouvelles informations et de forger de nouvelles collaborations avec nos collègues de partout au pays.

Les comités de planification générale et scientifique ont consacré d’innombrables heures à la mise au point d’un programme exceptionnel. Comme prévu, il y aura diverses présentations par affiches et orales d’études effectuées par nos étudiants, résidents, boursiers et collègues, ainsi que la remise de prix pour les meilleurs résumés présentés à la conférence. Le concours “L’ Incubateur » revient également avec d’autres approches novatrices. Les exposés de pointe porteront sur des technologies inédites dans le domaine de la microbiologie et feront état du traitement de l’hépatite C. Le Comité scientifique a participé à la mise sur pied de symposiums intégrés pour les délégués, et à un exposé spécial sur le sexe et l’infection qui amènera à se demander s’il est préférable d’être une femme. Plusieurs comités se réuniront pendant la conférence, y compris une autre séance ouverte du comité de la campagne « Choisir avec soin Canada » qui traite de la pédiatrie. Le Collège Canadien des Microbiologistes tiendra un atelier axé sur l’harmonisation mondiale du dépistage de la susceptibilité antimicrobiennne dans les laboratoires canadiens. La Journée des stagiaires comprendra également un après-midi mûrement préparé et instructif pour les résidents et le personnel junior. En outre, nous espérons que vous pourrez participer à la troisième course de la Fondation canadienne pour les maladies infectieuses qui aura lieu le samedi matin.

Nous aimerions souligner le soutien généreux et continu de nos partenaires de l’industrie, de nos commanditaires et de nos exposants qui nous a permis de continuer à offrir cette conférence de qualité. Nous vous encourageons à visiter le salon des exposants, à élargir votre réseau et à découvrir ce qu’il y a de nouveau et d’excitant dans le milieu.

Les activités sociales planifiées vous permettront aussi de renouer avec vos collègues et amis. La réception et le souper de bienvenue, qui auront lieu le jeudi soir dans le salon des exposants, sont toujours très prisés. Au lieu du souper de clôture habituel, nous vous proposons cette année diverses sorties informelles qui vous permettront de profiter du samedi soir au cœur de Toronto.

AMMI Canada et CACMID sont fiers de cette collaboration continue qui, depuis plus de dix ans, permet l’organisation d’une conférence de grande qualité. Au nom des comités de planification générale et scientifique, nous vous attendons à Toronto en grand nombre pour vous offrir non seulement un événement éducatif, mais de nombreuses possibilités de réseautage et de socialisation avec vos collègues, dans une atmosphère agréable.

Caroline Quach
President, AMMI Canada
Présidente, AMMI Canada

Jessica Minion
President, CACMID
Présidente, CACMID
The AMMI Canada - CACMID Annual Conference provides an interactive venue where experts in the fields of diagnostic microbiology, antimicrobial stewardship, infectious diseases, infection prevention and control, and public health meet. The conference attracts attendees from across Canada and internationally. As in previous years, the 2017 conference will provide updates on a variety of topics to a diverse audience of clinicians, microbiologists, laboratory technologists, public health professionals, infection prevention and control practitioners, students, and residents.

In addition to the pre-meeting workshops, the program will offer plenary sessions, state of the art clinical lectures, a special lecture, integrated symposia, short oral presentations, poster presentations, workshops, and interactive clinical vignettes. Following last year’s success of the Incubator (formerly the Innovation Academy), this session will again offer a forum where you can showcase your novel approaches to common challenges. We look forward to your submissions and your pitch. The 2017 meeting will be a chance for attendees to showcase their research as well as get up to speed with the latest in the areas of microbiology, adult and paediatric infectious diseases and related subjects. Dynamic expert speakers have been invited from across Canada and internationally to ensure another exciting meeting.

In addition to the scientific component, the meeting will provide ample opportunity for attendees to network, exchange ideas, and reconnect with colleagues.

The 2017 meeting will address topics including:

- Resurgent Infectious Diseases
- Antimicrobial Testing and Therapy in the Era of Increasing Resistance
- What’s Hot in Quality Improvement, Adult and Paediatric Infectious Diseases?
- Novel Technologies in Microbiology
- Hepatitis C Virus Update

And a whole lot more!

Welcome to Toronto 4
Central Planning Committee (CPC) 5
Scientific Planning Committee (SPC) 5
Collaborating Societies 5
AMMI Canada Council 6
CACMID Board 6
Abstract Review Committee 6
Are You a Member? 6
Accreditation 7
Education Grants 7
General Information 8
Exhibit Hours 9
Toronto, ON 9
CCM Workshop 10
Trainees’ Day 10
Merit and Association Awards Presentations 11
Poster and Research Awards Presentations 13
The AMMI Canada – CACMID Special Lecture 15
Incubator 15
Staying in Toronto Saturday Night? 16
Association, Committee & Other Group Meetings 17
Integrated Symposium 17
Workshops 17
Program 18
Wednesday, May 3 18
Thursday, May 4 20
Friday, May 5 23
Saturday, May 6 28
Save the Date 31
Poster Presentations 32
Author Index 43
Conflict of Interest 48
Speaker Biographies 52
Exhibitor Overview 57
Exhibitor Directory 58
Floor Plans 63
Sponsors 65
May 3, 2017

It is my pleasure on behalf of Tourism Toronto and the Province of Ontario to extend a very warm welcome to you. We are delighted to have the opportunity to host the AMMI Canada - CACMID Annual Conference 2017. Toronto is an astonishing and colourful mosaic of people and languages, cultures and lifestyles. It’s a destination of rare openness, energy and style, showcasing world-class dining, shopping, museums, galleries, theatre, history, and architecture. In short, it’s a city with personality. You’ll see this personality in our vibrant neighborhoods. And you’ll find it in the smiles on the faces of Torontonians as they welcome you to our great city. We look forward to showing you first-hand our warm Toronto hospitality. Make yourself at home! We’re glad you are here.

Warm regards,

Johanne R. Bélanger, CPA, CA
President and CEO
Co-Chairs
Jessica Minion
Caroline Quach

Scientific Planning Committee
Co-Chairs
Isabelle Chiu
Christine Turenne

Co-Treasurers
Matthew W. Gilmour
Andrew Simor

Sponsorship Committee Co-Chairs
Carmen Charlton
Shariq Haider

Abstract Chair
Paul N. Levett

Committee Members
Jeff Fuller
Daniel B. Gregson
Todd Hatchette

Isabelle Chiu
Co-Chair
Christine Turenne
Co-Chair
Edith Blondel-Hill
Shelly Bolotin
William Connors
Meghan Dey
Chelsey Ellis
Gerald Evans
Matthew W. Gilmour
Todd Hatchette

Jennie Johnstone
Paul N. Levett
Christopher Lowe
Nancy Matic
Matthew Oughton
David Patrick
Doris Poole
Susan Poutanen
Robert (Bob) Rennie
Earl Rubin
Anupma Wadhwa
Titus Wong
AMMI Canada Council

Caroline Quach (Montréal, QC) – President
Todd Hatchette (Halifax, NS) – President-Elect
Daniel B. Gregson (Calgary, AB) – Past President
Andrew Simor (Toronto, ON) – Treasurer
Deborah Yamamura (Hamilton, ON) – Secretary
Susan Poutanen (Toronto, ON) – Medical Microbiology Section Chair
Jennifer Grant (Vancouver, BC) – Infectious Disease Section Chair

Members of Council

Christian Lavallée (Montréal, QC)
Romina Reyes (Vancouver, BC)
Stephen Sanche (Saskatoon, SK)
Yoko Schreiber (Ottawa, ON)
Daniel Smyth (Moncton, NB)
Mark Tyndall (Vancouver, BC)

Ex-Officio Members

Nancy Matic (Toronto, ON) – Members-in-Training Committee Chair
Earl Rubin (Montréal, QC) – Paediatric Committee Chair
Donald Vinh (Montréal, QC) – Grants and Awards Committee Chair
Isabelle Chiu (Edmonton, AB) – Program Planning Committee Chair

Abstract Review Committee

Paul N. Levett (Regina, SK) – Chair
Heather Adam (Winnipeg, MB)
Ana C. Blanchard (Toronto, ON)
Andrée-Anne Boisvert (Montréal, QC)
Julie Carson (Calgary, AB)
Carmen Charlton (Edmonton, AB)
Jeanette Comeau (Halifax, NS)
William Connors (Calgary, AB)
Peter Daley (St John’s, NL)
Meghan Dey (Ottawa, ON)
Steven J. Drews (Edmonton, AB)
Chelsey Ellis (Moncton, NB)
Margaret Fearon (Toronto, ON)
David Fisman (Toronto, ON)
Élise Fortin (Quebec City, QC)
Jeff Fuller (London, ON)
Daniel B. Gregson (Calgary, AB)
Todd Hatchette (Halifax, NS)
B. Lynn Johnston (Halifax, NS)
Jennie Johnstone (Toronto, ON)
Philippe Lagacé-Wiens (Winnipeg, MB)
Christian Lavallée (Montréal, QC)
Christopher Lowe (Vancouver, BC)
Jessica Minion (Regina, SK)
Andrew Morris (Toronto, ON)
Shauna O’Donnell (Montréal, QC)
Dylan Pillai (Calgary, AB)
Yoko Schreiber (Ottawa, ON)
Christine Turenne (Winnipeg, MB)
Anu Wadhwa (Toronto, ON)
Bing Wang (Kelowna, BC)
Titus Wong (Vancouver, BC)
Deborah Yamamura (Hamilton, ON)

Councillors

Shelly Bolotin (Toronto, ON)
Carmen Charlton (Edmonton, AB)
Meghan Dey (Ottawa, ON)
Chelsey Ellis (Moncton, NB)
Christopher Lowe (Vancouver, BC)
Doris Poole (Charlottetown, PE)
Robert (Bob) Rennie (Edmonton, AB)

Are You a Member?

TO JOIN AMMI CANADA
PLEASE CONTACT:

Deborah Yamamura
Secretary, AMMI Canada
c/o AMMI Canada Secretariat
192 Bank Street
Ottawa, ON K2P 1W8
Toll-free: 1(866)467-1215
Tel.: (613)260-3233 ext. 103
Fax: (613)260-3235
membership@ammi.ca
For more information on AMMI Canada visit: www.ammi.ca

TO JOIN CACMID
PLEASE CONTACT:

Matthew W. Gilmour
Secretary Treasurer, CACMID
c/o National Microbiology Laboratory
1015 Arlington Street
Winnipeg, MB R3E 3R2
Toll-free: (204)789-2097
Tel.: (204)789-2097
Fax: (204)789-2097
matthew.gilmour@cacmid.ca
For more information on CACMID visit: www.cacmid.ca
Maximum credits possible: 28.25 hours

A. For specialists certified with the Royal College of Physicians and Surgeons of Canada (RCPSC): This educational event is approved as an Accredited Learning Activity, (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada.

MAINPORT - Transfer of Hours
The Royal College of Physicians and Surgeons of Canada allows for attendance data of Section 1, Group Learning activities to be transferred directly into participants’ MAINPORT Transfer of Hours.

Please indicate your RCPSC ID Number when registering.

B. For specialists certified with the American Medical Association (AMA):
Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Please indicate your AMA ID Number when registering.

C. For Fellows and Specialists of the Canadian College of Microbiologists and Diplomats of the American Board of Medical Microbiology: The Canada College of Microbiologists (CCM) accredits the AMMI Canada – CACMID Annual Conference for CE credits. Certificates of continuing education activity are available through the CCM for documentation of attendance and maintenance of certification. A one-hour educational activity is equivalent to one CE credit. Program evaluation forms and record of CE activity can be obtained and returned, once completed, at the conference registration desk or by email to the FCCM co-chair (hadam@dsmanitoba.ca) following the conference.

AMMI CANADA
For Members-in-Training only

Eligibility
The applicant must be an AMMI Canada Member-in-Training in good standing. To be eligible, the applicant must register for the AMMI Canada – CACMID Annual Conference 2017 and pay the full student conference registration fee. One-day registrants are not eligible.

Application
An education grant application form will be available at the registration desk during the conference or can be downloaded from the AMMI Canada website – annual conference section (www.ammi.ca). This form can be completed during the conference and handed in at the registration desk, or be completed after the conference and sent to membership@ammi.ca or faxed to 613-260-3235. All forms must be received by the AMMI Canada secretariat no later than Monday, May 29, 2017.

• $250 for Technical staff attending from Ontario
• $500 for Technical staff attending from Manitoba and Québec
• $750 for Technical staff attending from Saskatchewan, Alberta, British Columbia, PEI, New Brunswick, Nova Scotia, and Newfoundland
• $1,000 for Technical staff attending from NWT, Yukon, and Nunavut

N.B: Clinical microbiology fellows (all must be Canadian residents) may submit itemized expenses with receipts to a maximum of $1,000.

We’re Going Mobile!
Get the conference on the go!

Head over to http://bit.ly/AMMICACMIDapp on an iPhone, iPad or Android device (not a desktop or laptop) or scan the QR code. You will be taken to your device’s app store to download the app. Please note that the URL is case sensitive.

The mobile app provides access to conference information, including schedules, floor plans, abstracts, and much more – all at your fingertips!
Abstracts
There will be NO printed version of the abstracts. All abstracts can be found online in the conference sections of the AMMI Canada (www.ammi.ca) or CACMID (www.cacmid.ca) websites. They are also available as published in JAMMI, the official Journal of the Association of Medical Microbiology and Infectious Disease Canada.

Handouts
Handouts will NOT be available at the conference. Following the conference, presentations approved by speakers for posting will be uploaded to both the AMMI Canada (www.ammi.ca) and CACMID (www.cacmid.ca) websites.

Disclaimer
The Central Planning and Scientific Planning Committees will make every effort to present the program as published and printed. However, the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the annual conference, for any cause beyond their reasonable control. The above-mentioned are not liable for any loss or inconvenience caused as a result of such alteration. In the event of cancellation of the annual conference, all pre-paid fees will be refunded, however the Central Planning and Scientific Planning Committees, AMMI Canada, CACMID or their agents are not liable for any loss or inconvenience caused as a result of such cancellation, and delegates are therefore advised to take out their own travel insurance and extend their policy for personal possessions as the annual conference does not cover individuals against cancellations of bookings or theft or damage of belongings.

Notice
Satellite symposia, receptions, and meals provided by Industry Representatives surrounding or during the conference that are not in the official program are not sanctioned or approved by the annual conference, AMMI Canada, or CACMID.
Conference attendees should be cognizant of perceived or real conflicts of interests, and their ethical obligations as health care workers when making decisions on participating in such events.

Hotel Information
In the heart of downtown Toronto’s business and entertainment districts, the Sheraton Centre Toronto Hotel is the city’s most effortless address. The hotel is steps from the Eaton Centre shopping mall and it is conveniently connected to PATH, a 16-mile underground network of shops and services. Find your inspiration when you marvel at views of Toronto’s city skyline. Relax in the Waterfall Garden, a two-acre natural oasis, grab a quick workout in Toronto’s largest hotel fitness centre or meet friends and family in the open, energetic lobby. No matter what you choose, Sheraton Centre Toronto is sure to give you a distinct Toronto experience.

Sheraton Centre Toronto Hotel
123 Queen Street West
Toronto, ON M5H 2M9
Hotel Direct: (416) 361-1000
Toll Free: (866) 716-8101
Check in: 15:00
Check out: 12:00
Parking:
The Sheraton Centre Toronto Hotel offers valet parking for $50.00 CAD per night, subject to change, with unlimited in and out privileges. Availability is limited to 215 spots and are distributed first come, first served. Up to 30 minutes complimentary parking is extended in the Motor Court for the unloading of luggage at time of arrival. There are various City and privately owned parking lots in the neighbourhood of the hotel. Rates vary from $5.00 to $20.00 per hour, with daily maximums of $50.00. Full details of charges and lots are available at http://parking.greenp.com.

Conference Evaluations
The conference uses an online evaluation system.

Conference Attendees: Please click on the links below to access the 2017 conference evaluation and the 2017 program evaluations by day:
Wednesday, May 3, 2017 - CCM Workshop
Wednesday, May 3, 2017 - Trainees’ Day
Thursday, May 4, 2017
Friday, May 5, 2017
Saturday, May 6, 2017
2017 Conference Evaluation
All evaluations will be made available online on the event’s mobile app, the AMMI Canada website, and the CACMID website.
The program evaluations by day will not be live until the morning of the specified date. Therefore, you cannot complete Friday’s evaluation on Thursday, as the sessions have not yet taken place.

Handouts
Handouts will NOT be available at the conference. Following the conference, presentations approved by speakers for posting will be uploaded to both the AMMI Canada (www.ammi.ca) and CACMID (www.cacmid.ca) websites.
Lost and Found
Please go to the Registration Desk for lost or found items.

Registration Desk
Room: Vide
Wednesday, May 3: 12:00-18:00
Thursday, May 4: 07:00-17:30
Friday, May 5: 07:00-17:00
Saturday, May 6: 07:00-17:00

Speaker Ready Room
Room: Linden
Wednesday, May 3: 09:00-18:00
Thursday, May 4: 07:00-17:30
Friday, May 5: 07:00-17:00
Saturday, May 6: 07:00-12:00

Tourism Toronto
Concierge Service
Room: Vide
Wednesday, May 3: 12:15-15:00
Thursday, May 4: 12:15-15:00
Friday, May 5: 12:15-15:00
Saturday, May 6: 12:15-15:00

Toronto
As Canada’s largest city, Toronto is a vibrant, global hub for business, finance, arts and culture. Over 140 languages and dialects are spoken here and the city is consistently ranked as one of the world’s most livable and multicultural urban centres. Toronto is easy to navigate with a strong grid street layout, one of the most extensive public transit systems in North America and a large number of attractions concentrated in a walkable downtown. And while it features several of the tallest skyscrapers in the western hemisphere, Toronto also has more than 1,600 public parks and 600 km of trails.

We invite you to experience Toronto!

CLICK HERE to find out what Toronto holds in store for you.

EXHIBIT HOURS
Room: Sheraton Hall & Osgoode Ballroom
Thursday, May 4
12:30 – 14:35 Lunch
15:45 – 17:00 Afternoon Break
18:45 – 21:00 Welcome Reception and Stand Up Dinner

Friday, May 5
12:30 – 14:35 Lunch

Tourism Toronto will provide onsite concierge services for delegates. Well trained and knowledgeable staff will help you enjoy the perfect conference experience in Toronto and surrounding areas.

Services Include:
• Helping you find a perfect restaurant
• Helping you find information on a tourist attraction
• Providing maps and guides
• Outlining great shopping

The AMMI Canada – CACMID Annual Conference has received tremendous support from our exhibiting companies. We encourage you to visit the exhibit hall to discover the leading edge of business and research in the fields of medical microbiology, infectious diseases, medicine, pharmaceuticals, and diagnostics.

Lunch will be served in the exhibit hall on Thursday and Friday.

Don’t miss the opportunity to network with colleagues and friends during the Thursday evening welcome reception and stand up dinner!
A Brave New World: “Global Harmonization of Antimicrobial Susceptibility Testing in Canadian Laboratories”

Date: Wednesday, May 3
Time: 07:30 – 12:00
Breakfast Provided
Location: Sheraton Centre Toronto Hotel
Cost: $80 plus 13% tax
Room: Birchwood Ballroom

The workshop will provide an understanding of the importance of global standardization of antimicrobial susceptibility testing and reporting in Canadian laboratories. Participants will identify the microbiologic and pharmacologic development of global antimicrobial breakpoints using standardized methodologies, will review the development of the Canadian Committee on Antimicrobial Susceptibility Testing (CANCAST), and will identify processes for Canadian laboratories to implement changes in antimicrobial testing and reporting in a global environment.

EUCAST – The Mother Ship: Formation, Roles, and Laboratory Systems in Europe
Speaker: Gunnar Kahlmeter, Professor and Head of Department, Clinical Microbiology, Former Chair, EUCAST, Landstinget, Kronoberg, Sweden

Defining Antimicrobial Susceptibility for Laboratory Use: USCAST Experience
Speaker: Paul Ambrose, Ph.D., PharmD, Fellow, IDSA, President, Institute for Clinical Pharmacodynamics (ICPD), Latham, New York

CANCAST – Developing the Tools to Implement Standardization of Antimicrobial Susceptibility Testing at a National Level across Canada
Speaker: Robert (Bob) Rennie, Professor Emeritus, Laboratory Medicine and Pathology, University of Alberta, Clinical Microbiology Consultant, Alberta Health Services

The “Nuts and Bolts” – Making Antimicrobial Susceptibility Devices Functional in a New Environment (Roundtable and Panel Discussion)
Speakers: All

Question and answer, accreditation issues, etc.

Information on the requirements for membership in the Canadian College of Microbiologists is available at www.ccm.ca.

Trainees’ Day is an afternoon of interactive sessions for trainees in adult and paediatric infectious disease and clinical and medical microbiology.

Attendance is free of charge for all trainees, but for planning purposes we ask that you please register only if you are able to attend, and to notify the conference secretariat should your plans change for food and beverage planning purposes.

EUCAST – The Mother Ship: Formation, Roles, and Laboratory Systems in Europe
Speaker: Gunnar Kahlmeter, Professor and Head of Department, Clinical Microbiology, Former Chair, EUCAST, Landstinget, Kronoberg, Sweden

Defining Antimicrobial Susceptibility for Laboratory Use: USCAST Experience
Speaker: Paul Ambrose, Ph.D., PharmD, Fellow, IDSA, President, Institute for Clinical Pharmacodynamics (ICPD), Latham, New York

CANCAST – Developing the Tools to Implement Standardization of Antimicrobial Susceptibility Testing at a National Level across Canada
Speaker: Robert (Bob) Rennie, Professor Emeritus, Laboratory Medicine and Pathology, University of Alberta, Clinical Microbiology Consultant, Alberta Health Services

The “Nuts and Bolts” – Making Antimicrobial Susceptibility Devices Functional in a New Environment (Roundtable and Panel Discussion)
Speakers: All

Question and answer, accreditation issues, etc.

Trainees’ Day is an afternoon of interactive sessions for trainees in adult and paediatric infectious disease and clinical and medical microbiology.

Attendance is free of charge for all trainees, but for planning purposes we ask that you please register only if you are able to attend, and to notify the conference secretariat should your plans change for food and beverage planning purposes.
Thursday, May 4
Time: 17:15 – 17:45
Room: Grand Ballroom East & Centre

Masters of Ceremony:
Todd Hatchette (Halifax, NS)
Christine Turenne (Winnipeg, MB)

2016 AMMI Canada Distinguished Service Award

Dr. A. Mark Joffe is the recipient of the AMMI Canada Distinguished Service Award for his longstanding professional achievements and dedicated service to AMMI Canada. Dr. Joffe has been instrumental to the growth, development, promotion, and overall success of AMMI Canada. His formal contributions are numerous and include his participation and work with the Canadian Infectious Disease Society (CIDS) prior to the formation of AMMI Canada. He served as the Scientific Planning Committee chair in 2004, and played an integral role in developing the relationship and subsequent agreement between AMMI Canada and CACMID to create the conjoint conference that has been taking place since 2005. Dr. Joffe served as the AMMI Canada Program Planning Committee Chair and Annual Conference Scientific Planning Committee Co-Chair from 2005-2012. Thereafter he assumed the position of AMMI Canada President Elect (2010-2012), AMMI Canada President (2012-2014), and AMMI Canada Past-President (2014-2016).

Dr. Joffe needs to be recognized for undertaking the “herculean task” of re-writing the society’s by-laws as part of the new Corporations Canada not-for-profit act.

Dr. Joffe is dedicated to AMMI Canada and its mandate to serve as a leader in education, research, and training in the fields of medical microbiology and infectious disease in Canada.

Presenting the award:
Caroline Quach
President, AMMI Canada

2016 AMMI Canada Lifetime Achievement Award

Dr. Allison J. McGeer is the recipient of the AMMI Canada Lifetime Achievement Award, in recognition of her outstanding and distinguished career. Dr. McGeer has served as the Director of the Division of Infection Control at Mount Sinai Hospital since 1990. Throughout her career, she has played a key role in the investigation of antimicrobial resistance across Canada, as well as in the research and control of emerging infectious diseases both nationally and internationally. Dr. McGeer was the co-founder, and is currently the coordinating investigator, of the Toronto Invasive Bacterial Disease Network (TIBDN) which conducts population-based surveillance for bacterial and viral diseases causing hospitalization. She also serves as a leading advisor in the WHO investigation of MERS-CoV, among other advisory roles. Her current research is focused on improving the protection of older adults and hospitalized patients from antimicrobial resistant organisms and viral respiratory infections, as well as using surveillance to support research into the evolution of pathogens and improvements in diagnosis and management of serious infections.

Presenting the award:
Caroline Quach
President, AMMI Canada
John G. FitzGerald – CACMID Outstanding Microbiologist Award

Dr. R.E.W. (Bob) Hancock is the distinguished recipient of the 2017 John G. FitzGerald – CACMID Outstanding Microbiologist award. Dr. Hancock is a Professor of Microbiology and Immunology at the University of British Columbia, an Associate Faculty Member of the Wellcome Trust Sanger Institute, the Director of the Centre for Microbial Diseases and Immunity Research, and Canada Research Chair in Health and Genomics. His research interests include small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections and inflammation, the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, and antibiotic uptake and resistance. During his impressive career he has contributed more than 690 publications, has been awarded 55 patents, and is an ISI highly cited author in Microbiology with more than 69,000 citations. He has won many prestigious awards including the Aventis ICAAC Antimicrobial Research Award, the Prix Galien Canada Award, the Killam Prize for Health Research, the Michael Smith Prize in Health Research, and is an Officer of the Order of Canada. In addition to being the Founding Scientific Director of the Canadian Bacterial Diseases Network of Centres of Excellence, he is also the co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset, and the Centre for Drug Research and Development.

Presenting the award:
Jessica Minion
President, CACMID

Canadian College of Microbiologists (CCM) Distinguished Microbiologist Award

The Canadian College of Microbiologists (CCM) Distinguished Microbiologist Award is given to members of the Canadian College of Microbiologists in recognition of outstanding professional contributions to the field of microbiology in Canada in the areas of research, teaching and involvement in the Canadian College of Microbiologists. The recipient of the award this year is Stéphane Bourget, Lead Biosafety Inspector, Public Health Agency of Canada.

Presenting the award:
Steven J. Drews
President, CCM

Canadian Foundation for Infectious Diseases (CFID) Dr. R.E.W. (Bob) Hancock Award for Excellence in Infectious Diseases Research

Dr. Matthew Cheng (McGill University) is the recipient of the 2017 award for his manuscript entitled “Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.” He was supervised by Dr. Christina Greenaway. This award is given to an infectious diseases trainee in recognition of research excellence in infectious diseases as demonstrated through a published or submitted manuscript.

Presenting the award:
Coleman Rotstein
Chair, CFID Awards Committee

Canadian Foundation for Infectious Diseases (CFID) Dr. Juan A. Embil Mentorship Award in Infectious Diseases

Dr. Matthew Cheng (McGill University) is the recipient of the 2017 award for his manuscript entitled “Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis.” He was supervised by Dr. Christina Greenaway. This award recognizes clinical specialists in infectious diseases who have performed extraordinary service as role models and mentors to junior clinicians, faculty, fellows, and students involved in the field of infectious diseases.

Dr. Williams has been described by his colleagues as the one who provided them the inspiration for a career in Infectious Diseases and served as their role model for excellence in clinical care. He was extolled by undergraduate medical students as a brilliant and enthusiastic lecturer and educator. Most noteworthy, he provided mentorship to trainees and faculty in pursuing career goals in both research and clinical care. In particular, he was singled out for engaging people in caring for marginalized Aboriginal people with HIV. He is a perfect example of what a mentor should be.

Presenting the award:
Coleman Rotstein
Chair, CFID Awards Committee
Canadian Foundation for Infectious Diseases (CFID) Summer Student Research Award

The CFID Summer Student Research Awards were established to attract bright young minds with outstanding academic records to the field of infectious diseases, microbiology, and infection control; and to fulfill the CFID mission of supporting research in infectious diseases.

Thenuga Sasitharan (University of British Columbia) for her project entitled “Whole Genome Sequencing of Mumps Virus from an Adult Outbreak in British Columbia”, under the supervision of Dr. Agatha Jassem.

Presenting the award:
Susan Richardson
President, CFID

AMMI Canada Medical Student Research Awards

The goal of this award is to provide support for medical students who are interested in research in infectious diseases and microbiology who are supervised by an AMMI Canada member.

Lucy Smith (Memorial University) for her project entitled “Molecular Epidemiology of Mycobacterium tuberculosis in Newfoundland and Labrador”, under the supervision of Dr. Peter Daley.

Clara Van Ommen (University of British Columbia) for her project entitled “Exploring the Live Birth Rates of Women Living with HIV in British Columbia and the CARMA Cohort” under the supervision of Dr. Melanie Murray.

Presenting the award:
Susan Richardson
President, CFID

Canadian Foundation for Infectious Diseases (CFID) Safe Drinking Water Pilot Project Grant

This award was established to support research related to safe drinking water in Canada and throughout the world.

Dr. Anna Majury (Queen’s University) for her project entitled “Naturalized E. coli and fecal indicators in drinking water wells: implications for testing, risk assessment and as potential environmental reservoirs for antimicrobial resistance”.

Presenting the award:
Susan Richardson
President, CFID

AMMI Canada Trainee Research Award

This award is given to a trainee to promote scholarship and scientific excellence among trainees. It is awarded for excellence in primary research conducted during their infectious diseases or medical microbiology training, and demonstrated by publication of an original research article on a topic within the disciplines of infectious diseases or medical microbiology. The monetary value of the AMMI Canada Trainee Research Award is $1,000 CDN. The recipient of the award this year is Dr. Derek MacFadden for his manuscript titled, “Impact of Reported Beta-Lactam Allergy on Inpatient Outcomes: A Multicenter Prospective Cohort Study”.

Presenting the award:
Caroline Quach
President, AMMI Canada
AMMI Canada Young Investigator Award

This award recognizes a promising young investigator who has already made a substantial contribution to research in fields of Infectious Diseases or Medical Microbiology. The monetary value of the AMMI Canada Young Investigator Award is $1,000 CDN. The recipient of the award this year is Dr. Isaac Bogoch. Dr. Bogoch has been an Assistant Professor in the Department of Medicine, Infectious Diseases at the University of Toronto since 2014. Focusing primarily on HIV prevention research, Dr. Bogoch has established a dedicated HIV Prevention Clinic at the Toronto General Hospital which serves as a platform to conduct cutting edge clinical and health-systems research. Dr. Bogoch’s other research areas include global health and diagnostic platforms for neglected infections, particularly tropical infections. Notably, Discovery Magazine recognized Dr. Bogoch’s development of mobile-phone-based microscopy techniques for diagnosis of parasitic infections in resource-constrained areas as one of the top 100 scientific discoveries of the year 2014.

Presenting the award:
Caroline Quach
President, AMMI Canada

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Poster Award

Presenting the award:
Jessica Minion
President, CACMID

Canadian Association for Clinical Microbiology and Infectious Diseases (CACMID) Student Oral Presentation Award

Presenting the award:
Jessica Minion
President, CACMID

Canadian College of Microbiologists (CCM) Dr. Kenneth Rozee Memorial Poster Award

Presenting the award:
Steven J. Drews
President, CCM

The following award consists of $500 and an engraved plaque:
Dr. Susan King Paediatric Abstract Award

This award is given annually to the best abstract by a trainee on a paediatric topic. It is presented in honour of Dr. Susan King. Funds for this award are generously provided by the PICNIC team and the Hospital for Sick Children (Division of Infectious Diseases).

Presenting the award:
Joan Robinson
Chair, PICNIC
Sex and Infection—Is it Better to be a Woman?

Date: Thursday, May 4
Time: 17:45 – 18:45
Speaker: Sabra L. Klein (Baltimore, MD)
Room: Grand Ballroom

Males and females differ in their immunological responses to viral and vaccine antigens, with females typically mounting higher immune responses than males. These sex-based immunological differences contribute to variation in susceptibility to infectious diseases and responses to vaccines in males and females. The intensity and prevalence of viral infections are typically higher in males, whereas disease outcome can be worse for females, which in many cases is caused by an exaggerated immune response that damages tissue and causes pathology. In response to vaccines, females also mount higher immune responses and experience more adverse reactions than males. Several variables should be considered when evaluating male/female differences in responses to viral infection and treatment, which include: age, hormones, genes, and gender-specific factors related to access to, and compliance with, treatment. Knowledge that the sexes differ in their responses to infectious diseases and vaccines should influence the recommended course of action differently for males and females.

Objectives:
By the end of this session, participants should be able to:
• Discuss sex differences in immune responses to vaccines
• Recognize the need for age and sex-stratified reporting in vaccine trials
• Gain insights into how biological sex impacts responses to infection

Sabra L. Klein, Ph.D. received her B.A. in Psychology from Randolph-Macon College, her M.S. from the University of Georgia in Biological Psychology, and her Ph.D. in Behavioral Neuroscience from Johns Hopkins University. She did postdoctoral training at the Johns Hopkins Bloomberg School of Public Health in Molecular Microbiology and Immunology where she is now an Associate Professor. Dr. Klein is an expert on sex differences in immune responses and susceptibility to infection, with 100 peer-reviewed publications, several book chapters, and two edited books on the broad topics of sex differences in response to infection and treatments for infectious diseases. During the 2009 influenza pandemic, she was commissioned by the WHO to publish a report on the impact of sex, gender, and pregnancy on the outcome of influenza virus infection. Dr. Klein also has been invited to write reviews to introduce journal policies about sex reporting, wrote an Op Ed in the New York Times about sex-specific dosing of vaccines, and was lead author on an Opinion piece in PNAS defining the importance of sex as a biological variable in biomedical science. Her research has been highlighted in commentaries appearing in PNAS, Nature, and U.S. News and World Reports. In 2010, she won the Society for Women’s Health Research Medtronic Award for Science Contributions, which recognized her scientific contributions as well as her commitment to mentoring other female scientists.

Poster Presentations:
Date: Thursday, May 4
Time: 15:45 – 17:00
Room: Sheraton Hall & Osgoode Ballroom

Oral Pitch:
Date: Saturday, May 6
Time: 14:45 – 15:45
Room: Grand Ballroom

The new and creative approaches will first be presented in poster format on Thursday, May 4, for initial review and judging. Presenters will be at their posters between 15:45-17:00 to answer questions, and be judged. After judging, selected posters will move on to the oral “pitch” on Saturday, May 6. The “pitch” will convey the nature of the presenter’s project in an informative and energetic manner. Oral Pitch presentations will be adjudicated based on originality, creativity, applicability, and ease of duplication, sustainability and overall significance. An audience response system will be used.

Previous Winners
Automated Texting and Email
Victor Leung presented the innovation at the 2016 annual conference

The Automated Antimicrobial Prescription Surveillance System (APPS)
Vincent Nault presented the innovation at the 2013 annual conference.

MRSAid Photodisinfection Project
Titus Wong presented the innovation at the 2012 annual conference.
At the time of publication, space in the AMMI Canada – CACMID blocks may no longer be available. If requesting a new reservation, and for current availability, please contact the listed venue directly.

Enjoy an evening with colleagues and friends following the AMMI Canada – CACMID Annual Conference on **Saturday, May 6!** Please ask for the AMMI Canada – CACMID block when making your reservations for one of the options below.

Participants must place their own reservations and are responsible for associated costs and transportation.

**Amsterdam Brewhouse on the Lake**

245 Queens Quay West, South Building
(1.6 km from Sheraton Centre Toronto Hotel)

**For reservations:**
Please call 416-504-1020 ext. 310

Beautifully restored 1930s shipping warehouse with several beer options and varieties to choose from brewed onsite and a seasonally inspired menu. Complimentary brewery tours offered.

**360 The Restaurant at the CN Tower**

301 Front St West
(1.2 km from Sheraton Centre Toronto Hotel)

**For reservations:**
Please call 416-362-5411

Features unforgettable food combined with a magnificent revolving view of Toronto more than 351 metres (1,151 ft) below.

**The Second City**

19:30 or 22:00 show

51 Mercer Street
(1.2 km from Sheraton Centre Toronto Hotel)

**For reservations:**
Please call 416-343-0011

**Tickets:** $32 +HST

**Show:** Everything is Great Again

**Description:** Trump is in the White House; Farage, Le Pen and O’Leary are on the rise; and it seems our leaders can’t even correctly spell what they’re thinking. Are we reaching the era of peak a$hole? We’re still trying to figure that out... but we know laughing helps! Our superstar cast has created a deliriously funny revue to help you forget the world is in imminent danger of ending... for at least two hours.

A comedy institution – the world’s premier improv & sketch comedy theatre! Guests can also opt to purchase a dinner package with Wayne Gretzky’s Toronto Restaurant.

**Important:**
Space is limited and can only be held until each block is full, so book early! Questions should be directed to meetings@ammi.ca.

Should your plans change, and you need to cancel your reservation, please contact the restaurant or venue directly.
Wednesday, May 3
08:00 – 16:30
AMMI Canada Council Meeting
Room: Pinnacle
Chair: Caroline Quach
08:00 – 17:00
Royal College Infectious Diseases Examination Committee Meeting
Room: Cedar
Chair: Anu Wadhwa
13:30 – 17:00
Canadian Public Health Laboratory Network (CPHLN) Meeting
Room: Club Boardroom
Chairs: Matthew W. Gilmour
Graham Tipples
14:00 – 16:00
CCM Board Meeting
Room: Oak
Chair: Steven J. Drews
18:00 – 20:00
AMMI Canada Education / Continuing Professional Development Committee Meeting
Room: Club Boardroom
Chair: Anu Wadhwa
18:00 – 21:00
CACMID Board Meeting
Room: Pinnacle
Chair: Jessica Minion

Thursday, May 4
06:30 – 08:45
AMMI Canada AGM and Sections Meetings
Room: Grand Ballroom West
Chair: Caroline Quach
12:40 – 14:40
Royal College MM Specialty Committee Meeting
Room: Pinnacle
Chair: Roland Auer
12:40 – 14:35
AMMI Canada Paediatric Committee and PICNIC Meeting
Room: Cedar
Chairs: Earl Rubin
Joan Robinson
19:30 – 21:00
JAMMI Editorial Board Meeting
Room: Pinnacle
Chair: John Conly

Friday, May 5
07:00 – 08:45
CACMID AGM
Room: Grand Ballroom West
Chair: Jessica Minion
07:00 – 09:00
CFID Board Meeting
Room: Oak
Chair: Susan Richardson
07:15 – 08:45
AMMI Canada Communications Committee Meeting
Room: Club Boardroom
Chair: Daniel B. Gregson
07:30 – 08:45
AMMI Canada Indigenous Health Working Group Meeting
Room: Pinnacle
Chair: Yoko Schreiber

Saturday, May 6
07:15 – 08:45
AMMI Canada Guidelines Committee Meeting
Room: Pinnacle
Chair: Gerald Evans
12:40 – 14:35
AMMI Canada Choosing Wisely Canada Paediatric Campaign Meeting
Room: Birchwood Ballroom
Chair: Earl Rubin
12:40 – 14:35
MALDI-TOF Users Group Meeting
Room: Willow
Chairs: Kathryn Bernard
Philippe Lagacé-Wiens

Integrated Symposium
Current CMV Treatment Options and Management Strategies
Date: Thursday, May 4
Time: 12:40-14:40
Room: Grand Ballroom West

Workshops
Changing Landscape of STI Diagnosis in Canada
Date: Thursday, May 4
Time: 07:15-08:45
Room: Birchwood Ballroom
Management of MRSA/VRE Endocarditis in the Challenging Patient, a Case-based Discussion
Date: Friday, May 5
Time: 07:15-08:45
Room: Birchwood Ballroom
Antimicrobial Stewardship: Rapid Phenotypic Antibiotic Susceptibilities in the Management of Patients with Bacteremia
Date: Friday, May 5
Time: 18:00-19:30
Room: Birchwood Ballroom

AMMI Canada — CACMID Annual Conference | Conférence annuelle
May 3–6 | Sheraton Centre Toronto
Wednesday, May 3

07:30 – 12:00  CCM Workshop
(4 hours)

A Brave New World: “Global Harmonization of Antimicrobial Susceptibility Testing in Canadian Laboratories”

Room: Birchwood Ballroom
Moderator: Robert (Bob) Rennie
(Edmonton, AB)

07:30 – 08:00
Breakfast & Registration

08:00 – 09:00
EUCAST – The Mother Ship: Formation, Roles, and Laboratory Systems in Europe
Speaker: Gunnar Kahlmeter
(Landstinget, Kronoberg, Sweden)

Objectives:
By the end of this session, participants should be able to:
• Describe the role that EUCAST plays in antimicrobial susceptibility testing in Europe
• Identify implementation issues occurring in different countries in Europe and globally
• Recognize how lessons learned can be applied to a Canadian setting

09:45 – 10:30
CANCAST – Developing the Tools to Implement Standardization of Antimicrobial Susceptibility Testing at a National Level across Canada
Speaker: Robert (Bob) Rennie
(Edmonton, AB)

Objectives:
By the end of this session, participants should be able to:
• Outline the primary objectives of CANCAST in a global environment
• Identify lessons learned from other settings and how they can be applied to implementation of standardized testing and reporting across Canada
• Outline the role that Canadian microbiologists, technologists, and other health care partners can play in furthering CANCAST objectives
• Recognize gaps that need to be filled in achieving objectives

10:30 – 11:15
The “Nuts and Bolts” – Making Antimicrobial Susceptibility Devices Functional in a New Environment (Roundtable and Panel Discussion)
Speakers: All, with interaction from audience members

Objectives:
By the end of this session, participants should be able to:
• Identify lessons learned from European and more recent US experiences and put them into Canadian context
• Consider approaches to implement CANCAST objectives in a user-friendly environment
• Discuss perceived roadblocks and how Canadians can overcome these
• Identify 4-5 questions for the small group discussion and presentations

11:15 – 12:00
Developing Key Points of the Meeting for Future Actions
Small groups sessions:
• Each group has 20 minutes to tackle an issue with CANCAST implementation
• One member from each group will present solutions back to other groups

08:00 – 16:30
AMMI Canada Council Meeting
Room: Pinnacle

08:00 – 17:00
Royal College Infectious Diseases Examination Committee Meeting
Room: Cedar
### Program

#### 12:30 – 17:00 Trainees’ Day

**Room:** Birchwood Ballroom  
**Moderator:** Nancy Matic (Toronto, ON)  
**12:30 – 13:00**  
**Lunch & Registration**

**13:00 – 14:00**  
**Navigating Relations with the Pharmaceutical Industry**

- **Speaker:** Thomas Louie in Clinician-Industry Relations  
- **Objectives:** Identify which types of physician-industry interaction may enhance patient care

**14:00 – 15:00**  
**Exploring Job Opportunities**

- **Speakers:** Linda Hoang (Vancouver, BC)  
- **Objectives:** Describe human drug development in pharmaceutical companies

**14:00 – 15:00**  
**The Do’s and Don’ts of CV Development**

- **Speaker:** Stephen D. Shafran (Edmonton, AB)  
- **Objectives:** Recognize the challenges of building a clinical research program from scratch

**14:00 – 14:15**  
**Pimp Your Profile: Achieving Your Dream Practice**

- **Speaker:** Jeya Nadarajah (Toronto, ON)  
- **Objectives:** Identify an appropriate CV format and be able to populate key CV headings

**14:15 – 14:30**  
**It’s the Singer Not the Song – How to Give a More Effective Large Group Presentation**

- **Speaker:** Jay S. Keystone (Toronto, ON)  
- **Objectives:**第三者を認識し、契約を交渉して将来の実践に移行

**14:30 – 14:45**  
**Staying Sane and Being Successful in a New Practice: A Field Guide of What Not to Do**

- **Speaker:** Lisa Barrett (Halifax, NS)  
- **Objectives:** Define the key challenges in transitioning to clinical practice

**14:45 – 15:00**  
**Question and Answer Period (Panel Discussion)**

- **Speakers:** All  
- **Objectives:** Identify strategies to mitigate relevant questions

**15:00 – 15:15**  
**Break**

**15:15 – 16:00**  
**How to Write a Research Paper and Stay Sane**

- **Speaker:** Agatha Jassem (Vancouver, BC)  
- **Objectives:** Describe how to focus a manuscript by including and directing text based on impact

**16:00 – 17:00**  
**Canadian Public Health Laboratory Network (CPHLN) Meeting**

- **Room:** Club Boardroom

**14:00 – 16:00**  
**CCM Board Meeting**

- **Room:** Oak

**17:00 – 18:00**  
**Trainees’ Day Reception**

- **Room:** Pine

**18:00 – 20:00**  
**AMMI Canada Education/Continuing Professional Development Committee Meeting**

- **Room:** Club Boardroom

**18:00 – 21:00**  
**CACMID Board Meeting**

- **Room:** Pinnacle
Thursday, May 4
06:30 – 08:45
AMMI Canada AGM and Sections Meetings
Room: Grand Ballroom West
06:30 Breakfast begins
06:45 – 07:15 CIHR Presentation (M Ouellette)
07:15 – 08:45 AGM and Sections Meetings
07:15 – 08:45 Workshop (1 hour)
Changing Landscape of STI Diagnosis in Canada
Room: Birchwood Ballroom
Moderator: Christine Turenne (Winnipeg, MB)
Non-viral STIs: Benefits and Challenges of Molecular Testing
Speaker: Annie-Claude Labbé (Montréal, QC)
Objectives:
• Gain insights into the epidemiology and treatment of non-viral STIs
• Discuss benefits and challenges of incorporating molecular diagnostics for STIs into practice
The Changing Landscape of Neisseria gonorrhoeae and Mycoplasma genitalium Prevalence and Resistance: How to Maintain Surveillance in the Molecular Era
Speaker: Jo-Anne R. Dillon (Saskatoon, SK)
Objectives:
• Discuss the international and Canadian landscape for changing resistance to antimicrobial agents in N. gonorrhoeae and M. genitalium
• Review international and Canadian initiatives to enhance surveillance including those recommended by the World Health Organization
• Describe older and emerging mechanisms of resistance of gonococcal isolates
• Debate the pros and cons of various molecular strategies for surveillance of gonococcal resistance
08:45 – 09:00 Break
Room: Grand Ballroom Foyer
09:00 – 11:00 Plenary (2 hours)
Resurgent Infectious Diseases
Room: Grand Ballroom East & Centre
Moderators: Todd Hatchette (Halifax, NS) and Earl Rubin (Montréal, QC)
09:00 – 09:40 Measles and Mumps – Spotty Control and Swelling Numbers
Speaker: Natasha Crowcroft (Toronto, ON)
Objectives:
By the end of this session, participants should be able to:
• Compare and contrast the current state of measles elimination in different world regions
• Outline what is needed for successful measles elimination
• Compare and contrast the epidemiology of measles and mumps and explain why they differ
• Recognize the challenges in controlling viral infections with live vaccines

09:40 – 10:20
The Emergence of Zika Virus and Other Arboviruses: Diagnostic Challenges During Outbreak Scenarios and How We Can Best Prepare for the Next Resurgent Mosquito-Borne Virus Threat
Speaker: Michael Drebot (Winnipeg, MB)
Objectives:
By the end of this session, participants should be able to:
• Describe the complexity of developing and applying diagnostic platforms and algorithms for identifying infections associated with agents such as the Zika virus
• Describe how the ecology, global expansion and evolution of arboviruses and their vectors contribute to the epidemiology/outbreaks of disease
• Gain insights into some of the ongoing research initiatives that are contributing to our knowledge of arbovirus pathology and the implementation of vaccines/therapeutics for the prevention and/or treatment of infections by these pathogens
10:20 – 11:00
Clinical Recommendations and Arboviral Infections: Zika, and the Role of Evidence-Free Medicine
Speaker: Michael Libman (Montréal, QC)
Objectives:
By the end of this session, participants should be able to use the recent Zika outbreak as well as others as examples, to:
• Discuss the common clinical dilemmas in the management of arboviral infections
• Recognize how clinical guidelines are developed in the absence of good data
• Appreciate why the CATMAT Zika guidelines say what they say
11:00 – 11:15 Break
Room: Oral Presentation Foyers
11:15 – 12:30 Oral Presentations (1.25 hours)
Session A
Room: Willow
Moderator: Linda Hoang (Vancouver, BC)
A01.5 11:15 – 11:30
Enteropathogen Detection in Children with Acute Gastroenteritis: A Comparison of Rectal Flocked Swabs and Stool Specimens
B PARSONS1, S Freedman2,3, BE Lee1,3, J Xie2,3, A Nettel-Aguiré1, L Chui1,3, XL Pang1,3, R Zhou1, J Dickinson2,3, O Vanderkooi2,3, S Ali1,3, L Osterreicher2, K Lowerison1,3, P Tarr4
1University of Alberta, Edmonton, AB,
2University of Calgary, Calgary, AB,
3Alberta Health Services, AB,
4Washington University School of Medicine, St. Louis, MO, USA
A02 11:30 – 11:45
Clostridium difficile Colonization in Ontario (COLON): Acute Care Hospital Pilot Feasibility Study: Preliminary Findings
J JOHNSTONE1,2, G Broukhanski1, K Adomakoh1, E Nadoliny1, KC Katz2,3, C Vermeiren1, W Ciccotelli2, P Young3, A McGeer4, J Bartoszkowz5, D Chau1, L Rosella1,3, N Daneman1,3, S Weese7, V Allen1,3, G Garber1,3
1Public Health Ontario, Toronto, ON,
2North York General Hospital, Toronto, ON,
3Grand River Hospital, Kitchener, ON,
4Mount Sinai Hospital, Toronto, ON,
5University of Toronto, Toronto, ON,
6Institute for Evaluation Sciences, Toronto, ON,
7University of Guelph, Guelph, ON
A03 11:45 – 12:00
Identification of Shiga Toxin-Producing Shigella flexneri from Travel and Non-Travel Related Cases in Alberta
L Chu1,2, K Yuen1, S Zhi1, B Parsons1, S Delannoy3, P Fach1, C Ferrato2, KA Simmonds4
1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB, 3French Agency for Food Environmental and Occupational Health (Anses), Maisons-Alfort, France, 4Alberta Health, Edmonton, AB

A04 12:00 – 12:15
Norovirus Outbreak in Alberta, Canada – Which Strain will Win the Indy Race?
XL Pang1,2, ME Hasing3, YQ Qiu4, G Tipples1,2, BE Lee2
1Alberta Health Services, Edmonton, AB, 2University of Alberta, Edmonton, AB

A05 12:15 – 12:30
Norovirus Genotypes Analysis of Gastrointestinal Outbreaks in British Columbia from 2012 - 2016
FT Sang1, D Eisle1, A Li1, L Li1, S Man1, CT Chao1, B Auk1, N Prystajecky1,2
1British Columbia Centre for Disease Control, Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

B01 11:15 – 11:30
7 versus 14 days of Antibiotic Treatment for Critically Ill Patients with Bloodstream Infection: A Pilot Randomized Clinical Trial
N Daneman1, AH Rishu1, R Pinto1, P Aaslani1, SM Bagshaw1, A Carignan1, E Charbonney1, B Coburn2, DJ Cook3, M Detsky4, P Dodek2, R Hall4, A Kumar10, F Lamontagne5, F Lauzier6, JC Marshall12, CM Martin1, L McIntyre14, J Muscedere15, S Reynolds1, W Sligl1, HT Stefl16, E Wilcox1, R Fowler1
1Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, 2Université de Montréal, Montréal, QC, 3University of British Columbia, Vancouver, BC, 4Dalhousie University, Halifax, NS, 5University of Alberta, Edmonton, AB, 6McMaster University, Hamilton, ON, 7Queen’s University, Kingston, ON, 8University of Calgary, Calgary, AB, 9Dalhousie University, Halifax, NS, 10London Health Sciences Centre, London, ON, 11Vancouver Coastal Health, Vancouver, BC, 12University of Calgary, Calgary, AB, 13McGill University Health Centre, Montréal, QC, 14London Health Sciences Centre, Montreal, QC, 15WK Health Centre, Halifax, NS, 16Dalhousie University, Halifax, NS, 17University of Alberta, Edmonton, AB, 18University Health Network, University of Toronto, Toronto, ON, 19Children’s Hospital of Eastern Ontario, Ottawa, ON, 20Infection Prevention and Control, University Health Network, Toronto, ON, 21University of Toronto, Toronto, ON, 22Sinai Health System, Toronto, ON, 23Eastern Health, Health Sciences Centre, St. John’s, NF, 24Department of Microbiology, Infectious Diseases & Immunology, Université de Montréal, Montréal, QC, 25Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, 26Children’s Hospital, McGill University Health Centre, Montréal, QC, 27Infection Prevention and Control, University Health Network, Toronto, ON, 28University of Alberta, Edmonton, AB, 29Ottawa Hospital Research Institute, Ottawa, ON

B02 11:30 – 11:45
Implementation and Mixed Methods Evaluation of an Antimicrobial Stewardship Service with Hospitalist Physicians at a Large Tertiary Care University Centre
BR Dalton1, D Sabuda1, J Bonnett1, D Werry1, C Ondro1, PM Libin1, JM Conly1,2
1Alberta Health Services, Calgary Zone, Calgary, AB, 2Cumming School of Medicine, University of Calgary, Calgary, AB

B03.S 11:45 – 12:00
Antimicrobial Stewardship in Long-term Care: A Retrospective Cohort
C Penney1, S Boyd1, A Mansfield1, J Dalton2, J O’Keefe2, P Daley1
1Memorial University of Newfoundland, St. John’s, NL, 2Eastern Health – Regional Health Authority, St. John’s, NL

B04 12:00 – 12:15
JA Srigley1,2, L Pelude3, N Thampi4, J Vayalumkal5, K Amaratalunga1, K Bush1, JC Collet1, E Ellis1, J Embree1, L Forrester1, C Frenette1,3, E Henderson1, M John14, BL Johnston1,3, JM Langle1,3, BE Lee1,3, MA Lefebvre1, C Lemieux1,2, A McGeer1,2, S Miller1,3, N D’Amico4, C Quach2,3, J Dalton2, J O’Keefe2, K Weiss1, K Amaratalunga, D Gravel1, and Canadian Nosocomial Infection Surveillance Program1
1Center for Communicable Diseases and Infection Control, Ottawa, ON, 2Cumming School of Medicine, University of Calgary, Calgary, AB, 3Infectious Diseases & Immunology, University of Alberta, Edmonton, AB, 4McGill University Health Centre, Montréal, QC, 5TB Journal, 6North York General Hospital, North York, ON, 7Health PEI, Charlottetown, PE, 8Vancouver Island Health, Victoria, BC, 9Mount Sinai Hospital, Toronto, ON, 10Sunnybrook Health Sciences, Toronto, ON, 11The Ottawa Hospital, Ottawa, ON, 12Faculty of Pharmacy, Université de Montréal, Montréal, QC, 13The Ottawa Hospital, Montréal, QC, 14Infection Prevention and Control Program, Alberta Health Services, Calgary, AB, 15The Monarch Hospital, Horizon Health Network, Moncton, NB, 16The Children’s Hospital, Winnipeg, MB, 17Vancouver Coastal Health, Vancouver, BC, 18McGill University Health Centre, Montréal, QC, 19McGill University, Montréal, QC, 20London Health Sciences Centre, London, ON, 21Nova Scotia Health Authority, Halifax, NS, 22WK Health Centre, Halifax, NS, 23Dalhousie University, Halifax, NS, 24University of Alberta, Edmonton, AB, 25Montréal Children’s Hospital, McGill University Health Centre, Montréal, QC, 26Infection Prevention and Control, University Health Network, Toronto, ON, 27University of Toronto, Toronto, ON, 28Sunnybrook Health Sciences, Toronto, ON, 29Ottawa Hospital Research Institute, Ottawa, ON

B05 12:15 – 12:30
Quantitative Antimicrobial Usage Surveillance amongst CNISP Hospital Sites across Canada Stratified by Bed Sizes: Pilot Study Results 2009 to 2013
K Abdesselam1, JM Conly2, GE Evans3, KC Katz1, G GERMAN4, P Kibsey5, A McGeer7, L Pelude1, AE Simor6, K Suh1, D Thirion14, K Weiss1, K Amaratalunga, D Gravel1, and Canadian Nosocomial Infection Surveillance Program1
1Center for Communicable Diseases and Infection Control, Ottawa, ON, 2Cumming School of Medicine, University of Calgary, Calgary, AB, 3Infectious Diseases & Immunology, University of Alberta, Edmonton, AB, 4McGill University Health Centre, Montréal, QC, 5TB Journal, 6North York General Hospital, North York, ON, 7Health PEI, Charlottetown, PE, 8Vancouver Island Health, Victoria, BC, 9Mount Sinai Hospital, Toronto, ON, 10Sunnybrook Health Sciences, Toronto, ON, 11The Ottawa Hospital, Ottawa, ON, 12Faculty of Pharmacy, Université de Montréal, Montréal, QC, 13The Ottawa Hospital, Montréal, QC, 14Infection Prevention and Control Program, Alberta Health Services, Calgary, AB, 15The Monarch Hospital, Horizon Health Network, Moncton, NB, 16The Children’s Hospital, Winnipeg, MB, 17Vancouver Coastal Health, Vancouver, BC, 18McGill University Health Centre, Montréal, QC, 19McGill University, Montréal, QC, 20London Health Sciences Centre, London, ON, 21Nova Scotia Health Authority, Halifax, NS, 22WK Health Centre, Halifax, NS, 23Dalhousie University, Halifax, NS, 24University of Alberta, Edmonton, AB, 25Montréal Children’s Hospital, McGill University Health Centre, Montréal, QC, 26Infection Prevention and Control, University Health Network, Toronto, ON, 27University of Toronto, Toronto, ON, 28Sunnybrook Health Sciences, Toronto, ON, 29Ottawa Hospital Research Institute, Ottawa, ON
11:15 – 12:30 Oral Presentations (1.25 hours)

Session C
Room: Birchwood Ballroom
Moderator: Stuart Skinner (Saskatoon, SK)

C01 11:15 – 11:30
Fecal Microbiota Transplantation (FMT) Programs in Southern Ontario – A Descriptive Survey
A PATERSON1, S Surangiwala1,3,4, S Hota1,2, SM Poutanen1,2, Microbiota Therapeutics Outcomes Program (MTOP)1,2,3, Southern Ontario Fecal Transplant (SOFT) GROUP1,2,3, McMaster University4
1Sinai Health System, Toronto, ON, 2University Health Network, Toronto, ON, 3University of Toronto, Toronto, ON, 4McMaster University, Hamilton, ON

C02 11:30 – 11:45
Quality of Assessment and Linkage to Care for Newly Diagnosed Chronic Hepatitis B Patients
LT REMINGTON1, M Osman2, KA Simmonds2,6, C Charlton1,5, K Doucette1
1Division of Infectious Diseases, University of Alberta, Edmonton, AB, 2Alberta Health, Edmonton, AB, 3Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, 4Division of Public Health, Alberta Health, Edmonton, AB, 5Division of Infectious Diseases, University of Calgary, Calgary, AB, 6Provincial Laboratory for Public Health, Edmonton, AB, 6School of Public Health, University of Alberta, Edmonton, AB

C03 11:45 – 12:00
The Wellness Wheel: A Mobile Outreach Clinic to Address HIV and Hepatitis C in Saskatchewan First Nation Communities
S SKINNER1,2
1Regina Qu’Appelle Health Region, Regina, SK, 2University of Saskatchewan, Regina, SK

C04.S 12:00 – 12:15
Treatment Outcome in Chronic Hepatitis C Genotype 1 Patients Treated With 8 Weeks vs. 12 Weeks of Ledipasvir/Sofosbuvir based on Viral Load Criteria as Determined using The Abbott RealTime Assay
M REZAEEAVAL1, S Sumner2, S Shafran1,3, K Doucette1,4
1Department of Medicine, University of Alberta, Edmonton, AB, 2Hepatitis Support Program, AB Health Services, Edmonton, AB, 3Division Of Infectious Diseases, University of Alberta, Edmonton, AB

C05 12:15 – 12:30
Creating Capacity for HIV Care in Rural and Remote Communities of Saskatchewan
G Shumilak1, B WUDEL3, E Stevens1, K Ng1, A Mah1, K Stewart2, S Sanche2, K Kasper3, M Hull1, N Press1
1University of British Columbia, Vancouver, BC, 2University of Saskatchewan, Saskatchewan, SK, 3University of Manitoba, Winnipeg, MB

12:30 – 12:45 Exhibit Hall Lunch
Room: Sheraton Hall & Osgoode Ballroom

12:45 – 14:35 Poster Viewing
Room: Sheraton Hall & Osgoode Ballroom

12:45 – 14:40 Royal College ID Specialty Committee Meeting
Room: Pinnacle

12:45 – 14:40 Integrated Symposium (1.5 hours)
Current CMV Treatment Options and Management Strategies
Room: Grand Ballroom West
Moderator: Christopher Lowe (Vancouver, BC)

12:45 – 14:40 CMV Diagnostic Strategies: Current and Future
Speaker: Tony Mazzulli (Toronto, ON)

Objectives:
• Cite current tests available for the diagnosis and management of CMV disease in SOT and HSCT patients including resistance testing
• Interpret results of resistance testing
• Recognize future testing options

CMV Treatment and the Dilemma of Resistance
Speaker: Alissa Wright (Vancouver, BC)

Objectives:
• Review the current approaches to treatment of CMV disease for SOT and HSCT patients
• Discuss treatment challenges associated with patients with CMV resistance

14:45 – 15:45 State of the Art Clinical Lecture (1 hour)
Novel Technologies in Microbiology: Benefits Beyond the Lab
Room: Grand Ballroom East & Centre
Moderator: Titus Wong (Vancouver, BC)
Speaker: Susan M. Poutanen (Toronto, ON)

Objectives:
By the end of this session, participants should be able to:
• Describe advances in microbiology diagnostics and the paradigm shift associated with them
• Discuss the clinical impact of novel technologies in microbiology beyond the laboratory
• Outline future microbiology technologies that have the potential to improve patient care

15:45 – 17:00 Student and Incubator Poster Judging (Student (SP) and Incubator (IP) presenters)
Room: Sheraton Hall & Osgoode Ballroom

15:45 – 17:00 Afternoon Break in the Exhibit Hall
Room: Sheraton Hall & Osgoode Ballroom

17:15 – 17:45 Merit and Association Awards Presentations
Room: Grand Ballroom East & Centre
Friday, May 5

07:00 – 08:45 CACMID AGM
  Room: Grand Ballroom West

07:00 – 09:00 CFID Board Meeting
  Room: Oak

07:15 – 08:45 AMMI Canada Communications Committee Meeting
  Room: Club Boardroom

07:15 – 08:45 Workshop (1 hour)
  Management of MRSA/VRE Endocarditis in the Challenging Patient, a Case-based Discussion
  Room: Birchwood Ballroom
  Moderator: William Connors (Calgary, AB)
  Speaker: Donald P. Levine (Detroit, MI)

07:30 – 08:45 AMMI Canada Indigenous Health Working Group Meeting
  Room: Pinnacle

08:45 – 09:00 Break
  Room: Grand Ballroom Foyer

09:00 – 11:00 Plenary (2 hours)
  Antimicrobial Testing and Therapy in the Era of Increasing Resistance
  Room: Grand Ballroom East & Centre
  Moderators:
  Matthew W. Gilmour (Winnipeg, MB)
  Susan M. Poutanen (Toronto, ON)

09:00 – 09:40
  The Current State of Antimicrobial Resistance (AMR) in Canada
  Speaker: Michael Mulvey (Winnipeg, MB)

09:40 – 10:20
  Antibiotic Resistance Surveillance: A Global Perspective
  Speaker: Donald P. Levine (Detroit, MI)

10:20 – 11:00
  New Antimicrobials for the Treatment of Antimicrobial Resistant Gram-positive and Gram-negative Infections
  Speaker: George G. Zhanel (Winnipeg, MB)

11:00 – 11:15 Break
  Room: Oral Presentation Foyers

11:15 – 12:30 Oral Presentations (1.25 hours)

Session D

Room: Willow

Moderator: Michael Drebot (Winnipeg, MB)

D01 11:15 – 11:30
  Human seroprevalence of Borrelia miyamotoi in Manitoba, Canada: 2011-2014
  Speaker: Robert (Bob) Rennie (Edmonton, AB)
  Objectives:
  By the end of this session, participants should be able to:
  • Summarize the current treatments of MRSA, VRE, and MDR GNB
  • Describe the new and investigational treatments for MRSA and VRE
  • List the new and investigational treatments for MDR GNB
**Program**

**D02** 11:30 – 11:45
Evaluation of the ZEUS ELISA™ Borrelia VisE1/pepC10 IgG/IgM Enzyme Immunoassay (EIA) for Serological Detection of Lyme Disease

TF HATCHETTE1,2, JJ LeBlanc1,2, C Jackson1, C Roberts1, K Bernat1, C Loomer3, A Dibernardo1, LR Lindsay4
1Nova Scotia Health Authority, Halifax, NS, 2Dalhousie University, Halifax, NS, 3National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

**D03** 11:45 – 12:00
Specimens Yielding False-Reactive Results on the Abbott Architect HIV Ag/Ab Combo Assay Leading to Misdiagnosis and Negative Patient Impact

P Lacap1, K KADKHODA2, J Gill3, D Caswell4, PN Levet1, S Lavoie1, K Kadivar1, P Sandstrom1, J Kim1
1Public Health Agency of Canada, Winnipeg, MB, 2Cadham Provincial Health Laboratory, Winnipeg, MB, 3Alberta Health Services, Calgary, AB, 4Saskatchewan Disease Control Laboratory, Regina, SK

**E01.S** 11:15 – 11:30
Hospital-Acquired Methicillin-resistant Staphylococcus aureus Infections in Canada are an Expensive Problem Worth Preventing

DA WALDNER1, KA Simmonds2,3, EM Kirwin4, AM Joffe1,5, M Varughese3, S Smith1
1University of Alberta, Department of Medicine, Edmonton, AB, 2University of Alberta, School of Public Health, Edmonton, AB, 3Alberta Health, Edmonton, AB, 4University of Calgary, 5Department of Community Health Sciences, Calgary, AB, 6Alberta Health Services, Edmonton, AB

**E02.S** 11:30 – 11:45
Prospective Audit and Feedback of Carbapenem Use at a Tertiary Care Hospital in Edmonton AB

B SAVARYN1,2, SR Fryters1, AU Chandran1,2
1Royal Alexandra Hospital, Edmonton, AB, 2University of Alberta, Edmonton, AB

**E03** 11:45 – 12:00
ESBL Bacteremia Treatment: Carbapenem vs. De-escalated Therapy

M Holm1, A BROOKS1,2, N Irfan1, D Mertz1,2,3, M Duffett1
1Hamiton Health Sciences, Hamilton, ON, 2Department of Medicine, McMaster University, Hamilton, ON, 3Michael G. DeGroote Institute for Infectious Diseases Research (IIDR), Hamilton, ON

**E04** 12:00 – 12:15
Impact of a Choosing Wisely Campaign on Laboratory Utilization of Respiratory Virus Testing in a Paediatric Tertiary Hospital

A PETRICH1,2, D Savlov1,2, O Ostrow1,2, J Friedman1,2, S Richardson1,2
1The Hospital for Sick Children, Toronto, ON, 2University of Toronto, Toronto, ON

**E05** 12:15 – 12:30
A Novel Approach to Communication of Antimicrobial Utilization and Resistance Data in British Columbia: Interactive Web-based Dashboards

M MCCABE1, L Dale2, M Striha3, DM Patrick1,2
1BC Centre for Disease Control, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3Simon Fraser University, Burnaby, BC

11:15 – 12:30 Oral Presentations (1.25 hours)
Session F
Room: Birchwood Ballroom
Moderator: Caroline Quach (Montréal, QC)

**F01** 11:15 – 11:30
The Return of the “Frozen Berries” Hepatitis A Outbreak; Scary Food for Thought

J BORLANG1, S Smirra1, E Leonard2, T Arnason3, C Osiowy1,5, R McCormick4, A Andonov1,5
1Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, MB, 2Nova Scotia Health Authority, Halifax, NS, 3Department of Health and Wellness, Halifax, NS, 4Public Health Agency of Canada, Centre for Foodborne, Environmental & Zoonotic Infectious Diseases, Guelph, ON, 5University of Manitoba, Department of Medical Microbiology, Winnipeg, MB

**F02** 11:30 – 11:45
Ocular Syphilis: Case Series (2000-2015) From Two Tertiary Care Centers In Montréal

J Vadboncoeur1, Y Rabia1, MJ Aubin1,5, C Fortin1,5, L Jaworski1,2, B Sehiri1, A-C LABBE1,6
1Department of Ophthalmology, Université de Montréal, Montréal, QC, 2Service of Infectious Diseases and Medical Microbiology, Hôpital Maisonneuve-Rosemont, Montréal, QC, 3Service of Infectious Diseases and Medical Microbiology, Hôpital Notre-Dame, CHUM, Montréal, QC, 4Department of Ophthalmology, Hôpital Notre-Dame, CHUM, Montréal, QC, 5Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montréal, QC, 6Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC, 7Laboratoire de Santé publique du Québec, Ste-Anne-de-Bellevue, QC
Program

F03.S 11:45 – 12:00
Determinants Associated with Delay in Immunization and Days Underimmunized in the First 24 Months of Life in a Québec Cohort
S O’DONNELL1,2,3, E Dubé4, B Tapiero5, A Gagneur6, C Quach1,2,3,4,5,7
1EBOH McGill University, Montréal, QC, 2RI-MUHC, Montréal, QC, 3Infection Prevention & Control Unit, CHU Sainte-Justine, Université de Montréal, Montréal, QC, 4Direction des risques biologiques et de la santé au travail, INSPQ, Québec, QC, 5Division of Paediatric Infectious Diseases, CHU Sainte-Justine, Montréal, QC, 6Department of Paediatrics, University of Sherbrooke, Sherbrooke, QC, 7Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC

F04.S 12:00 – 12:15
The 2013-2016 Ebola Outbreak and Countries’ Response to the World Health Organization’s International Travel Recommendations
W RHYMER, R Speare

F05.S 12:15 – 12:30
Lymphogranuloma venereum (LGV): Description of the Current Outbreak in Québec
C-A BOUTIN1, S Venne2, M Fiset3, D Murphy4, A-C Labbe1,3
1Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, QC, 2Ministère de la santé et des services sociaux du Québec, Montréal, QC, 3Institut national de santé publique du Québec, Montréal, QC

12:30 – 14:35 Poster Viewing (Poster (P) presenters at posters)
Room: Sheraton Hall & Osgoode Ballroom

12:30 – 14:35 Exhibit Hall Lunch
Room: Sheraton Hall & Osgoode Ballroom

12:40 – 14:35 AMMI Canada Paediatric Committee and PICNIC Meeting
Room: Cedar

12:40 – 14:40 Royal College MM Specialty Committee Meeting
Room: Pinnacle

14:45 – 15:45 State of the Art Clinical Lecture (1 hour)
HCV Care – Engaging the Infectious Diseases Community
Room: Grand Ballroom East & Centre
Moderator: Anu Wadhwa (Toronto, ON)
Speaker: Curtis Cooper (Ottawa, ON)
Objectives:
By the end of this session, participants should be able to:
• Discuss the epidemiology of HCV in Canada including children
• Summarize the latest treatment options for patients infected with HCV
• Recognize the need for the Infectious Diseases community to become engaged in HCV care

15:45 – 16:00 Break
Room: Oral Presentation Foyers

16:00 – 17:45 Oral Presentations (1.75 hours)
Session G
Room: Willow
Moderators:
Jeff Fuller (London, ON)
Susan M. Poutanen (Toronto, ON)

G01 16:00 – 16:15
Antifungal Susceptibility of Invasive Candida isolates from Canadian Hospitals: Results of the CANWARD 2016 Study
J FULLER1, A Bull2, S Shokoples1, L Turnbull1, HJ Adam2,3, M Baxter2, DJ Hoban2,3, GG Zhanel2
1Provinceal Laboratory, Alberta Health Services, University of Alberta, Edmonton, AB, 2Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, 3Diagnostic Services of Manitoba, Winnipeg, MB

G02 16:15 – 16:30
Improved Detection of Carbapenemase-Producing Organisms (CPO) from Surveillance Specimens using Oxooids MacConkey-Cefpodoxime (McPOD) and MacConkey-Meropenem (McMEM) Agars: Time for a Bi-Plate?
BM WILLEY1, S Lee1, V Koren1, B Gascon1,2, S Surangiwala1, L Wisely1, A Paterson1, P Lo1, T Mazzulli1,2, SM Poutanen1,2
1Mount Sinai Hospital/University Health System, Toronto, ON, 2University of Toronto, Toronto, ON

G03 16:30 – 16:45
Molecular Characterization of a Vancomycin Dependant Enterococcus faecium Carrying both vanA and vanB Genes
P JAYARATNE1,2, C Rutherford1
1St. Joseph’s Healthcare, Hamilton, ON, 2McMaster University, Hamilton, ON

G04 16:45 – 17:00
Characterization of Colistin-Resistant Enterobacteriaceae Harbouring mcr-1 Identified from Food and Human Sources in Canada
L Mataseje1, D Boyd1, GG Zhanel2, L Hoang3, JE Rubin4, R Toye5, R Melano6, P Boerin7, B Avery7, J Robertson7, J Nash7, R Reid-Smith8, R Irwin9, MR MULVEY1,2,3,4,7,9
1Public Health Agency of Canada, Winnipeg, MB, 2University of Manitoba, Winnipeg, MB, 3BCCDC, Vancouver, BC, 4University of Saskatchewan, Saskatoon, SK, 5The Ottawa Hospital, Ottawa, ON, 6Public Health Ontario Laboratories, Toronto, ON, 7University of Guelph, Guelph, ON, 8Public Health Agency of Canada, Guelph, ON

May 3–6 mai | Sheraton Centre Toronto
Square (large) Square (small)
Horizontal (long) Horizontal (short) Landscape rectangle Portrait rectangle
Program

G05 17:00 – 17:15
Sensitivity of Different Anatomic Sites for Detection of Colonization with Carbapenemase-producing Enterobacteriaceae (CPE)

E BORGUNDVAAG1,2, S Shafiaz1,2, A Faheem1,4, I Armstrong1, B Coleman1,2, K Green1,2, K Jayasinghe2,3, J Johnstone1, KC Katz4, P Kohler1,2, A McGee1,2, R Melano1,11, M Muller2, S Patel1,3, SM Poutanen2,3, A Rebapragada2, D Richardson5, A Sabaria6, AE Simor1,2, BM Willey1, L Wisely2,3

1Toronto Invasive Bacterial Diseases Network, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON, 3University of Toronto, Toronto, ON, North York General Hospital, Toronto, ON, 4St. Michael’s Hospital, Toronto, ON, 5St. Joseph’s Healthcare Centre, Toronto, ON, 6Gamma-Dynacare, Toronto, ON, 7William Osler Health Centre, Toronto, ON, 8Credit Valley Hospital, Toronto, ON, 9Sunnybrook Hospital, Toronto, ON, 10Northern Ontario School of Medicine, Thunder Bay, ON, 11National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB

G06 17:15 – 17:30
Application of Genome Sequencing for Validation of a Cluster of bla\textsubscript{ndm} Producing Klebsiella pneumoniae in British Columbia

M Croxen1, L Wong2, K Hosford2, B Stroud2, C Mangat1, T Donovan2, P Welsh2, E Brodkin4, MR Mulvey4,5, L HOANG1,3

1BCCDC Public Health Laboratory, Vancouver, BC, 2Fraser Health Authority, BC, 3The University of British Columbia, Vancouver, BC, 4National Microbiology Laboratory, Winnipeg, MB, 5University of Manitoba, Winnipeg, MB

G07 17:30 – 17:45
Genomic Characteristics of Travel Related Strains of \textit{bla\textsubscript{ada}}\textsubscript{M}, \textit{bla\textsubscript{OXA-48}}\textsubscript{f}, \textit{bla\textsubscript{KPC}}\textsubscript{Strains Identified in BC

M Croxen1, R Azana1, E Brodkin1, L Wong1, T Wong1, L Forrester1, JA Srigley1, JC Chen1, B Wang2, J Moli3, P Kibsey4, B Ranns4, D Hembrouff5, L Materese6, G Han9, D Gamage9, MR Mulvey9, L HOANG1,3

1BC Centre for Disease Control Public Health Laboratory, Vancouver, BC, 2Infection Prevention & Control, Fraser Health Authority, BC, 3Infection Prevention & Control, Vancouver Coastal Health Authority, BC, 4Infection Prevention & Control, Interior Health Authority, BC, 5Infection Prevention & Control, Island Health Authority, BC, 6Infection Prevention & Control, Northern Health Authority, BC, 7National Microbiology Laboratory, Winnipeg, 8Provincial Infection Control Network, Vancouver, BC

16:00 – 17:45 Oral Presentations

(1.75 hours)

Session H

Room: Pine

Moderator: Jason LeBlanc (Halifax, NS)

G01 16:00 – 16:15
A Low Frequency of \textit{Bordetella holmesii} and \textit{B. parapertussis} in Specimens Tested for \textit{B. pertussis} in Alberta, Canada: 2016

H Zhou1, R Mah1, D Adachi1, D Burton1, R Lundeberg2, S Fatima3, H Usman1, S Shokoples1, S DREW1,4

1ProvLab Alberta, Edmonton, AB, 2Ministry of Alberta Health, Edmonton, AB, 3Public Health Surveillance and Infrastructure (PHSI), Alberta Health Services, Edmonton, AB, 4Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB

H02 16:15 – 16:30
Performance of Rapid Antigen Detection Testing for Group A Streptococcal Pharyngitis in a High Incidence Setting Involving Indigenous Populations

Y SCHREIBER1,2, G Tardi1, J Mashru1, B Voth3, S Brooks1, S Glenn1, M Haavaldsrud2

1University of Ottawa at The Ottawa Hospital, Ottawa, ON, 2First Nations and Inuit Health Branch, Health Canada, Ottawa, ON, 3Sioux Lookout Menu Yo Wa Health Centre, Sioux Lookout, ON

H03 16:30 – 16:45
Discrimination of Vaccine-Preventable Streptococcus pneumoniae Serotypes using PCR and Sequencing within the cps loci

H Gilliss1,2, D Gaston1,2, I Martin4, RJ Davison1,2, SA McNeil1,2,3, JJ LEBLANC1,2,3

1Canadian Center for Vaccinology (CCfV), IWK Health Centre, Halifax, NS, 2Nova Scotia Health Authority (NSHA), Halifax, NS, 3Dalhousie University, Halifax, NS, 4Streptococcus and STI Unit, National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, MB

H04.S 16:45 – 17:00
Characterization of the Four Most Common Streptococcus pneumoniae Serotypes Causing Both Invasive and Respiratory Infections in Canada: CANWARD 2007-2015

A GOLDEN1, HJ Adam1,2, M Baxter1, K Parkinson1, K Nichol1, I Martin1, W Demczuk2, M Gilmour1,3, JA Karlowsky1,2, DJ Hoban1,2, GG Zhanel1

1University of Manitoba, Winnipeg, MB, 2Diagnostic Services Manitoba, Winnipeg, MB, 3National Microbiology Laboratory, Winnipeg, MB

H05 17:00 – 17:15
Diagnostic Yield of Reverse Transcription PCR and IgM Serology for Confirmation of Mumps During an Adult Outbreak in British Columbia

A JASSEM1,2, A Nunn1, S Masud2, J Hiebert3, M Krajden1,2, M Naus1,2

1British Columbia Centre for Disease Control, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3National Microbiology Laboratory, Winnipeg, MB

H06 17:15 – 17:30
Validation at a Canadian Community Hospital of Influenza A/B and RSV Multiplex with the BD MAX Using Open System Reagents: The Importance of Curve Review

R Keenan, G GERMAN

Health PEI, Charlottetown, PE

H07 17:30 – 17:45
Consistent Presence of \textit{Haemophilus influenzae} Type A in Rural Northwestern Ontario

M ULANOVA1, V Eton1, E Nix1, RT Sang2, W McCready1

1Northern Ontario School of Medicine, Thunder Bay, ON, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB
16:00 - 17:30  Oral Presentations (1.5 hours)

Session I
Room: Birchwood Ballroom

Moderators:
Jennifer Grant (Vancouver, BC)
Christian Lavallée (Montréal, QC)

I01.S 16:00 – 16:15
The Prevalence and Risk Factors for Nontuberculous Mycobacterial Infection in Lung Transplant Patients and Its Impact on Patient Survival and Graft Function
D Friedman, C Cervera-Alvarez, K Halloran, G Tyrrell, K Doucette
University of Alberta, Edmonton, AB

I02.S 16:15 – 16:30
A Notable Increase in Class A Extended-Spectrum β-lactamase-Producing (ESBL) Escherichia coli in Bloodstream Infections over a Ten-Year Period in a Multi-Centre Study
S Smith1,2, R Wiens2, JN Kanji1,3, J Oda2, K Suh9, K Katzii, G Golding2, K Choi1, K Amaratunga1, D Moore3, AE Simon3, G Taylor6, C Frenette2, P Kibsey1, K Suh2, GE Evans10, D Mertz11, A Wong12, M Munira13, Y Longtin14, I Davis15, B Lee16, JC Collet17, JM Langley18, L Maze Dit Mieusement19, J Minion20, P Stagg21, C Lemieux22, S Hota23, M Science23, N Thampi24, C Quach25, S Richardson26, T Du27, S Alexandre28, and Canadian Nosocomial Infection Surveillance Program
1North York General Hospital, Toronto, ON, 2National Microbiology Laboratory, Winnipeg, MB, 3Public Health Agency Canada, Ottawa, ON, 4Montreal Children’s Hospital, Montréal, QC, 5Sunnybrook Health Sciences Centre, Toronto, ON, 6University of Alberta Hospital, Edmonton, AB, 7McGill University Health Centre, Montréal, QC, 8Royal Jubilee Hospital, Victoria, BC, 9The Ottawa Hospital, Ottawa, ON, 10Kingston General Hospital, Kingston, ON, 11Hamilton Health Sciences, Hamilton, ON, 12Royal University Hospital, Saskatoon, SK, 13Vancouver Coastal Health, Vancouver, BC, 14Jewish General Hospital, Montréal, QC, 15QEI Health Sciences Centre, Halifax, NS, 16University of Alberta, Edmonton, AB, 17BC Children’s & Women’s Hospitals, Vancouver, BC, 18WK Health Centre, Halifax, NS, 19Mount Sinai Hospital, Toronto, ON, 20Regina General Hospital, Regina, SK, 21Western Memorial Hospital, Corner Brook, NL, 22University Health Network, Toronto, ON, 23The Hospital for Sick Children, Toronto, ON, 24Children’s Hospital of Eastern Ontario, Ottawa, ON, 25CHU Sainte-Justine, St-Justine, QC

I03 16:30-16:45
An Outbreak of Klebsiella pneumoniae producing NDM in an Acute Care Hospital: The Importance of Patient Room Sharing in Transmission and Regional Tracing in Containment
S Smith1,2, R Wiens3, JN Kanji1,3, J Oda2, L Mataseje4, MR Mulvey4, G Taylor1,2
1University of Alberta, Edmonton, AB, 2Alberta Provincial Laboratory of Public Health, Edmonton, AB, 3National Microbiology Laboratory, Winnipeg, MB

I04 16:45-17:00
Molecular and Epidemiological Characterization of Healthcare-Associated Clostridium difficile Infections Among Adults in Canada, 2009-2015
KC Katz2, G Golding2, K Choi1, K Amaratunga1, D Moore3, AE Simon3, G Taylor6, C Frenette2, P Kibsey1, K Suh2, GE Evans10, D Mertz11, A Wong12, M Munira13, Y Longtin14, I Davis15, B Lee16, JC Collet17, JM Langley18, L Maze Dit Mieusement19, J Minion20, P Stagg21, C Lemieux22, S Hota23, M Science23, N Thampi24, C Quach25, S Richardson26, T Du27, S Alexandre28, and Canadian Nosocomial Infection Surveillance Program
1North York General Hospital, Toronto, ON, 2National Microbiology Laboratory, Winnipeg, MB, 3Public Health Agency Canada, Ottawa, ON, 4Montreal Children’s Hospital, Montréal, QC, 5Sunnybrook Health Sciences Centre, Toronto, ON, 6University of Alberta Hospital, Edmonton, AB, 7McGill University Health Centre, Montréal, QC, 8Royal Jubilee Hospital, Victoria, BC, 9The Ottawa Hospital, Ottawa, ON, 10Kingston General Hospital, Kingston, ON, 11Hamilton Health Sciences, Hamilton, ON, 12Royal University Hospital, Saskatoon, SK, 13Vancouver Coastal Health, Vancouver, BC, 14Jewish General Hospital, Montréal, QC, 15QEI Health Sciences Centre, Halifax, NS, 16University of Alberta, Edmonton, AB, 17BC Children’s & Women’s Hospitals, Vancouver, BC, 18WK Health Centre, Halifax, NS, 19Mount Sinai Hospital, Toronto, ON, 20Regina General Hospital, Regina, SK, 21Western Memorial Hospital, Corner Brook, NL, 22University Health Network, Toronto, ON, 23The Hospital for Sick Children, Toronto, ON, 24Children’s Hospital of Eastern Ontario, Ottawa, ON, 25CHU Sainte-Justine, St-Justine, QC

I05 17:00-17:15
Burden of Illness and Outcome of Viral Respiratory Tract Infection in Hospitalized Adults
S Smith1,2, L Zapernick1, A Crocker2, JN Kanji1,3, G Taylor1,2
1University of Alberta, Edmonton, AB, 2Alberta Health Services, Calgary, AB, 3Alberta Provincial Laboratory of Public Health, Edmonton, AB

I06 17:15-17:30
Monitoring Healthcare Worker Colonization with MRSA, VRE and C. difficile on the Bone Marrow Transplant Ward
T Wojnow1, T Wong13, A Stefanovic1,3, M Croxon1,2, L Hoang13, R Broady1, R Dixon1, E Bryce1,3
1Medical Microbiology and Infection Control, Vancouver Coastal Health, Vancouver, BC, 2BC Centre for Disease Control Public Health Microbiology and Reference Laboratory, Vancouver, BC, 3University of British Columbia, Vancouver, BC, *Coalition for Healthcare Acquired Infection Reduction, Vancouver, BC

18:00 – 19:30  Workshop (1 hour)

Antimicrobial Stewardship: Rapid Phenotypic Antibiotic Susceptibilities in the Management of Patients with Bacteremia
Room: Birchwood Ballroom
Moderator: Edith Blondel-Hill (Kelowna, BC)

Clinical Challenges and Antibiotic Stewardship Issues Related to the Management of Patients with Bacteremia
Speaker: Nick Daneman (Toronto, ON)

Objectives:
• Describe the clinical challenges in utilizing antibiotic susceptibility results in the management of patients with bacteremia
• Discuss how the clinical management of bacteremic patients is impacted by the Canadian National Action Plan for Antimicrobial Stewardship
• Consider the effect of reducing the time to effective therapy and time to antibiotic optimization on bacteremic patient outcomes

Rapid Phenotypic Susceptibility Platforms: Scientific Principles and Clinical Utility
Speaker: Susan M. Poutanen (Toronto, ON)

Objectives:
• Discuss recent advances in rapid phenotypic susceptibility testing options and their scientific principles compared to genotypic methods
• Describe the impact of rapid phenotypic susceptibility testing platforms on antimicrobial stewardship in patients with bacteremia

19:30 – 22:00  JAMMI Editorial Board Meeting
Room: Pinnacle
Program

Saturday May 6

07:00 – 08:30 CFID Bug Run

07:15 – 08:45 AMMI Canada Guidelines Committee Meeting
Room: Pinnacle

08:45 – 09:00 Break
Room: Grand Ballroom Foyer

09:00 – 11:00 Plenary (2 hours)
What’s Hot in Quality Improvement, Adult and Paediatric Infectious Diseases?
Room: Grand Ballroom East & Centre
Moderators: Edith Blondel-Hill (Kelowna, BC) and William Connors (Calgary, AB)

09:00 – 09:40 Experimenting with New Systems of Care to Improve Patient Safety
Speaker: Jerome A. Leis (Toronto, ON)

Objectives:
By the end of this session, participants should be able to:
• Appreciate the need for new models of care to achieve sustainable improvements in infection prevention and antimicrobial stewardship
• List examples of changes that could be made in your organization to promote safer healthcare
• Identify strategies to address barriers to implementation of organizational changes

09:40 – 10:20 My Pick for the Top 3 Stories of 2016 in Adult Infectious Diseases
Speaker: Sumon Chakrabarti (Mississauga, ON)

Objectives:
By the end of this session, participants should be able to:
• Highlight new developments in adult infectious diseases over the past year
• Discuss controversies arising in the field of adult infectious diseases
• Identify further areas of study that are needed in adult infectious diseases

10:20 – 11:00 What’s Hot in Paediatric Infectious Diseases?
Speaker: Sarah Forgie (Edmonton, AB)

Objectives:
By the end of this session, participants should be able to:
• Complete this sentence: “The coolest findings related to paediatric ID published 2016-17 were...”
• Determine which of these cool findings apply to their practice

11:00 – 11:15 Break
Room: Oral Presentation Foyer

11:15 – 12:30 Oral Presentations (1.25 hours)

Session J
Moderator: Steven J. Drews (Edmonton, AB)

J01.S 11:15 – 11:30 Neisseria gonorrhoeae Treatment Failure in Québec, Preliminary Results of an Enhanced Surveillance Program
V BOISSONNEAULT1, S Venne2, C Fortin1,3, B Lefebvre3, A-C Labbé1,3
1Département de microbiologie, infectiologie et immunologie de l’Université de Montréal, Montréal, QC, 2Ministère de la santé et des services sociaux du Québec, Montréal, QC, 3Institut national de santé publique du Québec, Montréal, QC

J02 11:30 – 11:45 High Levels of Antimicrobial Susceptibility to Antibiotics No Longer Used for Treatment in Neisseria gonorrhoeae Isolates from Saskatchewan (2003-2015)
J R DILLON1, PN Levett2, GB Horsman2, SD Thakur1
1University of Saskatchewan, Saskatoon, SK, 2Saskatchewan Disease Control Laboratory, Regina, SK

J03 11:45 – 12:00 Delayed Serological Response against Treponema pallidum may attribute to Upsurge of Syphilis Cases in MSM Populations
M MORSHED1,2, M-K Lee1, S Mann1,1, Y Simpson1, Q Wong1, C Montgomery2, S Makaroff3, J Wong1, T Gannon3, M Tyndall3, M Krajden1,3
1BCDC Public Health Laboratory, Vancouver, BC, 2BCDC Clinical Prevention Services, Vancouver, BC, 3University of British Columbia, Vancouver, BC

J04 12:00 – 12:15 Mycoplasma genitalium Antibiotic Resistance Mediated Mutations in Canadian Women with and Without Chlamydia trachomatis Infection
M CHERNESSKY1, D Jang1, I Martin2, L Hoang1, P Naidu1, PN Levett2, J Wylie3, A Rebbapragada4, S Ratnam5, M Smeja1, B Weinbaum3, D Getman9
1St. Joseph’s Healthcare/McMaster University, Hamilton, ON, 2National Microbiology Laboratory, Winnipeg, MB, 3BCCDC Public Health Laboratory, Vancouver, BC, 4Provincial Health Laboratory, Edmonton, AB, 5Saskatchewan Disease Control Laboratory, Regina, SK, 6Cadham Provincial Laboratory, Winnipeg, MB, 7Dynacare Medical Laboratory, Brampton, ON, 8Newfoundland & Labrador Public Health Laboratory, St. John’s, NL, 9Hologic Inc., San Diego, CA, USA

J05 12:15 – 12:30 Urinary Meatal Swabbing Detects More Men Infected with Mycoplasma genitalium and Four Other Sexually Transmitted Infections Than First Catch Urine
D JANG1, I Martin2, M Smeja1, B Weinbaum3, D Getman9, M Chernesky1
1St. Joseph’s Healthcare/McMaster University, Hamilton, ON, 2National Microbiology Laboratory, Winnipeg, MB, 3Hologic Inc., San Diego, CA, USA

28 | AMMI Canada • CACMID Annual Conference | Conférence annuelle
A Prospective Observational Cohort Study

Infections in Hospitalized Adult Patients:
Smell in the Evaluation of Urinary Tract

The Clinical Utility of Urine Turbidity and
K02 11:30 – 11:45

Beta-lactam Allergy Skin Testing (BLAST) at the Point-of-care for Patients with Infectious Diseases: A Pragmatic Multicentre Evaluation

Session K
Room: Pine
Moderator: Daniel B. Gregson (Calgary, AB)

11:15 – 12:30
Oral Presentations
(1.25 hours)

K01 11:15 – 11:30
Beta-lactam Allergy Skin Testing (BLAST) at the Point-of-care for Patients with Infectious Diseases: A Pragmatic Multicentre Evaluation

JA LEIS1,4, L Palmay1, G Ho2, S Raybardhan1, S Gill1, T Kan1, J Campbell1, S Walker1, JB McCreedy2,4, P Das1,4, B Minnema1,4, JE Powis1,4, H Ferguson1, B Wong, E Weber1
1 Sunnybrook Health Sciences Centre, Toronto, ON, 2 Michael Garron Hospital, Toronto, ON, 3 North York General Hospital, Toronto, ON, 4 Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON, 5 Centre for Quality Improvement and Patient Safety, University of Toronto, Toronto, ON

K02 11:30 – 11:45
The Clinical Utility of Urine Turbidity and Smell in the Evaluation of Urinary Tract Infections in Hospitalized Adult Patients: A Prospective Observational Cohort Study

G Shumilak1, K Ng1, J Kosar2, C MAREK3, S Stewart1, S Shah2,3
1 University of British Columbia, Vancouver, BC, 2 University of Saskatchewan, Saskatoon, SK, 3 University of Alberta, Edmonton, AB

K03 11:45 – 12:00
Utilization of Antibiotics in Long Term Care Facilities in British Columbia, Canada

F Marra1, P Sharma1, M MCCABE2, B Zhao2, D George2, C Mill2, M Chong2, DM Patrick1,2
1 University of British Columbia, Vancouver, BC, 2 BC Centre for Disease Control, Vancouver, BC

K04.S 12:00 – 12:15
Infectious Diseases Specialist Management Improves Outcomes for Outpatients Diagnosed with Cellulitis in the Emergency Department: A Double Cohort Study

S JAIN1,3, S Hosseini-Moghadam2, P Dwek1, K Gupta2, S Elsayed2, G Thompson1, R Dagnone1, K Hutt1, M Silverman1
1 Schulich School of Medicine and Dentistry, London, ON, 2 St. Joseph’s Hospital, London, ON, 3 Ottawa University, Ottawa, ON

K05 12:15 – 12:30
Methicillin-resistant Staphylococcus aureus (MRSA) infections in Hospitalized Pediatric Patients in Canada 2008-2015 – Canadian Nosocomial Infection Surveillance Program (CNISP)

J VAYALUMKAL1,2, L Pelude1,3, BE Lee4,5, K Amaratunga1,2, J Durand1, J Embil6,7, J Embree8, L Forrester9, C Frenette10,11, C Gitters11,12, G Golding13, A Ivy14,5, KC Katz15,14,15, P Kibsey14,5, JM Langley16,17, M-A Lefebvre9,10, A McGee14,18, D Ormiston11, C Quach19,20, S Richardson14,18, M Science14,18, AE Simor14,12,21, S Smith14,18, J So12, JA Stigley22, P Stagg22, N Thampi23,24
1 University of Calgary, Calgary, AB, 2 University of British Columbia, Vancouver, BC, 3 Public Health Agency of Canada, Ottawa, ON, 4 University of Alberta, Edmonton, AB, 5 Stollery Children’s Hospital, Edmonton, AB, 6 University of Manitoba, Winnipeg, MB, 7 Health Sciences Centre, Winnipeg, MB, 8 Vancouver Coastal Health, Vancouver, BC, 9 McGill University, Montréal, QC, 10 McGill University Health Centre, Montréal, QC, 11 Hamilton Health Sciences, Hamilton, ON, 12 National Microbiology Laboratory, Winnipeg, MB, 13 WK Health Center, Halifax, NS, 14 University of Toronto, Toronto, ON, 15 North York General Hospital, Toronto, ON, 16 Vancouver Island Health Authority, Vancouver, BC, 17 Dalhousie University, Halifax, NS, 18 Sinai Health System, Toronto, ON, 19 Université de Montréal, Montréal, QC, 20 Centre hospitalier universitaire Sainte-Justine, Montréal, QC, 21 Hospital for Sick Children, Toronto, ON, 22 Sunnybrook Health Sciences Centre, Toronto, ON, 23 University of Alberta Hospital, Edmonton, AB, 24 BC Children’s & Women’s Hospitals, Vancouver, BC, 25 University of British Columbia, Vancouver, BC, 26 Western Memorial Hospital, Corner Brook, NF, 27 University of Ottawa, Ottawa, ON, 28 Children’s Hospital of Eastern Ontario, Ottawa, ON

L01 11:15 – 11:30
Evaluation of Alifax HB&L UROQUATTRO for Rapid Detection of Bacteria from Sterile Site Fluid Specimens

H Almohi, E NAGAI
LifesLabs Medical Laboratory Services, Toronto, ON

L02.S 11:30 – 11:45
Test Method Evaluation for a Direct MALDI-TOF MS Identification (ID) Protocol of Organisms from Positive Blood Cultures from the BD Bactec Fx System

C MACDONALD1,2, L Fehr1, T Dingle1,3, G Tyrrel1,2, P Naidu1
1 Alberta Provincial Laboratory for Public Health, Edmonton, AB, 2 Department of Medical Microbiology and Immunology, Edmonton, AB, 3 Department of Lab Medicine and Pathology, Edmonton, AB

L03.S 11:45 – 12:00
Eggerthella lenta Blood Stream Infections are Associated with Increased Mortality Following Empiric Piperacillin-Tazobactam Monotherapy: A Single-Centre Retrospective Cohort Study

A UGARTE-TORRES1, M Gillrie1, T Griener1, D Church1
1 University of Calgary, Calgary, AB, 2 Calgary Laboratory Services, Calgary, AB

L04 12:00 – 12:15
Urine Flow Cytometry (UFC), A Rapid Method to Screen and Eliminate Urines from Culturing

A Stefanovic1, C Porter1, A Lim1, M Pudek1,2, R Ranasinghe3, T Wong1,2, J Grant1,2, E Bryce1,2, K Ng1, D ROCO1,2
1 Department of Pathology and Laboratory Medicine, Vancouver, BC, 2 University of British Columbia, Vancouver, BC, 3 Provincial Infection Control Network, Vancouver, BC
12:30 – 14:35 Delegate Lunch  
Room: Grand Ballroom West  

12:40 – 14:35 AMMI Canada Choosing Wisely Canada Paediatric Campaign Meeting  
Room: Birchwood Ballroom  

12:40 – 14:35 MALDI-TOF Users Group Meeting  
Room: Willow  

14:45 – 15:45 The Incubator: “The Pitch”  
Room: Grand Ballroom East & Centre  

15:45 – 16:00 Break  
Room: Grand Ballroom Foyer  

16:00 – 16:30 Poster and Research Awards Presentations  
Room: Grand Ballroom East & Centre  

16:30 – 18:00 Clinical Vignettes (1.5 hours)  
Room: Grand Ballroom East & Centre  
Chairs: Jennifer Grant (Vancouver, BC) Michael Libman (Montréal, QC)  
Discussants: Gerald Evans (Kingston, ON) Sarah Foggie (Edmonton, AB) Donald Vinh (Montréal, QC)  
The audience, using an audience response system, along with discussants, will work through the cases to try and solve them.  

19:00 – 22:00 Toronto Evening Activities (reservations made by participants)  

Join your colleagues, friends, competitors or just challenge yourself to a Bug Run/Walk in support of the Canadian Foundation for Infectious Diseases charitable mission. Win a prize!!  
Registration is $50. The CFID Bug Run will include both a 2.5K and 5K run from the hotel/conference centre through beautiful mid-town Toronto at the height of spring.  
Online registration is available until midnight on May 5. Online registration also includes the option for participants to provide donations to CFID and to seek donations from friends and relatives.  
On-site registration and race kit pick-up will be available at the CFID booth in the Exhibit Hall on Thursday and Friday, May 4-5. In addition, registration will be possible in the lobby of the Sheraton Centre from 06:30 – 06:55 prior to the start of the race at 07:00.  
Click here to register and keep posted about details.
Vancouver 2018
SAVE THE DATE
AMMI Canada – CACMID Annual Conference 2018 Conférence annuelle
Dates: May 2-5 / 2-5 mai • Location: Sheraton Vancouver Wall Centre, Vancouver, BC
Thursday, May 4, and Friday, May 5
Room: Sheraton Hall & Osgoode Ballroom
Poster Viewing
Thursday, May 4:
Lunch 12:30 – 14:35
Afternoon Break 15:45 – 17:00
Welcome Reception 18:45 – 21:00
Friday, May 5:
Lunch 12:30 – 14:35

Presenters at Posters
Thursday, May 4: 15:45 – 17:00
– Student (SP) and Incubator (IP) Presenters
Friday, May 5: 12:30 – 14:35
– Poster (P) Presenters

Student Poster Presentations
(SP01 – SP48)
Incubator Poster Presentations
(IP01 – IP12)
Poster Presentations
(P01 – P72)

Student Posters

<table>
<thead>
<tr>
<th>SP01</th>
<th>Staphylococcus aureus Interaction with Pseudomonas aeruginosa Biofilm Associated with Tobramycin Resistance and Failure of Eradication Therapy in Children with Cystic Fibrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D CHAHAL, S Lother, J Hajek, T Wong</td>
</tr>
<tr>
<td></td>
<td>University of British Columbia, Vancouver, BC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SP02</th>
<th>Knowledge of Hepatitis C and Treatment Willingness Amongst People Who Inject Drugs in an Era of Direct Acting Antivirals</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A MAH1, M Hull1,2, K DeBeck2,3, M-J Milloy1,2, S Dobrer2, E Nosova3, E Wood1,2, T Kerr1,2, K Hayashi1,2</td>
</tr>
<tr>
<td></td>
<td>1Department of Medicine, University of British Columbia, Vancouver, BC, 2British Columbia Center for Excellence in HIV/AIDS, University of British Columbia, Vancouver, BC, 3School of Population and Public Health, University of British Columbia, Vancouver, BC, 4Faculty of Health Sciences, Simon Fraser University, Burnaby, BC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SP03</th>
<th>HIV Infection After Prenatal Screening: An Open Window Leading to Perinatal Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R LANG1, S Skinner2, J Ferguson2, T Jadavji5, M Stadnyk4, J Gill1</td>
</tr>
<tr>
<td></td>
<td>1Department of Medicine, University of Calgary, Calgary, AB, 2Department of Medicine, University of Saskatchewan, Regina, SK, 3Department of Obstetrics and Gynecology, Regina, SK, 4School of Medicine, University of Alberta, Edmonton, AB, 5Department of Pediatrics, University of Calgary, Calgary, AB</td>
</tr>
</tbody>
</table>
**Poster Presentations**

**SP05**
How Many Bronchial Alveolar Lavage Specimens Do We Need?
BA ALBARAD1,3, L Jiao1, C Hamielec1,2, C Main1,2

1McMaster University, Hamilton, ON, 2Hamilton Health Sciences, Hamilton, ON, 3King Fahad Specialist Hospital, Dammam, Saudi Arabia

**SP06**
How Frequently Does Mycoplasma pneumoniae Cause Infection in Children Admitted to the Paediatric Intensive Care Unit?
H ALFARAIDI, K Luinstra, M Smieja, P Jayaratne, JM Pernica
Department of Paediatrics, McMaster University, Hamilton, ON

**SP07**
Genomic Epidemiology and Characterization of CTX-M-15-producing Escherichia coli Isolated from Patients in Canadian Hospitals
AJ DENISUIK1, HJ Adam1,2, P Lagacé-Wiens1,2, MR Mulvey1,2, M Baxter1, JA Karlovsky1,3, M Gilmour1,3, DJ Hoban1,2, GG Zhaneti1

1University of Manitoba, Winnipeg, MB, 2Diagnosti- s栝 hiters Laboratory, Winnipeg, MB, 3National Microbiology Laboratory, Winnipeg, MB

**SP08**
Rapid, Reagent-Free Bacterial Identification Based on Whole-Organism Fingerprinting by Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy with Subspecies-Level Discriminatory Capability
L LAM1, P Lebel1, M Langella1, H Kim1, S Lévesque1, I Iugovaz1, J Sedman1, A Ismail1

1McGill University, Ste-Anne-de-Bellevue, QC, 2McGill University Health Centre, Montréal, QC, 3Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, QC, 4Health Canada, Longueuil, QC

**SP09**
Colorimetric Screening of Antibiotic Resistance Biomarkers Using Nucleic Acid Enzymes and Gold Nanoparticles
M MOHAMED, J Kim, K Zagorovsky, W Chan
University of Toronto, Toronto, ON

**SP10**
Evaluating Patient Interest in Fecal Transplantation for Non-Alcoholic Fatty Liver Disease
J TAT-KO1,2, M Beaton1, S Parvathy1,2, L Craven1, J Burton1, A Rahman1, T Joy1, K Qumosani1, M Silverman1,2

1St. Joseph’s Health Care London, London, ON, 2University of Western Ontario, London, ON

**SP11**
The Association between Respiratory Pathogens and Exacerbation Severity, Health Care Utilization, Treatment Response and Morbidity in Children with an Asthma Exacerbation: A Systematic Review
J MERCKX1, H Kraicer-Melamed1, FM Ducharme2, C Quach1,3,4

1Department of Epidemiology, Biostatistics & Occupational Health, McGill University Montréal, QC, 2Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montréal, QC, 3Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montréal, QC, 4Infection Control & Prevention Unit, Division of Paediatric Infectious Diseases and Department of Medical Microbiology, CHU Sainte-Justine, Université de Montréal, Montréal, QC

**SP12**
Evaluation of the β-Lacta Test for Detection of ESBL-Producing Organisms Directly from Positive Blood Cultures Using Smudge Plates
M HASSO1, V Porter1, AE Simori1,2

1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 2Department of Microbiology, Sunnybrook Health Science Centre, Toronto, ON

**SP13**
Case Conferences for Infective Endocarditis: A Quality Improvement Study
C TAN1, M Hansen2, G Cohen2, K Boyle3, A Yang1, N Daneman1,2,3, N Adhikari1,2,3

1Sunnybrook Research Institute, Toronto, ON, 2Division of Cardiology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, 3Division of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON

**SP14**
Comparison of the Carbapenem Inactivation Method and ROSCO KPC/MBL Confirm Kit for Detection of Carbapenemase-Producing Enterobacteriaceae
N MATIC1, R Melano1,2, S Patel1,2, B Tam3, M Bignell1, LA Matukas1,2, M Tadros1,3

1Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, 2Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, 3Department of Critical Care, University of Toronto, Toronto, ON

**SP15**
Impact of Galactomannan Screening for invasive Aspergillosis in High Risk Haematology Patients
L MUSIELAK1,2, M Duffett1, S Haider1,2, A Brooks1,2

1Juravinski Hospital, Hamilton, ON, 2Hamilton Health Sciences, Hamilton, ON
**Poster Presentations**

**SP16**
Increased Incidence of HIV, Hepatitis C, Invasive Group A Streptococcal Disease and Endocarditis in PWIDs: London-Middlesex, Ontario

L BALL1, G Hovhannisyan2, K Gupta3, S Koivu4, T Coleman5, A Sherazi1, D Lacz3, T Mele4, M Silverman4
1Schulich School of Medicine & Dentistry, London, ON, 2London-Middlesex Public Health Unit, London, ON, 3Department of Medicine, Division of Infectious Disease, Schulich School of Medicine & Dentistry, Western University, London, ON, 4Department of Family Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON, 5Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, ON

**SP17**
Severe Multifocal Tuberculosis with Dilated Cardiomyopathy in a Young Patient: Revisiting ‘The Great Mimicker’

C HOGAN1, L Y Kong1, M Palayew2, DC Vinh1, C Greenaway2
1McGill University Health Centre, Montréal, QC, 2Department of Medicine, Jewish General Hospital, Montréal, QC

**SP18**
Syphilis Re-Infection Amid a Global Resurgence: A Systematic Review and Meta-Analysis

A SHAKER1,2, B Wong3, A Burchell5, DHS Tan1, A Al-Salman2, DG Gesink1, V Allen1, S Araf1, C Ziegler3, S Mishra3
1University of Toronto, Toronto, ON, 2Royal College of Surgeons, Dublin, Ireland, 3Public Health Ontario, Toronto, ON, 4Centre for Disease Control and Prevention, Atlanta, GA, USA, 5St. Michael’s Hospital, Toronto, ON

**SP19**
Tuberculosis After Lung Transplantation: Safety and Efficacy of rifabutin Based Treatment in The Setting of Transplant Immunosuppression

C O’NEIL, K Doucette, R Long, R Cooper
University of Alberta, Edmonton, AB

**SP20**
What Could Rates of Syphilis Re-Infection Tell Us About Transmission Dynamics of Syphilis Epidemics? Insights from Mathematical Modelling

J FELDMAN1, S Vivona2, N Moquete1, S Mishra1
1Dalhousie University, Halifax, NS, 2McMaster University, Hamilton, ON, 3St. Michael’s Hospital, Toronto, ON

**SP21**
Mutations in Penicillin Binding Protein 3 are Common Among β-lactam Exposed Pseudomonas aeruginosa from Cystic Fibrosis Patients

S CLARK1,2, Y Zhang2, P Wang1, J Diaz Caballero1, E Tullis1, D Guttman1, D Hwang1,2
1University of Toronto, Toronto, ON, 2Toronto General Hospital Research Institute, Toronto, ON, 3St. Michael's Hospital, Toronto, ON

**SP22**
Testing Assumptions Surrounding Rebounds in Syphilis Epidemics: An Exploratory Modeling Analysis

S VIVONA1,5, N Moquete2,3, J Feldman1,5, S Mishra1,4
1McMaster University, Hamilton, ON, 2McGill University, Montréal, QC, 3University of King’s College, Halifax, NS, 4University of Toronto, Toronto, ON, 5St. Michael’s Hospital, Toronto, ON

**SP23**
HIV and Malaria Co-Infection: A Complex Interaction

LY KONG1, T Nguyen1, M Libman1, C Greenaway2
1McGill University Health Centre, Montréal, QC, 2Jewish General Hospital, Montréal, QC

**SP24**
Retrospective Review of 103 Prosthetic Joint Infections at A Single Institution in Toronto from 2013-2014

C KANDEL, D Backstein, A McGeer
University of Toronto, Toronto, ON

**SP25**
The Prevalence of Antibiotic Use in Bacterial Enteric Illnesses in Canada, 2010-2015

B DOUGHERTY1, R Finley2, B Marshall2, D Dumoulin2, A Pavletic1, J Dow1, T Hlucky1, R Asplin5, J Stone5
1Department of Population Medicine, University of Guelph, Guelph, ON, 2Centre for Food-borne, Environmental, and Zoonotic Infectious Diseases, Public Health Agency of Canada, Guelph, ON, 3Middlesex London Health Unit, London, ON, 4Alberta Health Services, Calgary, AB, 5Fraser Health Authority, Surrey, BC

**SP26**
Timeliness of Diagnosis of HIV in Newfoundland: A Quantitative and Qualitative Analysis

S BOYD1, J Allison1, C Penney1, K Burt1, P Daley1,2
1Memorial University of Newfoundland, St. John’s, NL, 2Eastern Health, St. John’s, NL

**SP27**
Stool Specimens that are Toxic for Cell Culture Should be Tested for Clostridium difficile Cytotoxin

A LANG, L Mushanski, PN Levett
Saskatchewan Disease Control Laboratory, Regina, SK

**SP28**
Improved Isolation of Salmonella enterica serovar Typhimurium Using the Walk-Away Specimen Processor and FecalSwab System

L GONEAU1, A Mazzulli1, X Trimi2, A Cabrera3, P Lo1, T Mazzulli1,2
1University of Toronto, Toronto, ON, 2University Health Network/Sinai Health System, Toronto, ON

**SP29**
Detection of Viral Antibodies via Dried Oral Swabs

D SPEICHER1,2,3, K Luinstra2, S Castriciano4, M Smieja1,2
1McMaster University, Hamilton, ON, 2St. Joseph’s Healthcare Hamilton, Hamilton, ON, 3Griffith University, Gold Coast, QLD, Australia, 4Copan Italia, Brescia, Italy
Poster Presentations

SP30
Household Environmental Contamination and Transmission of carbapenemase-producing Enterobacteriaceae
A Jamal1,2, A Faheem1,2, S Shafinaz1,2, I Armstrong1,2, E Bourgundy1,2, B Coleman1,2, K Green1,2, K Jayasinghe1,2, J Johnston1,2, K C Katz1,2, P Kohier1,2, A McGeer1,2, R Melano1,2, M Muller1,2, S Patel1,2, SM Poutanen1,2, A Rebbaragada1,2, D Richardson1,2, A Sarabia1,2, AE Simor1,2, BM Willey1,2, L Wisely1,2
1Toronto Invasive Bacterial Diseases Network, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON

SP31
Candidemia in a Tertiary-Care University Hospital: What Saves Lives?
XS Wang1, MP Cheng1,2, TC Lee1,2
1McGill University, Montreal, QC, 2Division of Infectious Diseases and Department of Medicine, McGill University Health Centre, Montreal, QC

SP32
Fluconazole Utilization Evaluation, and Review of Invasive Candidiasis in the McMaster University Neonatal Intensive Care Unit (NICU)
S Alghamdi1, D Mertz, S Khan, M Sung
1McMaster University, Hamilton, ON

SP33
Impact of CMV Infection Post-liver Transplantation According to CMV Serostatus
L Mclaughlin, C Hernandez, K Doucette, D Kabbani, S Fuentes, C Cervera-Alvarez
University of Alberta Hospital, Edmonton, AB

SP34
Impact of an Antimicrobial Stewardship Program to Reduce Drug-Resistant Bacteremia in Patients with Hematological Malignancies
Y Natori
University Health Network, Toronto, ON

SP35
HIV Serology Signal-to-Cutoff Ratio as a Rapid Method to Predict Confirmation of HIV Infection
L Li1, D Puddicombe1, S Champagne1, A Jassem2, M Krajen2, C Lowe1, M Payne1
1St. Paul’s Hospital, Vancouver, BC, 2BC Centers of Disease Control, Vancouver, BC

SP36
Carbapenemase Producing Enterobacteriaceae Outbreak in a Large Community Hospital due to Horizontal Dissemination of blaKpc, between Different Genera of Enterobacteriaceae
H Candon1,2, LM Matukas1,2, S Patel1,2, R Melano1,2, N Tijet1,2, A Eshaghi1,2, A McGeer1,2, J Johnston2,3,5
1Mackenzie Health, Richmond Hill, ON, 2St. Joseph’s Health Centre, Toronto, ON, 3Public Health Ontario, Toronto, ON, 4McMaster University, Hamilton, ON

SP37
Fosfomycin Resistant Escherichia coli and Staphylococcus pseudintermedius Isolated from Canine Urinary Tract Infections
R Courtice, MAR Priyantha, M Sniatynski, JE Rubin
University of Saskatchewan, Saskatoon, SK

SP38
Clinical and Echocardiographic Predictors of Embolism in Infective Endocarditis
A Yang1, C Tan1, N Daneman1,2, N Adhikari1,2, G Cohen1,2, K Boyle1,2, M Hansen1,2
1University of Toronto, Toronto, ON, 2Sunnybrook Health Sciences Centre, Toronto, ON

SP39
Examining the Effects of Microgravity on the Pathogenicity and Drug Resistance of Candida albicans using a Microfluidics-based Nanosatellite
University of Toronto, Toronto, ON

SP40
Herpes simplex virus Colitis Superinfection in Crohn’s Disease: A Rare Association
H Jafari, D Kalina, T Aziz, S Haider
McMaster University, Hamilton, ON

SP41
Following the Path: A Case Report of Gram-positive Rods in Association with Cystic Neutrophilic Granulomatous Malignancies
G Patrichquin1, T Burdz2, KA Bernard2,3, P Barnes1, TF Hatchette1
1Dalhousie University, Halifax, NS, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3Department of Medical Microbiology, University of Manitoba, Winnipeg, MB

SP42
Raltegravir Induced Alopecia Areata in an HIV Positive Female
A Kapoor1, S Haider1, M Patel2
1McMaster University, Hamilton, ON, 2Royal College of Surgeons in Ireland, Dublin, Ireland

SP43
Alveolar echinococcosis in Alberta: An Emerging Infectious Disease in North America?
S Belga1, K Doucette1, J Preiksaitis1, A Massolo2, C Klein3, K Kowalewska-Grochowska1, B Sis1, S Houston2
1University of Alberta, Edmonton, AB, 2University of Calgary, Calgary, AB

SP44
Hemophagocytic Lymphohistiocytosis presenting as Acute HIV Infection: Case Report and Review of the Literature
F Manji, E Wilson, E Mahe, J Gill, JM Conly
University of Calgary, Calgary, AB
**Poster Presentations**

**IP01**

The Effect of An Infection Prevention and Control Mobile Application on Patient and Family Knowledge

C. Tsang¹, C. Pearce¹, M. Lernay¹,³, L. Kamhuka²,³, L. VanRooyselaar¹, J. Vayalumkal²,³,⁴

¹Bachelor of Health Sciences Student, University of Calgary, Calgary, AB. ¹Infection Prevention and Control, Alberta Health Services, Calgary, AB. ²Section of Infectious Diseases, Department of Pediatrics, Alberta Children’s Hospital, Calgary, AB. ³Alberta Children’s Hospital Research Institute, Calgary, AB

**IP02**

Prevention of Clostridium difficile Infections Through the Detection and Isolation of C. difficile asymptomatic carriers – a three-year follow-up study

Y. Longtin¹,², P. Gervais³,⁴, J-F. Roussy³,⁴, B. Paquet-Balduc³,⁴, J. Longtin⁴, S. Trottier³,⁴

¹Jewish General Hospital, Montreal, QC. ²McGill University, Montreal, QC. ³Quebec Heart and Lung Institute, Quebec City, QC. ⁴Laval University, Quebec City, QC. ⁵Institut de Santé Public du Quebec, Montreal, QC

**IP03**

ABSTRACT WITHDRAWN

**IP04**


A. Cabrera¹, LM Matukas¹,², MP Muller¹,³, M. Tadros¹,²

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON. ²Microbiology, Department of Laboratory Medicine, St. Michael’s Hospital, Toronto, ON. ³Department of Medicine, St. Michael’s Hospital, Toronto, ON

**IP05**

Impact of Automatic Infectious Diseases Consultation for Patients with Staphylococcus aureus Bacteremia

L. Djelic¹,², N. Andany¹,², J. Craig¹,², A. E. Simor¹,², N. Daneman¹,², J. A. Leis¹,²,³

¹Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON. ²Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON. ³Centre for Quality Improvement and Patient Safety, University of Toronto, Toronto, ON

**IP06**

Antibiotic Utilization Feedback Reports on General Internal Medicine Service

S. Rai¹, M. Elligsen¹, S. Walker¹, C. Peragine¹, N. Alattas¹, N. Daneman¹,², J. A. Leis¹,²,³,⁴

¹Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto and Lesley Dan Faculty of Pharmacy, University of Toronto, Toronto, ON. ²Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, ON. ³Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, ON. ⁴Centre for Quality Improvement and Patient Safety, University of Toronto, Toronto, ON

**IP07**

Effect of a Comprehensive Model for HIV Care in an Urban Canadian Population with a High Prevalence of Injection Drug Use and Homelessness

K. Gupta¹, K. Cassidy², S. Morris-Rice², M. Silverman¹

¹Western University, London, ON. ²London Intercommunity Health Center, London, ON

---

**SP45**

Influenza A Virus Replication and Bioaerosol Production in a Ferret Model; Evaluation of Bioaerosol Samplers

C. Bekking¹,², L. Yip², N. Doggett¹,², M. Finn², S. Mubareka¹,²

¹University of Toronto, Toronto, ON. ²Sunnybrook Research Institute, Toronto, ON

**SP46**

Mechanism of Antibacterial Activity of Carvacrol against Streptococcus pyogenes: Effect on Bacterial Cell Wall/Membrane Disruption and Permeability

N. M. Wijsundara¹,², HPV. Rupasinghe¹,²,³

¹Department of Biology, Faculty of Science, Dalhousie University, Halifax, NS. ²Department of Food, Environmental Sciences, Faculty of Agriculture, Dalhousie University, Truro, NS. ³Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS

**SP47**

Epidemiology of Multidrug-Resistant Gram-negative Bacteremia in a Hospital-Based Pediatric Population

R. Geile¹,², S. Liu², S. Hughes¹, R. Rassekh¹, J. Ting¹, A. Roberts¹, P. Tilley¹, K. T. Kang¹

¹British Columbia Children's Hospital, Vancouver, BC. ²University of British Columbia, Vancouver, BC

**SP48**

Thrombin Cleavage of Plasmodium falciparum Erythrocyte Membrane Protein-1 Inhibits Cytoadherence

M. R. Gillrie¹, B. Renaux¹, E. Russell-Goldman¹, M. Avril¹, A. J. Brazier³, K. Mihara¹, E. Di Cera¹, D. A. Milner², M. D. Hollemb¹, J. D. Smithh¹, M. Ho²

¹University of Calgary, Calgary, AB. ²Harvard Medical School, Boston, Massachusetts, USA. ³Saint Louis University School of Medicine, St. Louis, Missouri, USA

---

**IP01**

The Effect of An Infection Prevention and Control Mobile Application on Patient and Family Knowledge

C. Tsang¹, C. Pearce¹, M. Lernay¹,³, L. Kamhuka²,³, L. VanRooyselaar¹, J. Vayalumkal²,³,⁴

¹Bachelor of Health Sciences Student, University of Calgary, Calgary, AB. ²Infection Prevention and Control, Alberta Health Services, Calgary, AB. ³Section of Infectious Diseases, Department of Pediatrics, Alberta Children’s Hospital, Calgary, AB. ⁴Alberta Children’s Hospital Research Institute, Calgary, AB

**IP02**

Prevention of Clostridium difficile Infections Through the Detection and Isolation of C. difficile asymptomatic carriers – a three-year follow-up study

Y. Longtin¹,², P. Gervais³,⁴, J-F. Roussy³,⁴, B. Paquet-Balduc³,⁴, J. Longtin⁴, S. Trottier³,⁴

¹Jewish General Hospital, Montreal, QC. ²McGill University, Montreal, QC. ³Quebec Heart and Lung Institute, Quebec City, QC. ⁴Laval University, Quebec City, QC. ⁵Labana de Santé Publique du Quebec, Montreal, QC

**IP03**

ABSTRACT WITHDRAWN

**IP04**


A. Cabrera¹, LM Matukas¹,², MP Muller¹,³, M. Tadros¹,²

¹Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON. ²Microbiology, Department of Laboratory Medicine, St. Michael’s Hospital, Toronto, ON. ³Department of Medicine, St. Michael’s Hospital, Toronto, ON
**Poster Presentations**

**P01** Rapid Accurate Distinction of KPC Carbapenemase-Producing Organisms (CPO) from other CPO Genotypes and Non-CPO using the Coris BioConcept’s KPC K-Set Immuno-Chromatographic Assay

BM WILLEY1, S Lee1, V Koren1, B Gascon1,2, S Surangiwal1, J Bartoszko1,2, HC Kim1,2, P Lo1, T Mazzulli1,2, SM Poutanen1,2
1Mount Sinai Hospital/University Health Network, Toronto, ON, 2University of Toronto, Toronto, ON

**P02** Antimicrobial Susceptibility of Helicobacter pylori Isolates in Manitoba

P LAGACÉ-WIENS1,2, C Turenne1,2, HJ Adam1,2, A Walkty1,2, JA Karlowsky1,2
1Diagnostic Services Manitoba, Winnipeg, MB, 2University of Manitoba, Winnipeg, MB

**P03** ABSTRACT WITHDRAWN

**P04** Comparison of Three Rapid MALDI-TOF Identification Methods for Positive Blood Cultures

P LAGACÉ-WIENS1,2, HJ Adam1,2, P Pieroni1, N Konzie1, K Glor1, S Kassam1, W Leduc1, J Terrick1, C Espenell1, JA Karlowsky1,2
1Diagnostic Services Manitoba, Winnipeg, MB, 2University of Manitoba, Winnipeg, MB

**P05** Comparison of Three Methods of Environmental Sampling for the Recovery of MRSA, VRE and CPO from the Hospital Environment: A Quality Improvement Initiative

L Turnbull1, L Chui1,2, G Taylor1,2, P NAIDU1,2
1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health, Edmonton, AB

**P06** Antibiotic Prophylaxis in Acute Ischemic and Hemorrhagic Stroke Patients: A Systematic Review and Meta-Analysis

E RENNERT-MAY1, C Zerna1, L Bresee1,2
1University of Calgary, Calgary, AB, 2CADTH, Calgary, AB

**P07** A Cost-Effectiveness Analysis of a Decolonization Protocol for Staphylococcus aureus Prior to Knee Arthroplasty in Alberta, Canada

E RENNERT-MAY1,2, JM Conly1,2, B Manns1,2
1University of Calgary, Calgary, AB, 2Alberta Health Services, Calgary, AB

**P08** Hand Hygiene Knowledge, Attitudes, and Practices among Hospital Inpatients: A Mixed Methods Study

JA SRIGLEY1,2, S Cho1, C O’Neill1, C Lee1,2,4, D Mertz1,2, P NAIDU1,2
1BC Children’s & Women’s Hospitals, Vancouver, BC, 2University of British Columbia, Vancouver, BC, 3McMaster University, Hamilton, ON, 4Hamilton Health Sciences, Hamilton, ON, 5St. Joseph’s Healthcare Hamilton, Hamilton, ON, 6Island Health Authority, Victoria, BC
Corynebacterium kroppenstedtii in Breast Abscess and Granulomatous Mastitis: not to be Dismissed as a Mere Skin Contaminant
C HOGAN1, Y Longtin2, K Weiss3
1McGill University Health Centre, Montréal, QC; 2Johnson & Johnson; 3American Society for Investigative Pathology

Cumulative Antimicrobial Susceptibilities of Anaerobic Bacterial Isolates at a Tertiary Care Hospital in Vancouver, BC (2013-2016)
M Payne1, C LOWE1, I Sekirov, M Romney, S Champagune
1Pathology and Laboratory Medicine, Providence Health Care, Vancouver, BC; 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

Multitarget Plasmid Controls for Conventional and Real-Time PCR Serotyping of Streptococcus pneumoniae
J Schembri1, H Gillis1,2, SA McNeil1,2,3, JJ LEBLANC1,2,3
1Dalhousie University, Halifax, NS; 2Canadian Center for Vaccinology (CCV), IWK Health Centre, Halifax, NS; 3Nova Scotia Health Authority (NSHA), Halifax, NS

Comparison of the In Vitro Activity of Telavancin and Vancomycin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolated from Blood Cultures across Canada: TELA-CHESS 2016
M BAXTER1, HJ Adam1,2, C Lowe1, SM Poutanen1,2, K Nichol1, DJ Hoban1,2, GG Zhanel1
1University of Manitoba, Winnipeg, MB; 2Diagnostic Services Manitoba, Winnipeg, MB; 3Providence Health Care, Vancouver, BC; 4University Health Network, Toronto, ON; 5Sinai Health Systems, Toronto, ON; 6University of Toronto, Toronto, ON

In Vitro Activity of Fosfomycin (FOS) against Antimicrobial-Resistant Escherichia coli (EC) Isolated from Outpatient Urine Samples: CANWARD Surveillance Study 2007-2015
JA Karlowsky1,2, HJ Adam1,2, M BAXTER1, GG Zhanel1
1University of Manitoba, Winnipeg, MB; 2Diagnostic Services Manitoba, Winnipeg, MB

Threat Scoring for Emerging Infectious Disease Events to Enable Public Health Decisions in Canada
L VRBOVA1, RG Thomas-Reilly2, A Demarsh2
1Public Health Agency of Canada, Toronto, ON; 2Public Health Agency of Canada, Ottawa, ON

Emendation of the Genus Clostridium and Validation of the Description of Clostridium neonatae’ Species Novum, as a Member of that Genus
KA BERNARD1, A-M. Bernier2
1National Microbiology Laboratory, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB

Genotypic Analysis of Borrelia burgdorferi Isolated in British Columbia
M-K LEE1, MI Uyaguari Diaz1,2, M Croxen1,2, S Man1, K Fernando1, Q Wong1, M Morshed1,2
1BC Centre for Disease Control - Public Health Laboratory, Vancouver, BC; 2Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

Rapid Identification of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Isolates Directly From Positive Blood Cultures Using the BD MAX™ StaphSR Assay
V PORTER1, M Chouinard1, AE Simor1,2
1Department of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON; 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON

Utilizing Opiate Substitution Therapy (OST) as a Tool for Long-term Engagement in HCV Infected People Who Inject Drugs (PWID)
A Almohammadi, G Kiani, T Raycraft, R Shahi, A Singh, B CONWAY
Vancouver Infectious Diseases Centre, Vancouver, BC

Cost-Efficiency Analysis of the Potential Addition of MRSA Chromogenic Media in the Management of Skin-Soft Tissue Infections: An Attempt to Decrease the Use of Vancomycin
C BOGATY1, P Lagace-Wiens1,2
1Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB; 2St Boniface Hospital, Winnipeg, MB

Cascade of Care of HIV Patients Followed at a Canadian STI Clinic
P SMYCZEK1,2, J Gratrix1, S Hewitt1, P Parker1, S Plitt1,5, KA Simmonds4,5, A Singh1,5
1Alberta Health Services-Edmonton STI Clinic, Edmonton, AB; 2Alberta Health Services-Centralized STI Services, Edmonton, AB; 3Public Health Agency of Canada, ON, Ottawa, ON; 4Alberta Health, Edmonton, AB; 5University of Alberta, Edmonton, AB
P22
Appropriateness of Empiric Antibiotic Therapy in Patients with Gram-negative Bacteremia: A Multi-sited Retrospective Study
R LEE1, C Graham1, T Fernandes1,2, A Sengar1
1Trillium Health Partners, Toronto, ON, 2Leslie Dan Faculty of Pharmacy at the University of Toronto, Toronto, ON

P23
Impact of MALDI-TOF and Short-Incubation Subcultures on Time to Identification and Antimicrobial Susceptibility Testing of Gram-Negative Bacilli from Positive Blood Cultures in a Clinical Microbiology Laboratory
N MATIC1, BM Willey2, E Cudek3, P Lo2, SM Poutanen1
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 2Department of Microbiology, University Health Network & Mount Sinai Health System, Toronto, ON

P24
What is the Utility of Collecting Urine Cultures for Mycobacterium in Tuberculosis Patients?
A MCFARLANE1, D Kunimoto1, G Tyrrell1
1Division of Infectious Diseases, University of Alberta, Edmonton, AB, 2Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, 3Provincial Laboratory for Public Health, Edmonton, AB

P25
Galactomannan Screening Protocol in High-Risk Hematology Patients: Adherence and Outcomes
S Harricharan1, K Biederman1, AM BOMBASSARO1,2, A Lazo-Langner1,2, S Elsayed1,2, A Fulford1,2, J Delport1,2, A Xenocostas1,2
1London Health Sciences Centre, London, ON, 2Western University, London, ON

P26
ABSTRACT WITHDRAWN

P27
Z-PROFILE: Real-World Utilization and Effectiveness of Elbasvir/Grazoprevir in Adult Patients with Chronic Hepatitis C in Canada
B CONWAY1, E Tam2, C Fraser3, J Tremblay4, B Trottier4, A Ramji5, S Borgia6, K Stewart7, JB Trepanier8, Y Chalabi9
1Vancouver Infectious Diseases Centre, Vancouver, BC, 2LAIr Centre, Vancouver, BC, 3The Cool Aid Community Health Centre, Vancouver, BC, 4Centre Sida Amélit, St-Jérôme, QC, 5Clinique Mèdicale du Quartier Latin, Montréal, QC, 6GRI Research Institute (GRI), Gastroenterology Division, Vancouver, BC, 7William Osler Health System, Brampton, ON, 8Saskatchewan Infectious Disease Care Network, Saskatoon, SK, 9Merck Canada Inc., Kirkland, QC

P28
Copper Alloy Tail Pieces Reduce Bacterial Contamination of Sink Surfaces and Adjacent Air in an Intensive Care Unit
N KHAN1, S Saeed1, J Bartoszko1, V Koren1, E Plevneshi1, S Thomas1, L Wisely1, C McLeod2, A McGee1, A Vegg1
1Mount Sinai Hospital, Toronto, ON, 2Oakville Stamping and Bending, Oakville, ON

P29
Performance Characteristics of Droplet Digital PCR (ddPCR) in Clinical Virology
A CABRERA1, Y Amerniya2, M Finn2, L Yip2, A Seth1,2, S Mubareka1,2
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, 2Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON

P30
Point Prevalence Survey of Antimicrobial Use at a Tertiary Care Children’s Hospital
M ALEBEBRE1, AA Longpre, J Papenburg, D Moore
Montreal Children’s Hospital, McGill University Health Centre, Montréal, QC

P31
Development and Evaluation of Molecular Screening Assay for Legionella in Water
D YU1, F Tsang1, D Eisler1, C Tchao1, S Man1, V Yu1, B Auk1, N Prystajecky1
1British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P32
Antimicrobial Susceptibilities of Escherichia coli in Canadian Hospitals through the Analysis of Annual Antibiogram Summaries
G GERMAN1, L Pelude2, J Minion1, SM Poutanen1, B Lee1, J Davis1, K Suh7, N Thampi8, O Larics9, M-A Lefebvre1,2, C Ellis1,2, C Lavallée13, GG Zhanel13, K Amarantunga, MR Mulvey1,13, and Canadian Nosocomial Infection Surveillance Program
1Health PEI, Charlottetown, PE, 2Public Health Agency of Canada, Ottawa, ON, 3Regina Qu’Appelle Health Region, Regina, SK, 4University Health Network, Toronto, ON, 5Stollery Children’s Hospital, Edmonton, AB, 6OEI Health Sciences Centre, Halifax, NS, 7The Ottawa Hospital, Ottawa, ON, 8Children’s Hospital of Eastern Ontario, Ottawa, ON, 9Alberta Children’s Hospital, Calgary, AB, 10Montreal Children’s Hospital, Montréal, QC, 11The Moncton Hospital, Horizon Health Network, Moncton, NB, 12Hôpital Maisonneuve-Rosemont, Montréal, QC, 13University of Manitoba, Winnipeg, MB, 14Public Health Agency of Canada, Winnipeg, MB

P33
Uptake of Provincial (PEI) Empiric Guidelines Likely a Cause for Reduced C. difficile and Drug Resistant Uropathogens Based on Community and Hospital Antibiotic Use Changes
G GERMAN, J Boswell
Health PEI, Charlottetown, PE

P34
Clinical Impact of Cerebrospinal Fluid (CSF) Gram Stain and Culture, a Retrospective Cohort Study
J Joyce1, D Garcia2, P DALEY2
1University of Manitoba, Winnipeg, MB, 2Memorial University, St. John’s, NL
P35
Dengue Transmission Dynamics: Epidemiological and Geographic Identification of High Risk Settings in Medellín, Colombia
M CARABALÍ1, D Calle2, E Henao3, G Parra4, JS Kaufman1, BN Restrepo2
1McGill University, Montréal, QC, 2Universidad CES-ICMT, Medellín, Antioquia, Colombia, 3Public Health Office, Medellín, Antioquia, Colombia

P36
Real-time PCR for the Detection and Speciation of Plasmodium Infections
T LEE1, K Adie1, T Lo1, M Lee1, B Auk1, Q Wong1, N Prystajecy1,2, M Morshed1,2
1BCCDC Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P37
Automated Workflow for Bacterial Whole Genome Sequencing in a Public Health Laboratory
T LEE1, R Azana1, V Tang1, KA MacDonald1,2, B Auk1, N Prystajecky1,2, L Hoang1, M Croxen1
1BCCDC Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P38
Development and Validation of a Real-time, Reverse Transcription PCR Assay for Rapid and Low-cost Genotyping of Hepatitis C Virus Genotypes 1a, 1b, 2, and 3a
T LEE1, A Olmstead2, R Chow1, K Gunadasa1, B Auk1, M Krajden1,2, A Jassem1,2
1BCCDC Public Health Laboratory, Vancouver, BC, 2University of British Columbia, Vancouver, BC

P39
The Canadian Nosocomial Infection Surveillance Program (CNISP) a Historical Perspective: 1995 to 2016 and Beyond
JL LANGLEY1,2, C Frenette3,4, D Grave1, G Golding6, MR Mulvey5, K Amarantunga5, L Pelude5, and Canadian Nosocomial Infection Surveillance Program
1IWK Health Centre, Halifax, NS, 2Dalhousie University, Halifax, NS, 3McGill University Health Centre, Montréal, QC, 4McGill University, Montréal, QC, 5Public Health Agency of Canada, Ottawa, ON, 6Public Health Agency of Canada, Winnipeg, MB

P40
Disseminated Chronic Histoplasmosis Presenting as Acute Splenic Rupture in a Patient with Rheumatoid Arthritis Treated with Biologic Therapy
JN KANJII1,2,4, SZ Brown1,3, R Rennie1,2
1University of Alberta, Edmonton, AB, 2Provincial Laboratory for Public Health (Microbiology), Edmonton, AB, 3DynaLife Dx, Edmonton, AB, 4Missicordia Hospital, Covenant Health, Edmonton, AB

P41
Review of Primary Joint Arthroplasties at a Large Urban Community Tertiary Hospital for Potential Factors Contributing to Post-Operative Surgical Site Infections
JN KANJII1,2, S Jacka2, K Wyndham2, S Patel2, E Myles1, LR Boychuk1,2
1University of Alberta, Edmonton, AB, 2Infection Prevention & Control, Covenant Health, Edmonton, AB

P42
Bone Marrow Transplant Room Makeovers: Re-engineering Patient Rooms Can Lead to a More Sanitary Environment
E Bryce1, A Stefanovic1, T WONG1, T Woznow1, R Broady1, L Hoang3, M Croxen1
1Vancouver Coastal Health, Vancouver, BC, 2BC Centre for Disease Control, Vancouver, BC

P43
Detection of Clostridium difficile Colonization Using Rectal Swabs and Lab-Developed LAMP Assay
Y YU1, A Hadzie2, D Mertz2, P Jayaratne1,2, M Smejka1,2
1Hamilton Regional Laboratory Medicine Program, Hamilton, ON, 2McMaster University, Hamilton, ON

P44
Detection of Enteropathogens in Children with Acute Gastroenteritis Presenting with Isolated Vomiting – APPETITE Study
B LEE1, XL Pang1, R Zhuo1, B Parsons1, L Chui1, J Xie2, K Lowerson2, L Osterreicher3, S Ali3, S Freedman2
1University of Alberta, Edmonton, AB, 2University of Calgary, Calgary, AB, 3Alberta Health Services, Calgary, AB

P45
Improving Management of Clostridium difficile Infection by Direct Notification to Pharmacists
R DHAM1,2,3, Z Popovski1, S Elsayed1,2, M Juba1
1London Health Sciences Centre, London, ON, 2University of Waterloo, Waterloo, ON, 3Western University, London, ON

P46
Experience with Face-to-Face and Remote Provision of Antimicrobial Stewardship Recommendations for a General Medicine Inpatient Population
R Dhani1,2, Z Popovski1, M Juba1, S Elsayed1,3
1London Health Sciences Centre, London, ON, 2University of Waterloo, Waterloo, ON, Western University, London, ON

P47
Automated Phylogenetic Analysis of Enteric Pathogens
KA MacDonald1,2, R Azana1, T LEE2, A Paccagnella1, L Hoang1,3, M Croxen1
1University of Waterloo, Waterloo, ON, 2National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, 3Department of Pathology and Laboratory Medicine, University of British Columbia (UBC), Vancouver, BC

P48
Outbreak of Group A Streptococcus (GAS) in a Shelter for Homeless Men, Toronto, Canada
M FINKELSTEIN1,3, A McGeer1,5, H Sachdeva1,3, C Dohoo1,2, R Stuart1, E Kaplan1, D Hayden2, R Rea1,2, E Gournis1,3
1University of Toronto, Toronto, ON, 2Public Health Agency of Canada, Vancouver, BC, 3Toronto Public Health, Toronto, ON, 4University of Minnesota Medical School, Minneapolis, MN, USA, 5Mount Sinai Hospital, Toronto, ON
P49  
Resistance Patterns of enterobacteriaceae in Urines are Similar in Symptomatic and Asymptomatic Patients  
F AL DUFAIRI1, C Ellis3, L Maze Dit Mieusement4, A McGeer145, D Mertz1,2  
1McMaster University, Hamilton, ON, 2Hamilton Health Sciences, Hamilton, ON, 3The Moncton Hospital, Horizon Health Network, Moncton, NB, 4University of Toronto, Toronto, ON

P50  
Analysis of the Indigenous Microbial Community Structure Dynamics During the Biofiltration of Oil Sands Process-Affected Water (OSPW)  
L ZHANG, M Gamal El-Din  
University of Alberta, Edmonton, AB

P51  
Evaluation of Chromogenic Screening Agars for the Detection of Carbapenemase Producing Organisms (CPO) and Extended Spectrum Beta Lactamase (ESBL) Producers  
L TURNBULL1, T Dingle1,2, P Naidu1,2  
1Provincial Laboratory for Public Health, Edmonton, AB, 2University of Alberta, Edmonton, AB

P52  
Evaluation of BD MAX™ System for Confirmation of Neisseria gonorrhoeae Positive Viper XTR™ Results  
H ALMOHRI, D Leto  
LifeLabs Medical Laboratory Services, Toronto, ON

P53  
Stability of SurePath Liquid Base Cytology Samples for Detection and Genotyping of HPV on Roche cobas® 4800  
H ALMOHRI, E Nagai  
LifeLab Medical Laboratory Services, Toronto, ON

P54  
Prescriber Tendencies Influence Antibiotic Initiation, Selection and Duration in Long Term Care Facilities  
N DANEMAN1,2,3,4, MA Campitelli1,3, V Giannakes1, AM Morris1,2, CM Bell4,5,6, CJ Maxwell1, L Jeffs8, PC Austin1,5, SE Bronskill1,5  
1Institute for Clinical Evaluative Sciences, Toronto, ON, 2Sunnybrook Research Institute, Toronto, ON, 3Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, 4Dept. of Medicine, University of Toronto, Toronto, ON, 5Institute Health Policy, Management & Evaluation, Toronto, ON, 6Sunnybrook Health System, Toronto, ON, 7University of Waterloo, Waterloo, ON, 8St. Michael’s, Toronto, ON

P55  
New Technology, Best Practice Training and Improved Processes Impact Blood Culture Quality  
J. VANDERLAAN  
Grand River Hospital, Kitchener, ON

P56  
Airborne Survival and Inactivation of Human Pathogens Indoors: Studies with a Room-sized Aerobiology Chamber  
B ZARGAR1, MK Ijaz2, JR Rubino2, SA Sattar3  
1CREM Co Labs, Mississauga, ON, 2RB, Montvale, New Jersey, USA, 3University of Ottawa, Ottawa, ON

P57  
Landscape of Antimicrobial Stewardship Programs in Ontario Hospitals: 2016 Snapshot  
V LEUNG1, J Hui-Chih Wu1, B Langford1, G Garber1,2,3  
1Public Health Ontario, Toronto, ON, 2University of Toronto, Toronto, ON, 3University of Ottawa, Ottawa, ON

P58  
A Comparative Study of Conventional Identification and Disk Susceptibility Testing of Microorganisms to an Automated System Phoenix 100  
ST HAKIM1,2, SG Nadeem2, T Bashir2  
1Jinnah University for Women, Department of Microbiology, Jinnah University for Women, Karachi, Pakistan, 2Oxford College of Arts, Business and Technology, Scarborough, ON

P59  
Using Quality Improvement Methods to Sustain Optimal Antimicrobial Use in the ICU Setting  
L Jeffs1, M ZAHRADNIK1, M Law2, M Steinberg2, S Kruger2, Y Nakamachi2, CM Bell2, AM Morris2  
1St Michael’s Hospital, Toronto, ON, 2Mount Sinai Hospital, Toronto, ON, 3Brock University, St Catharines, ON

P60  
Performance of the FilmArray Respiratory Panel for the Detection of Respiratory Pathogens in Bronchoscopy Specimens  
K LOCHER1, A Stefanovic1, A Jassem2, L Hoang3, T Wong3, E Bryce3, J Grant4, D Roscoe1  
1Vancouver General Hospital, Division of Medical Microbiology and Infection Control, Vancouver, BC, 2British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC

P61  
A Comparison of eSwab™ and M40 Swabs for Testing for Group B Streptococcus Among Pregnant Women  
MH Yudin1,2, M Tadros1,2, J Nadarajah3,2, M HASSO2, C Beatty1, V Cirone1, M Lacroix1,2, M deSouza1, M Geary1,2, LM Matukas1,2  
1St. Michael’s Hospital, Toronto, ON, 2University of Toronto, Toronto, ON, 3Markham Stouffville Hospital, Toronto, ON
Poster Presentations

P62
Mandatory Infectious Disease Consultation and Adherence to an Internal Evidence-based Guideline for Candidemia: A Pre and Post Intervention Study
B GHADAKI1,2, D Mertz1
1McMaster University, Hamilton, ON, 2Niagara Health, St. Catharines, ON

P63
Escherichia coli Harbouring mcr-1 and blaNDM Plasmid Genes in a Returning Traveller from China: The Importance of Coordinated Surveillance
M Croxen1, R Azana1, D Purych2, E Brodkin3, L HOANG1
1BC Centre for Disease Control Public Health Laboratory, Vancouver, BC, 2Fraser Health Authority Medical Microbiology Laboratory, Surrey, BC, 3Fraser Health Authority Infection Prevention and Control, Surrey, BC

P64
Invasive Aspergillus Infections Post Cardiac Surgery – New lessons we learned
N ALMASSI1, MR Rezaei2, N Samiei3, MM Peighambari2
1Rajaee Heart Center, Tehran, Iran, 2Tehran Heart Center, Tehran, Iran, 3Heart Valve Disease Research Center, Rajaee Heart Center, Tehran, Iran

P65
Clinical and Echocardiographic Predictors of Embolism in Infective Endocarditis – A Systematic Review and Meta-Analysis
A YANG1, C Tan1, N Daneman1,2, M Hansen1,2, G Cohen1,2, K Boyle1,2, N Adhikari1,2
1University of Toronto, Toronto, ON, 2Sunnybrook Health Sciences Centre, Toronto, ON

P66
Neutropenia Rates of Antiviral Prophylaxis in CMV High Risk Solid Organ Transplant Recipients
S BELGA, C Hernandez, D Kabbani, K Doucette, S Fuentes, D Chiang, C Cervera-Alvarez
University of Alberta, Edmonton, AB

P67
The Customization and Development of an Automated Electronic Health Record Surveillance System for Detection and Reporting of Hospital Acquired Infections
R MEDFORD1,2, S Thomas2
1Stanford University School of Medicine, Division of Clinical Informatics, Palo Alto, California, USA, 2Lucile Packard Children's Hospital: Stanford Children's Health, Palo Alto, California, USA

P68
Investigating the Epidemiology of Resistance and Virulence Genes in Listeria monocytogenes using BioNumerics® 7.6
B WEST, K Vranckx, K De Bruyne, H Pouseele
Applied Maths, Sint-Martens-Latem, Belgium

P69
Provider Education Strategies to Decrease Ciprofloxacin Prescriptions in Patients with Acute Uncomplicated Cystitis
J DICKTER1, R Guo2, D Nguyen7, K Nguyen2, S Park2, S Ko2, V Chiu2, P Cho2
1City of Hope, Duarte, CA, USA, 2Kaiser Permanente, Fontana, CA, USA

P70
Severe Human Respiratory Bocavirus Infection; Time to Acknowledge It!
S NASSIR, S Malik
Hereford County hospital, Hereford, UK

P71
Risk Factors for Mortality in Patients with Pseudomonas aeruginosa Bacteremia
D YAHAV1,2, Y Weissman1,2, L Leibovici1,2
1Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel, 2Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel

P72
Is the Time Ripe to Begin Routine Susceptibility Testing for Candida albicans Isolated from Blood Stream Infections?
S CHOU DHURY
Tan Tock Seng Hospital, Singapore, Singapore
<table>
<thead>
<tr>
<th>Author</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td></td>
</tr>
<tr>
<td>K</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td></td>
</tr>
<tr>
<td>O</td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
</tr>
<tr>
<td>Q</td>
<td></td>
</tr>
<tr>
<td>R</td>
<td></td>
</tr>
<tr>
<td>S</td>
<td></td>
</tr>
<tr>
<td>T</td>
<td></td>
</tr>
<tr>
<td>U</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
</tr>
<tr>
<td>W</td>
<td></td>
</tr>
<tr>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>Z</td>
<td></td>
</tr>
</tbody>
</table>
Author Index

K

Kabbani D
Kadivar K
Kadkhoda K
Kain K
Kalina D
Kamhuka L
Kan T
Kandel C
Kang KT
Kanj JN
Kaplan E
Kapoor A
Karlskowsky JA
Kasper K
Kassam S
Katz KC
Kaufman J
Kaufman JS
Keenan R
Kerr T
Khan S
Khan N
Kiani G
Kibsey P
Kim J
Kim H
Kim SH
Kim HC
Kiwim EM
Kisssoo M
Klein C
Ko S
Kohler P
Koivu S
Kong LY
Konzie N
Koren V
Kosar J
Kowalewska-Grochowska K
Krajeńska R
Krause P
Kruger S
Kumar A
Kunimoto D
Kupis J

L

Labbé A-C
Lacap P
Lacroix M
Laczo D
Lagacé-Wiens P
Lam L
Lamongagne F
Lang R
Lang A
Langella C
Langford B
Langley JM
Larios O
Lauzier F
Lavalée C
Lavoie S
Law M
Lazo-Langner A
Lebel P
Leblanc JJ
Lee BE
Lee S
Lee M-K
Lee TC
Lee C
Lee R
Lee T

Lee M
Lefebvre B
Lefebvre M-A
Leibovici L
Leis JA
Lerny M
Lermitte C
Lévesque S
Levetz P
Li A
Libin PM
Libman M
Lim A
Lindsay LR
Liu S
Lo P
Locher K
Long R
Longpré AA
Longtin Y
Longtin J
Loomer C
Lothier S
Lowe C
Lowerison K
Luinstra K
Lundeberg R

M

MacDonald C
MacDonald KA
Mah A
Mah R
Mahe E
Main C
Mak A
Makaroff S
Makil S
Man S
Mangat C

Manji F
Manns B
Mansfield A
Marek C
Marra F
Marshall JC
Marshall B
Martin CM
Masloko A
Masud S
Matasaje L
Matasje Matic
Matasje
Matasje
Matasje
Matasje
Matasje
Matasje
Matasje
Matasje
Matasje
Matasje
Matasje

May 3–6 mai | Sheraton Centre Toronto
AMMI Canada — CACMID
Annual Conference
Conférence annuelle
AMMI Canada — CACMID
Annual Conference
Conférence annuelle
AMMI Canada — CACMID
Annual Conference
Conférence annuelle
AMMI Canada — CACMID
Annual Conference
Conférence annuelle
Author Index

Shokoples S  
G01, H01
Shumilak G  
C05, K02
Silverman M  
K02, SP10, SP16, IP07
Simmonds KA  
A03, C02, E01.S P21
Simor AE  
B05, G05, I04, K05, P18, SP12, SP30, IP05
Simpson Y  
J03
Singh A  
P19, P21
Sis B  
SP43
Skinner S  
C03, SP04
Sligl W  
B01
Smieja M  
J04, J05, P43, SP06, SP29
Smirra S  
F01
Smith S  
B04, E01.S, I03, I05, K05
Smith JD  
SP48
Smyczek P  
P21
Sniatynski M  
SP37
So J  
B04, K05
Southern Ontario Fecal Transplant (SOFT) Group  
C01
Speare R  
F04.S
Speicher D  
SP29
Srigley JA  
B04, G07, K05, P08
Stadnyk M  
SP04
Stagg P  
I04, K05
Stefanovic A  
I06, L04, P42, P60
Steinberg M  
IP08, P59
Stelfox HT  
B01
Stevens E  
C05
Stewart K  
C05, P27
Stewart S  
K02
Stone J  
SP25
Striha M  
E05
Stroud B  
G06
Stuart R  
P48
Suh K  
B04, B05, I04, P32
Summer S  
C04.S
Sung M  
SP32
Surangiwala S  
C01, G02, L05, P01
Tan C  
SP13
Tan DHS  
SP18
Tan C  
P65, SP38
Tang V  
P37
Tannerbaum D  
IP08
Tapiero B  
F03.S
Tardif G  
H02
Tarr P  
A01.S
Tat-Ko J  
B04, I03, I04, I05, P05
Taylor G  
A05, P31
Tchao C  
P04
Terrerick J  
J02
Thakur SD  
B04, I02.S, K03, P32
Thampi N  
B05
Thirion D  
P28, P67
Thomas S  
P14
Thomas-Reilly RG  
SP02
Thomson G  
K04.S
Tijet N  
SP36
Tilley P  
SP47
Ting J  
SP47
Tipples G  
G04
Toye R  
P27
Tremblay J  
P27
Trepanier JB  
P27
Trimi X  
SP28
Trottier S  
P02
Trottier B  
P27
Truong C  
SP39
Tsang R  
H07
Tsang C  
P01
Tsang F  
A05, P31
Tullis E  
SP21
Turenne C  
P02
Turnbull L  
G01, P05, P51
Tyndall M  
J03
Tyrell G  
I01.S, L02.S, P24
Ugarte-Torres A  
L03.S
Ulanaova M  
H07
Urch B  
IP11
Usman H  
H01
Uyaguar Diaz Ml  
P16
V  
Vadboncoeur J  
F02
Vanderkooi O  
A01.S
Van Derlaan J  
P55
VanRooyselaar L  
IP01
Varyalural J  
E01.S
Vu Ngoc Minh  
B04, K05, IP01
Vegh A  
P28
Venne S  
F05.S, J01.S
Vermeerken C  
A02
Vinh DC  
SP17
Vivona S  
SP20, SP22
Vogel D  
SP39
Voit B  
H02
Vranckx K  
P68
Vrbova L  
P14
W  
Waldner DA  
K01, IP06
Walker S  
P02
Walkty A  
G07
Wang B  
SP21
Wang P  
SP31
Wang X  
SP02
Waters V  
K01
Webber E  
A02
Weese S  
J04, J05
Weinbaum B  
P09
Weissman Y  
P67
Welsh P  
P13
West B  
P43
Werry D  
P61
Wessel MH  
Yuen K  
A03
X  
Xenocostas A  
P25
Xie J  
A01.S, P44
Y  
Yahav D  
P71
Yang A  
P65, SP13, SP38
Yang N  
SP39
Yau Y  
P02
Yen M  
P29, SP45
Yip L  
A02
Yu D  
P31
Yu V  
P43
Yudin MH  
P61
Z  
Zagorovsky K  
SP09
Zahradnik M  
P59
Zapernick L  
P06
Zargar B  
P56
Zerna C.  
P50
Zhanel GG  
P06
Zhang Y  
P21
Zhang L  
P12
Zhao B  
K03
Zhao Z  
P05
Zhanel G  
P05
Zhang L  
A01.S
Zhang Y  
P41
Zhau R  
P14
Ziegler C  
A03
Zulfifar A  
SP39

47 | AMMI Canada • CACMID Annual Conference | Conférence annuelle
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al Sidairi, Hilal</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ambrose, Paul</td>
<td>CCM Workshop Speaker</td>
<td>Advisory Board: Arsanis, Cempra, Cidara, Entasis, Spero, VenatoRx, Zevante (either through projects related to ICPD or as a consultant). Grants: Achaogen, Cellceutix, Cidara, Cubist, Debiopharm, Geom, GSK, Insmed, MedCo., Meiji, Melinta, Paratek, Poly-Medix, Polyphor, Roche, Tetraphase, USCAST, Wockhardt; Zavante (received as ICPD funding). Honoraria: Cidara, Motif Biosciences, Nabriva, Roche, Tetraphase and University of Toledo (consultant work)</td>
</tr>
<tr>
<td>Barrett, Lisa</td>
<td>Trainees’ Day Speaker</td>
<td>Advisory Board: Abbvie, Viiv, Merck, Gilead, BMS, Independent unrestricted grant (Investigator-initiated study); Gilead; Clinical Trial Site: Abbvie, Merck</td>
</tr>
<tr>
<td>Blondel-Hill, Edith</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Boissonneault, Vincent</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Bolotin, Shelly</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Borgundvaag, Emily</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Bonin, Jannie</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Boutin, Catherine-Audrey</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Brooks, Annie</td>
<td>Oral Presenter</td>
<td>Advisory Board: Merck</td>
</tr>
<tr>
<td>Chahil, Navdeep</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Chakrabarti, Surnon</td>
<td>Plenary Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Charlton, Carmen</td>
<td>Central Planning Committee</td>
<td>In-kind (kits for validation): Biorad, Roche, Siemens; Grant: Merck</td>
</tr>
<tr>
<td>Chen, Justin</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Cherian, Sarah</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Chernesky, Max</td>
<td>Oral Presenter</td>
<td>Payment: Hologic (funding to present data at meetings)</td>
</tr>
<tr>
<td>Chiu, Isabelle</td>
<td>Central and Scientific Planning Committees</td>
<td>Advisory Board: Cubist (now Merck), Janssen, Merck, Sunovion; Speakers bureau: Merck, Sunovion; Payment/Grants: Cubist (now Merck), Janssen, Merck, Sunovion; Clinical trial via University of Alberta Division of ID Clinical Trials (no direct financial transactions)</td>
</tr>
<tr>
<td>Chui, Linda</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Connors, William</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Cooper, Curtis</td>
<td>State of the Art Lecturer</td>
<td>Advisory Board: Gilead, Abbvie, Merck (re: HCV), Speakers bureau: Gilead, Abbvie, Merck, Bristol-Myers Squibb (re: HCV); Payment: Gilead, Abbvie, Merck, Bristol-Myers Squibb (role on ad board); Grants: Gilead, Abbvie, Merck (HCV program support and research); Clinical Trials: Gilead, Abbvie, Merck (re: HCV)</td>
</tr>
<tr>
<td>Crowcroft, Natasha</td>
<td>Plenary Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Dalton, Bruce R.</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Daneman, Nick</td>
<td>Workshop Speaker/ Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Dey, Meghan</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Dillon, Jo-Anne R.</td>
<td>Workshop Speaker/ Oral Presenter</td>
<td>Payment: Hologic (speaker expenses)</td>
</tr>
<tr>
<td>Drebolt, Michael</td>
<td>Plenary Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Drews, Steven J.</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ellis, Chelsey</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Evans, Gerald</td>
<td>Scientific Planning Committee</td>
<td>Clinical Trial: Astellas (Isavaconazole study)</td>
</tr>
<tr>
<td>Forgic, Gerald</td>
<td>Plenary Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Friedman, Daniel</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Fuller, Jeff</td>
<td>Central Planning Committee/Oral Presenter</td>
<td>Grants: Amplyx Pharmaceuticals, Astellas, Merck, Pfizer (antifungal susceptibility testing and surveillance)</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Disclosure</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Furuya, Andrea M.</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Gaudreault, Éric</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>German, Gregory</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Gilmour, Matthew W.</td>
<td>Central and Scientific Planning Committees</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Golden, Alyssa</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Goneau, Lee</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Gregson, Daniel B.</td>
<td>Central Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Haider, Shariq</td>
<td>Central Planning Committee</td>
<td>Advisory Board: Merck, Gilead, Abbvie; Clinical Trials: Merck, Abbvie</td>
</tr>
<tr>
<td>Hatchette, Todd F.</td>
<td>Central and Scientific Planning Committees/ Oral Presenter</td>
<td>Grants: GSK/Pfizer (Investigator initiated collaborative research agreement - anchor lab for the SOS network looking at vaccine effectiveness and CAP (S. McNeil PI))</td>
</tr>
<tr>
<td>Hoang, Linda</td>
<td>Trainees’ Day Speaker/ Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Jain, Shilpa</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Jang, Dan</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Jassem, Agatha</td>
<td>Trainees’ Day Speaker/ Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Jayaratne, Padman</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Johnstone, Jennie</td>
<td>Scientific Planning Committee/ Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Kadkhoda, Kamran</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Kahlmeter, Gunnar</td>
<td>CCM Workshop Speaker</td>
<td>Payment: Thermo Fisher (following technical advice primarily on disc quality control)</td>
</tr>
<tr>
<td>Katz, Kevin</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Disclosure</td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Keystone, Jay S.</td>
<td>Trainees’ Day Speaker</td>
<td>Advisory Board: Valneva (Japanese encephalitis vaccine), Speakers Bureau: Merck, Frosst, Sanofi, Valneva (adult immunizations)</td>
</tr>
<tr>
<td>Klein, Sabra L.</td>
<td>Special Lecturer</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Kozak, Robert</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Labbé, Annie-Claude</td>
<td>Workshop Speaker/ Oral Presenter</td>
<td>Advisory Board: Merck (C. difficile Infection Consultation Meeting), Roche (Herpes simplex infections: laboratory diagnostic tests); Payment: Hologic (speaker expenses); Grants: Sunovion and Merck (coordination of professional development program), Lab Studies: Abbott, BD, Cepheid, Hologic, Roche (co-investigator of a provincial lab study), Roche (supervisor for a contract with the laboratory)</td>
</tr>
<tr>
<td>LeBlanc, Jason</td>
<td>Oral Presenter</td>
<td>Grants: Pfizer, Merck, GSK (honorarium/ expenses for presentations from Pfizer and Merck, grants by CIHR SOS funded in part by Pfizer and GSK)</td>
</tr>
<tr>
<td>Leis, Jerome A.</td>
<td>Plenary Speaker/ Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Levett, Paul N.</td>
<td>Central and Scientific Planning Committees</td>
<td>Advisory Board: Roche Diagnostics (molecular diagnostics); Honorarium: Roche Diagnostics (for attending advisory board).</td>
</tr>
<tr>
<td>Levine, Donald P.</td>
<td>Workshop Speaker</td>
<td>Advisory Board: Actavis, Allergan, Forest, Genentech, Theravance, Melinta, Contrafect, Novartis, Speakers Bureau: Actavis, Forest, Merck, Sunovion; Payments: Actavis, Forest, Merck, Sunovion (honoraria for consulting or speaking); Grants: NIH, AstraZeneca, Allergan, Cubist (for industry sponsored and investigator initiated research); Clinical Trial: Novartis (adjudication panel for a funded study); Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. &quot;off-label&quot; use of medication)</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Disclosure</td>
</tr>
<tr>
<td>--------------------</td>
<td>-------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Li, Lisa</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Libman, Michael</td>
<td>Plenary Speaker</td>
<td>Clinical Trials: Medicago (principal investigator for influenza vaccine)</td>
</tr>
<tr>
<td>Louie, Thomas</td>
<td>Trainees’ Day Speaker</td>
<td>Advisory board: Actelion (for cadazolid); Rebiotix (FM); BioK+; Payment: Merck, BioK (meeting costs); Grant: Actelion (microbiome research); Patent: Optimer/Cubiet/Merck (2007 patent on microbiome sparing properties); Clinical Trial: Actelion, Pfizer Strive (C. difficile staph vaccine)</td>
</tr>
<tr>
<td>Lowe, Christopher</td>
<td>Scientific Planning Committee</td>
<td>Honorarium: Pendopharm (attendance at a board meeting to discuss telavacin indications and microbiology testing); Clinical Trial: Sage Products, L.L.P (research grant for trial of chlorhexidine gluconate, investigator initiated)</td>
</tr>
<tr>
<td>MacDonald, Clayton</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Marek, Caitlyn</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Masud, Shazia</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Matic, Nancy</td>
<td>Trainees’ Day and Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Mazzulli, Tony</td>
<td>Integrated Symposium Speaker</td>
<td>Advisory Board: Merck, Pfizer, Speakers Bureau; Merck (speaker honorarium); Clinical Trials: Qvella (blood culture study)</td>
</tr>
<tr>
<td>McCabe, Mark</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Minion, Jessica</td>
<td>Central Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Morshed, Muhammad</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Mulvey, Michael</td>
<td>Plenary Speaker/ Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Nadarajah, Jeya</td>
<td>Trainees’ Day Speaker</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Nagai, Esther</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>O’Donnell, Shauna</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Oughton, Matthew</td>
<td>Scientific Planning Committee</td>
<td>Honorarium: Merck (presented on therapies for MDROs)</td>
</tr>
<tr>
<td>Pang, Xiaoli</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Parsons, Brendon</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Paterson, Aimee</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Patrick, David</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Penney, Carla</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Petrich, Astrid</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Poole, Doris</td>
<td>Scientific Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Poutanen, Susan M.</td>
<td>Scientific Planning Committee/ State of the Art Lecturer/ Workshop Speaker</td>
<td>Advisory Board: Accelerate Diagnostics, Merck, Paladin Labs; Grants: Accelerate Diagnostics and Bio-Rad, Honorarium: Merck (speaking events)</td>
</tr>
<tr>
<td>Quach, Caroline</td>
<td>Central Planning Committee</td>
<td>Grants: GSK, Pfizer, AbbVie, Sage (PI-initiated, paid to institution), Co-chair of the MUHC Vaccine Study Centre where clinical trials are run</td>
</tr>
<tr>
<td>Remington, Leah T.</td>
<td>Oral Presenter</td>
<td>Honorarium: Gilead (for speaking)</td>
</tr>
<tr>
<td>Rennie, Robert (Bob)</td>
<td>Scientific Planning Committee/ Plenary Speaker/ CCM Workshop Speaker</td>
<td>Advisory Board: Thermo Fisher Scientific (Clinical Risk Assessments); Honoraria: Thermo Fisher Scientific, Copan Italia</td>
</tr>
<tr>
<td>Rezaeeaval, Maryam</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Rymer, Wendy</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Roscoe, Diane</td>
<td>Oral Presenter</td>
<td>Grant: bioMérieux (Study: Impact of the use of rapid respiratory pathogen testing)</td>
</tr>
<tr>
<td>Rubin, Earl</td>
<td>Scientific Planning Committee</td>
<td>Clinical Trials: Merck (investigator or co-investigator for vaccine trials carried out at the McGill Vaccine Centre)</td>
</tr>
<tr>
<td>Savaryn, Bohdan</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Schreiber, Yoko</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Sekirov, Inna</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Disclosure</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Shafran, Stephen D.</td>
<td>Trainees’ Day Speaker</td>
<td>Advisory Board: Gilead, Merck, Honoraria: Bristol-Myers Squibb, Gilead, Pfizer, Merck (for lectures); Clinical Trials: conduct antiviral drugs sponsored by AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck</td>
</tr>
<tr>
<td>Simor, Andrew</td>
<td>Central Planning Committee</td>
<td>Advisory Board: Merck Canada, Honoraria: Merck (as advisory board member and as speaker)</td>
</tr>
<tr>
<td>Skinner, Stuart</td>
<td>Oral Presenter</td>
<td>Grants: Gilead Sciences, Merck, Viiv Healthcare, and Abbvie. Advisory Board: Merck and Viiv</td>
</tr>
<tr>
<td>Smith, Stephanie</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Srigley, Jocelyn A.</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Stokes, William</td>
<td>Trainees’ Day Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Tsang, Frankie</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Turelle, Christine</td>
<td>Central and Scientific Planning Committees</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ugar-Te-Torres, Alejandra</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Ulanova, Marina</td>
<td>Oral Presenter</td>
<td>Grant: Pfizer (Investigator-initiated research unrelated to presentation) Clinical Trial: Pfizer (unrelated to presentation)</td>
</tr>
<tr>
<td>Vayalumkal, Joseph</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Wadhva, Anupma</td>
<td>Planning Committee</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Waldner, David</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Willey, Barbara</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Wong, Titus</td>
<td>Scientific Planning Committee/Oral Presenter</td>
<td>Advisory Board: Merck; Payment: Theravance; Grants: Biomerieux, Teck; Clinical Trial: Pfizer</td>
</tr>
<tr>
<td>Wright, Alissa</td>
<td>Integrated Symposium Speaker</td>
<td>Grants: Astellas, Merck, Pendopharm (speaking at conferences – grants were unrestricted companies had no say into final talks; has participated in meetings on ceftolozane/tazobactam, telavancin, and Merck’s CMV/antifungal meeting); Clinical Trials: Gilead, Shire (unsuccessful attempt to open study site for NCT02254408, now attempting to open study site for NCT02927067); Intends to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication)</td>
</tr>
<tr>
<td>Wudel, Beverly</td>
<td>Oral Presenter</td>
<td>No Conflict Declared</td>
</tr>
<tr>
<td>Zhanel, George G.</td>
<td>Plenary Speaker</td>
<td>Research Grants: Achaogen, Astellas, Paratek, Merck, Pfizer, TMC; Sunovion; Tetraphase, Paladin labs</td>
</tr>
</tbody>
</table>
Barrett, Lisa
Dr. Lisa Barrett is Assistant Professor in the Division of Infectious Diseases and Department of Microbiology and Immunology at Dalhousie University in Halifax. She is Royal College certified in Internal Medicine and Infectious Disease and is also a viral immunologist studying chronic viral infection. She utilizes hepatitis C and HIV treatment and cure to study immune aging, as well as models of health care delivery that support disease elimination.

Chakrabarti, Sumon
Dr. Sumon Chakrabarti is originally from Sarnia, ON, and did his MD at University of Western Ontario (Schulich School of Medicine) and his internal medicine and infectious diseases residencies at University of Toronto. He has a special interest in tropical medicine, and specifically in imported diseases and post-travel medicine. He did extra training in tropical medicine with Dr. Jay Keystone at Toronto General Hospital and also got his Diploma of Tropical Medicine & Hygiene from Universidad Peruana Cayetano Heredia in Lima, Peru. Currently he works as an Infectious Diseases consultant at Trillium Health Centre in Mississauga Ontario. Aside from his clinical duties, he has an administration role as the Division Head for Infectious diseases and is also involved in medical education as the Internal Medicine Clerkship lead.

In his spare time he loves to play guitar, is an avid Blue Jays & Montreal Canadiens fan, and is one of the few people who still actively watches pre-1990 Doctor Who, by choice.

Cooper, Curtis
Dr. Curtis Cooper trained at the University of Saskatchewan (MD 1994). He received certification in Internal Medicine in 1997 and in Infectious Diseases in 1999 while at the University of Manitoba. He completed an HIV Research Fellowship and Masters of Epidemiology in 2002 at the University of Ottawa. He is currently an Associate Professor with the University of Ottawa, Scientist with the Ottawa Hospital Research Institute, Infectious Diseases Consultant with the Ottawa Hospital Division of Infectious Diseases and Director of The Ottawa Hospital Viral Hepatitis Program. He holds an Applied HIV Research Chair with the Ontario HIV Treatment Network. As a clinical researcher, his research activities encompass viral hepatitis, HIV, and vaccine development. His work is focused on the development of new therapeutic agents and the delivery of treatment that maximizes safety, adherence and effectiveness. He is an active researcher with several cohort studies (CANOC, OHTN Cohort Study, CanHepC). He is president of the Canadian Association for HIV Researcher, member of MAC-FI on HIV, and co-chair of the CIHR Canadian HIV Trials Network Co-Infection Core research group.

Crowcroft, Natasha
Dr. Natasha Crowcroft is Chief of Applied Immunization Research at Public Health Ontario and a Professor in Laboratory Medicine and Pathobiology and the Dalla Lana School of Public Health at the University of Toronto. She is a practicing public health physician with 25 years’ experience, of which nearly a decade has been in Canada. She has contributed to nearly 200 scientific papers and is an active researcher in the Canadian Immunization Research Network (CIRN). Dr. Crowcroft was a member of the Canadian National Advisory Committee on Immunization (NACI) from 2008-2013 and is a current member of the NACI Pertussis working group. She is also currently a member of the WHO Strategic Advisory Group of Experts Working Group on Measles and Rubella, the South East Asia Regional Office Measles and Rubella Regional Verification Committee, and PAHO’s International Expert Committee. She is an Associate Editor for Eurosurveillance and an International Board Member for Lancet Infectious Diseases. She trained in public health and preventive medicine in the UK and is an alumna of the European Programme for Intervention Epidemiology Training (EPIET).

Daneman, Nick
Dr. Nick Daneman is a clinician scientist in the division of infectious diseases at Sunnybrook Health Sciences Centre, is cross-appointed in the institute of Health Policy Management and Evaluation, at the University of Toronto, and is an adjunct scientist at the Institute for Clinical Evaluative Sciences. He is supported by a Clinician Scientist salary award from the Canadian Institute for Health Research. Using hospital, clinical trial, and population-based data sources, his research program aims to optimize the treatment and prevention of healthcare associated infection, with overlapping themes including antibiotic stewardship, critical care infections and C. difficile.

Dillon, Jo-Anne R.
Dr. Jo-Anne R. Dillon PhD, FCAHS, FRSc is Professor and Head of the Department of Microbiology and Immunology, College of Medicine and a Research Scientist at the Vaccine and Infectious Disease Organization – International Vaccine Centre (University of Saskatchewan, Saskatoon, Canada). Her major research interests include the biology and molecular epidemiology of sexually transmissible diseases, in particular Neisseria gonorrhoeae and the surveillance and molecular biology of antimicrobial resistance. Dr. Dillon has extensive academic and public sector administrative leadership experience, has led several national and international scientific organizations, and has consulted nationally and internationally in the area of STIs and public health. Dr. Dillon has authored numerous publications with a special focus on international trends in antimicrobial resistance, molecular typing of bacterial pathogens and the cell biology of Neisseria gonorrhoeae. She is a Fellow of the Canadian Academy of Health Sciences and the Royal Society of Canada.

Drebot, Michael
Dr. Michael Drebot received his PhD in Microbiology in 1988 from Dalhousie University and was then awarded a postdoctoral fellowship in genetics from the Hospital for
Forgie, Sarah
Dr. Sarah Forgie received a BSc in Microbiology and Immunology from the University of Toronto, and completed her MD and specialty training at the University of Manitoba. She joined the University of Alberta in the Department of Pediatrics in 2003 where she is currently a Professor in the Division of Infectious Diseases. She has been awarded many teaching awards including the 3M National Teaching Fellowship in 2012, and she recently completed a Master’s in Education from the University of Alberta. Sarah’s research focuses on innovative medical education interventions and infection prevention. She has also performed many administrative duties including being the Site Medical Lead for Infection Prevention and Control at the Stollery Children’s Hospital for over a decade, and in the fall of 2015, she was appointed Vice-Provost (Learning Initiatives) at the University of Alberta.

Hoang, Linda
Dr. Linda Hoang received her Master’s and Medical Degrees from UBC and is FRCP(C) qualified in Medical Microbiology (UBC). She also obtained a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Epidemiology, UK. Dr. Hoang has been formally based at the BC Centre for Disease Control as the Program Head for Bacteriology & Mycology laboratory since 2006, but has been involved in BCCDC-led projects in Vietnam and BC starting in 1998. She enjoys teaching and is the BCCDC site-supervisor for the UBC Medical Microbiology Residency Training Program. Her clinical and academic interests include agents of bioterrorism and containment level-3 pathogens, healthcare-acquired infections and antibiotic resistant organisms such as carbapenemase producing organisms, Cryptococcus gattii, and enteric bacterial pathogens related outbreaks in BC.

Jassem, Agatha
Dr. Agatha Jassem is a Clinical Microbiologist at the BCCDC Public Health Laboratory and a Clinical Assistant Professor at the UBC Department of Pathology and Laboratory Medicine. Agatha completed her PhD at UBC and was a Fellows at the National Institutes of Health Clinical Centers. Agatha’s research focuses on the detection and characterization of healthcare- and community-associated infections, emerging pathogens, and drug resistance determinants. In particular, she is interested in evaluating novel comprehensive molecular- and genomic-based techniques for routine clinical and epidemiological use. She is also passionate about teaching and science communication, having been involved in several outreach initiatives and University-based courses.

Keystone, Jay S.
Dr. Jay Keystone graduated from University of Toronto Medical School, studied internal medicine at the University of Michigan Medical Center and tropical medicine at the London School of Hygiene and tropical medicine. He has worked in Africa, India and South America. Currently, he is a staff physician at the Tropical Disease unit, Toronto General Hospital, the Director of Toronto Mediys and Queens University Travel Medicine Clinics, and Professor of Medicine at the University of Toronto. In 2008 he was awarded the Ben Kean medal from the American Society of Tropical Medicine for excellence in teaching and mentoring, and in 2015, the Order of Canada for his contributions as a clinician and educator in expanding the discipline of tropical and travel medicine.

Klein, Sabra L.
Dr. Sabra L. Klein received her B.A. in Psychology from Randolph-Macon College, her M.S. from the University of Georgia in Biological Psychology, and her Ph.D. in Behavioral Neuroscience from Johns Hopkins University. She did postdoctoral training at the Johns Hopkins Bloomberg School of Public Health in Molecular Microbiology and Immunology where she is now an Associate Professor. Dr. Klein is an expert on sex differences in immune responses and susceptibility to infection, with 100 peer-reviewed publications, several book chapters, and two edited books on the broad topics of sex differences in response to infection and treatments for infectious diseases. During the 2009 influenza pandemic, she was commissioned by the WHO to publish a report on the impact of sex, gender, and pregnancy on the outcome of influenza virus infection. Dr. Klein also has
Labbé, Annie-Claude
Dr. Annie-Claude Labbé is an Infectious Diseases Specialist and Medical Microbiologist at the Hôpital Maisonneuve-Rosemont and an Associate Professor in the Department of Infectious Diseases, Microbiology and Immunology at the Université de Montréal. She is a member of the expert working group for the development and revisions of the Canadian STI Guidelines as well as the Comité sur les infections transmissibles sexuellement et par le sang (CITSS). Dr. Labbé is also the president of the Comité sur les analyses de laboratoire en lien avec les ITSS (CALI) of the Institut national de santé publique du Québec. She is a member of AMMI Canada’s Grants and Awards committee and coauthor of 77 peer-reviewed journal publications.

Levine, Donald P.
Dr. Donald P. Levine earned his doctor of medicine degree from Wayne State University School of Medicine, Detroit, Michigan in 1972 and completed his internship and residency at Wayne State from 1972 to 1975. He was an infectious diseases fellow at Wayne State University from 1975 through 1977 and a special fellow of the National Institute of Neurological andCommunicative Diseases and Stroke from 1977-1978. Dr. Levine joined the faculty of the Department of Medicine at Wayne State University in 1978 and was named professor of medicine in 1994 and Professor Emeritus in 2016. He was interim chief of Infectious Disease in 1984-1985 and chief of the Division of General Internal Medicine from 2000-2012. He became Assistant Chair for Continuing Medical Education and Community Affairs from 2012-2015. Dr. Levine is board certified in internal medicine and infectious diseases. Dr. Levine has been involved in clinical research on antimicrobials since 1981, and his numerous scientific writings include more than 100 original peer-reviewed publications and book chapters, and presentations at international, national, and local meetings spanning 30 years. Dr. Levine is a member or fellow of several professional organizations, among them the American College of Physicians, Society of General Internal Medicine, Infectious Diseases Society of America, the American Society for Microbiology, and the International Society for Cardiovascular Infectious Diseases.

Libman, Michael
Dr. Michael Libman is director of the J.D. MacLean Centre for Tropical Diseases at McGill University and former Director of the Division of Infectious Diseases at McGill University and the McGill University Health Centre. He holds specialty certifications in Internal Medicine, Infectious Diseases, and Medical Microbiology from the Royal College of Physicians and Surgeons of Canada. He holds the academic rank of Professor in the Department of Medicine at McGill University. He has worked at the McGill Centre for Tropical Disease for over 20 years. This is a fairly unique clinical unit which combines daily tropical medicine clinics serving a wide variety of travelers, immigrants, and visitors, a large pre-travel clinic, a regional reference centre for clinical parasitology and the Canadian national reference centre for parasite serology and molecular diagnostics. He directs the teaching of tropical medicine through the Centre, which has become a training unit for residents and fellows from universities throughout Quebec and Canada. He works as a visiting professor in the Infectious Disease training program at Addis Ababa University, Ethiopia and a co-director of the annual international course in tropical medicine given at the Christian Medical College in Vellore, India. His research interests have focused mostly on the effective use and interpretation of diagnostic testing procedures, and the epidemiology of imported infections.

Louie, Thomas
Dr. Thomas Louie MD, FRCPC, completed ID training at UCLA and Tufts University with Drs. Sherwood Gorbach and John Bartlett as supervisors in the mid-1970s. Since
returning to Canada in 1978, he has been attending physician and infection control officer in hospitals in Winnipeg and Calgary. Throughout his career, an interaction with the pharmaceutical industry where better patient care and advancement of biotherapeutics intersect, and which fulfill criteria for academic excellence has been pursued. Interactions between individual physicians, groups of physicians including trainees and the objectives developing out of pharmaceutical research interests should be carefully considered, depending on the case mix available, position of team ID/MM in the provision of primary versus consultative care, logistical and cost structure of studies, and the significance of the research objective. For the past 15 years, one of the areas of interest has been treatment of C. difficile infections.

**Mazzulli, Tony**

Dr. Tony Mazzulli specialized in Internal Medicine, Infectious Diseases and Medical Microbiology at the University of Toronto. Prior to coming on staff at Mount Sinai Hospital, he spent two years as an MRC Fellow at the Massachusetts General Hospital, Harvard University, studying antiviral resistance in HIV.

He is the Microbiologist-in-Chief and an Infectious Diseases Specialist at Mount Sinai Hospital and University Health Network as well as a staff Microbiologist at Public Health Ontario Laboratories. He is a Professor in the Departments of Medicine and Laboratory Medicine and Pathobiology at the University of Toronto. He is the Program Director for the Medical Microbiology Residency Program, the Postdoctoral Training (Diploma) Program in Clinical Microbiology and the Postgraduate Medical Education Programs in the Faculty of Medicine at the University of Toronto. His primary research interests include antiviral drug susceptibility testing, mechanisms of anti-viral resistance and rapid diagnostic testing. He is involved in studies looking at the epidemiology of antimicrobial resistance in urinary tract pathogens and respiratory pathogens. Dr. Mazzulli is the current president of the Canadian Association of HIV Clinical Laboratory Specialists (CAHCLS) and an active member of several hospital and non-hospital committees and organizations.

He has been the recipient of several teaching awards in recognition of his achievements and the esteem in which he is held by medical and undergraduate students.

**Mulvey, Michael**

Dr. Michael Mulvey obtained his Ph.D. from the University of Manitoba in 1990 where he discovered rpoS, the gene responsible for the stationary phase regulon in E. coli. After a post-doc studying picornavirus infection at University of Alberta, he moved to Health Canada in 1996, now the Public Health Agency of Canada, where he established the Antimicrobial Resistance and Nosocomial Infections (ARNI) Laboratory. ARNI provides diagnostic and outbreak investigation services to reference and clinical labs in Canada. The ARNI laboratory also provides support for numerous surveillance programs focused on antimicrobial resistance involving MRSA, VRE, C. difficile, ESBL/carbapenemase producers, Streptococci, and Neisseria gonorrhoeae. He is also responsible for tracking AMR in Salmonella and E. coli from farm to fork.

Dr. Mulvey’s research interests include the molecular mechanisms and epidemiology of antimicrobial resistance and the translation of resistance data into interventions to limit the spread of resistant organisms. He has co-authored over 210 peer-reviewed publications.

Dr. Mulvey is the Co-Chair of the Canadian Public Health Laboratory Network Working Group on AMR, sits on the Executive Board of the Canadian Committee on Antimicrobial Susceptibility Testing (CANCAST), is a member of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee on the role of whole genome sequencing in antimicrobial susceptibility testing, and has sat on the CIHR Institute of Infection and Immunity Institute Advisory Board for the last five years. Dr. Mulvey has received numerous awards including the 2015 Honorary Membership in the Association of Medical Microbiology and Infectious Diseases Canada (AMMI Canada) and the 2016 University of Manitoba Faculty of Science Honoured Alumni of the Year.

**Nadarajah, Jeya**

Dr. Jeya Nadarajah attended Medical School followed by an Internal Medicine Residency at McMaster University. She completed a combined fellowship program in Infectious Diseases and Medical Microbiology at the University of Toronto along with a Master’s in Microbiology. She currently works mainly at Markham Stouffville Hospital and St. Michael’s Hospital in Toronto. Her practice encompasses clinical obligations in Internal Medicine and Infectious Diseases including administrative roles as the medical lead for Antimicrobial Stewardship and Infection Prevention and Control. She has a lead quality role in the microbiology section of the clinical laboratory. She functions as a courtesy Medical Microbiologist at St. Michael’s hospital.

Dr. Nadarajah is the vice president of the Medical Staff Association at Markham-Stouffville hospital and is a member of the board of directors and the Finance and Audit Committee of the hospital. She is a member of the Microbiology residency training committee. She is dedicated to teaching through the medical school curriculum and various residency programs.

**Poutanen, Susan M.**

Dr. Susan Poutanen is a Medical Microbiologist and Infectious Diseases Physician at Mount Sinai Hospital & University Health Network in Toronto, Canada and an associate professor in the Department of Laboratory Medicine and Pathobiology and Department of Medicine at the University of Toronto.

Dr. Poutanen received her Medical Degree from the University of Toronto in 1996 and completed Internal Medicine and Medical Microbiology Residencies at the University of Toronto and an Infectious Diseases Fellowship.
at Stanford University, California. She received her Masters of Public Health with a focus on Epidemiology from the University of California, Berkeley in 2002. Her broad research interests include: the epidemiology and detection of antimicrobial resistance; the diagnosis of and preparedness for emerging infectious diseases; the use of fecal microbiota transplantation in patients with recurrent *Clostridium difficile* infection and other emerging indications; and the optimization of microbiology laboratory practices to support antimicrobial stewardship and patient care.

**Rennie, Robert (Bob)**

Dr. Robert Rennie has been a clinical microbiologist since 1973 and is Professor Emeritus of Laboratory Medicine and Pathology, University of Alberta. From Winnipeg, Manitoba, Dr. Rennie received his BSc and MSc at University of Manitoba, and his PhD in Medical Microbiology at University of Glasgow, Scotland. Dr. Rennie has held Clinical Microbiology positions at Sunnybrook Hospital, Toronto ON, Henderson Hospital, Hamilton ON, Royal University Hospital, Saskatoon SK and University of Alberta Hospital, Edmonton AB. He was Head of Medical Microbiology at University Hospital Saskatoon (1986 – 91) and University Hospital, Edmonton (1992 – 2006). He was Clinical Department Head, Laboratory Medicine and Pathology, Edmonton Zone (2006 – 2012). Dr. Rennie serves on Canadian Standards Association, Z252 Committee – Quality and competence in Medial Laboratories, CSA ISO Sterilization Committee, ISO 17025 Accreditation group for Standards Council of Canada, and advises CLSI Antimicrobial Susceptibility Testing Subcommittee, and USCAST Committee. Recently he initiated the Canadian Committee on Antimicrobial Susceptibility Testing (CANCAST) to promote global harmonization of antimicrobial susceptibility testing and reporting in Canada. Dr. Rennie is the author of more than 100 peer reviewed publications, book chapters and many abstracts presented at national and international meetings over the past 43 years. His research interests include antimicrobial susceptibility testing and resistance, invasive fungal infections and quality control and assurance studies of antimicrobials in clinical microbiology.

**Shafran, Stephen D.**

Dr. Stephen D. Shafran received his MD from the University of Toronto. He trained in Internal Medicine at the University of Toronto and in Infectious Diseases at UBC. After an initial academic appointment at the University of Saskatchewan from 1986-1989, he moved to the University of Alberta in 1989 and was promoted to Professor in 1998. He has held the positions of Director of the Infectious Diseases Training Program, Director of Undergraduate Education for the Department of Medicine and Director of the Division of Infectious Diseases (1998-2008, 2014-2015). He has served the Canadian Infectious Disease Society (predecessor of AMMI Canada) in several capacities, including as President. He has received teaching awards from both the University of Saskatchewan and the University of Alberta. He received an award from the American Society for Microbiology for the best abstract in the subject of antiviral therapy. His research focuses on clinical trials of antiviral agents and viral vaccines in adults. He has over 140 publications and over 130 abstracts. His outpatient practice is focused primarily on HIV, HCV, and HBV infections. He also provides hepatitis and HIV care to inmates in two Federal prisons in northern Alberta and is a consultant to Correctional Services Canada.

**Wright, Alissa**

Dr. Alissa Wright is a Clinical Assistant Professor at the University of British Columbia (UBC) within the Division of Infectious Disease. She received her medical degree from the University of Toronto. She completed her training in Infectious Disease at UBC before going on to complete a two year fellowship in Transplant Infectious Disease at Massachusetts General Hospital in Boston. Her priority is to establishing a comprehensive Transplant Infectious Disease program for the province of British Columbia for both solid organ and hematopoietic stem cell transplant recipients. Her clinical responsibilities include the care of pre- and post-transplant patients at Vancouver General Hospital and St Paul’s Hospital in Vancouver. She is a consultant for BC Transplant on infectious disease issues in organ donors.

**Zhanel, George G.**

Dr. George Zhanel received his Ph.D. in the Department of Medical Microbiology/Infectious Diseases at the Faculty of Medicine, University of Manitoba and a Doctor of Clinical Pharmacology at the University of Minnesota. He is presently Professor in the Department of Medical Microbiology/Infectious Diseases, College of Medicine; Course Leader, Infectious Diseases Teaching, College of Medicine, University of Manitoba; Coordinator of Antibiotic Resistance in the Departments of Medicine and Clinical Microbiology, Health Sciences Centre; and Research Director of the Canadian Antimicrobial Resistance Alliance (CARA). Dr. Zhanel is the founding and Chief Editor of the Canadian Antimicrobial Resistance Alliance (CARA) website (www.can-r.ca).

Dr. Zhanel has published over 1000 papers, chapters and abstracts in the area of antimicrobial resistant infections. He has presented over 1000 lectures as an invited speaker at international, national, and local meetings speaking on the topics of antimicrobial resistant infections as well as treatment and prevention of infectious diseases in Canada, United States, Central America, Western and Eastern Europe including Russia, Australia, Southern and Northern Africa, the Middle East and Asia. As research director of the Canadian Antimicrobial Resistance Alliance, Dr. Zhanel has received or been nominated for 48 teaching awards and is a member of the Who’s Who in Medical Sciences Education (WWMSE).
<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>BOOTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Laboratories</td>
<td>203</td>
</tr>
<tr>
<td>Accelerate Diagnostics Inc.</td>
<td>218</td>
</tr>
<tr>
<td>Alere Canada</td>
<td>205</td>
</tr>
<tr>
<td>Anaerobe Systems</td>
<td>225</td>
</tr>
<tr>
<td>Applied Maths, Inc.</td>
<td>109</td>
</tr>
<tr>
<td>BD Diagnostic Systems</td>
<td>249</td>
</tr>
<tr>
<td>Beckman Coulter</td>
<td>233</td>
</tr>
<tr>
<td>bioMérieux Canada, Inc.</td>
<td>232</td>
</tr>
<tr>
<td>BioNuclear Diagnostics Inc.</td>
<td>223</td>
</tr>
<tr>
<td>Bio-Rad Laboratories Canada</td>
<td>229</td>
</tr>
<tr>
<td>Bruker Corporation</td>
<td>221</td>
</tr>
<tr>
<td>Canadian Foundation for Infectious Diseases (CFID)</td>
<td>212</td>
</tr>
<tr>
<td>CEDARLANE</td>
<td>215</td>
</tr>
<tr>
<td>CIHR Institute of Infection and Immunity (III)</td>
<td>239</td>
</tr>
<tr>
<td>COPAN Diagnostics, Inc.</td>
<td>207</td>
</tr>
<tr>
<td>DiaSorin Canada Inc.</td>
<td>208</td>
</tr>
<tr>
<td>EUROIMMUN Medical Diagnostics Canada</td>
<td>228</td>
</tr>
<tr>
<td>Fusion Genomics</td>
<td>204</td>
</tr>
<tr>
<td>Gold Standard Diagnostics Corp.</td>
<td>217</td>
</tr>
<tr>
<td>Hologic Canada Limited</td>
<td>241</td>
</tr>
<tr>
<td>Infectious Diseases Society of America and IDWeek</td>
<td>222</td>
</tr>
<tr>
<td>Innovatek Medical</td>
<td>220</td>
</tr>
<tr>
<td>Inter Medico</td>
<td>106</td>
</tr>
<tr>
<td>Lumed</td>
<td>211</td>
</tr>
<tr>
<td>Merck Canada Inc.</td>
<td>230</td>
</tr>
<tr>
<td>MiraVista Diagnostics, LLC</td>
<td>210</td>
</tr>
<tr>
<td>Nosotech</td>
<td>243</td>
</tr>
<tr>
<td>Pfizer Canada Inc.</td>
<td>247</td>
</tr>
<tr>
<td>Phoenix AirMid Biomedical Corp.</td>
<td>248</td>
</tr>
<tr>
<td>Pro-Lab Diagnostics Inc.</td>
<td>214</td>
</tr>
<tr>
<td>Quidel Corporation</td>
<td>226</td>
</tr>
<tr>
<td>Roche Diagnostics Canada</td>
<td>234</td>
</tr>
<tr>
<td>Seegene Canada Inc.</td>
<td>102</td>
</tr>
<tr>
<td>Somagen Diagnostics Inc.</td>
<td>244</td>
</tr>
<tr>
<td>Starplex Scientific Inc.</td>
<td>101</td>
</tr>
<tr>
<td>Sunovion Pharmaceuticals Canada Inc.</td>
<td>237</td>
</tr>
<tr>
<td>The University of Toronto Press Journals Division</td>
<td>202</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>240</td>
</tr>
<tr>
<td>Thermo Fisher Scientific - Microbiology</td>
<td>224</td>
</tr>
<tr>
<td>VidaShield Canada</td>
<td>105</td>
</tr>
</tbody>
</table>

**AMMI Canada • CACMID Annual Conference | Conférence annuelle**

May 3–6 | Sheraton Centre Toronto
Abbott Laboratories  
**BOOTH # 203**  
We are a global, broad-based health care company devoted to discovering new medicines, new technologies and new ways to manage health. We are displaying products from our Molecular and Diagnostic Divisions.

**Brad Thomas**  
*Molecular Account Executive*  
7115 Millcreek Drive  
Mississauga, Ontario L5N 3R3  
Phone: 800-387-8378, ext. 4603  
Email: bradley.thomas@abbott.com  
Website: www.abbottmolecular.com

Accelerate Diagnostics Inc.  
**BOOTH # 218**  
Accelerate Diagnostics, Inc., is an in vitro diagnostics company providing solutions for the global challenge of antibiotic resistance and hospital acquired infections.

**Cathy Gawronski**  
*Associate Marketing Manager*  
3950 S Country Club Road  
Tucson, Arizona 85714 USA  
Phone: 520-343-9788  
Fax: 520-269-6580  
Email: CGawronski@axdx.com  
Website: www.axdx.com

Alere Canada  
**BOOTH # 205**  
Alere Canada is a foremost leader in laboratory diagnostics that delivers reliable and actionable information through rapid diagnostic tests resulting in better clinical outcomes. Alere has well respected brands specializing in the areas of cardiovascular and infectious disease. Alere has recently launched Alere i, the first point-of-care rapid molecular diagnostic assay for influenza A & B.

**Kim Orr**  
*Marketing Co-ordinator*  
1-57 Iber Road  
Ottawa, Ontario K2S 1E7  
Phone: 613-271-1144  
Fax: 613-271-1148  
Email: kim.orr@alere.com  
Website: www.alere.ca

Anaerobe Systems  
**BOOTH # 225**  
Manufacturer of PRAS culture and transport media. Manufacturer and distributor of ergonomic and maintenance free anaerobe chambers. Educational workshops. Anaerobe educator software.

**Steve Cox**  
*President*  
15906 Concord Circle  
Morgan Hill, California 95037 USA  
Phone: 408-782-7557  
Fax: 408-782-3031  
Email: stevecox@anaerobesystems.com  
Website: www.anaerobesystems.com

Applied Maths, Inc.  
**BOOTH # 109**  
BioNumerics offers one bioinformatics solution to store and analyze all your biological data. Powerful databasing, integrated networking and a wide range of analysis options available.

**Mohamed Ahmed**  
*Associate Product Manager, Diagnostic Systems*  
100-2100 Derry Road West  
Mississauga, Ontario L5N 0B3  
Phone: 905-288-6038  
Email: mohamed.ahmed@bd.com  
Website: www.bd.com/ds

BD Diagnostic Systems  
**BOOTH # 249**  
BD Diagnostic Systems delivers innovative solutions to improve patient outcomes by reducing process variability, increasing diagnostic accuracy and minimizing time to actionable results.

**Mohamed Ahmed**  
*Associate Product Manager, Diagnostic Systems*  
100-2100 Derry Road West  
Mississauga, Ontario L5N 0B3  
Phone: 905-288-6038  
Email: mohamed.ahmed@bd.com  
Website: www.bd.com/ds

Beckman Coulter  
**BOOTH # 233**  
Beckman Coulter brings a new level of workflow efficiency to today’s microbiology lab. Combining the MicroScan system’s accuracy with automation, we provide a portfolio of solutions to improve lab productivity.

**John Carey**  
*Sales Manager*  
7075 Financial Drive  
Mississauga, Ontario L5N 6V8  
Phone: 800-463-7828  
Email: jmcarey02@beckman.com  
Website: www.beckmancoulter.com

bioMérieux Canada, Inc.  
**BOOTH # 232**  
bioMérieux is a worldwide group specialized in the field of *in vitro* diagnostics. We design, develop, manufacture and market systems used in infectious diseases.

**François Turgeon**  
*Clinical Marketing Manager*  
7815 Henri-Bourassa West  
Saint-Laurent, Québec H4S 1P7  
Phone: 514-336-7321  
Fax: 514-807-0015  
Email: francois.turgeon@biomerieux.com  
Website: www.biomerieux.ca

---

58 | AMMI Canada • CACMID Annual Conference | Conférence annuelle
BioNuclear Diagnostics Inc.

BOOTH # 223

BND is a leading supplier of infection control, diagnostics, medical disposables and laboratory products. We are the sole distributor of Diasorin Diagnostics’ molecular detection platform.

Franklin Chan
Molecular Accounts Manager
1791 Albion Road
Toronto, Ontario M9W 5S7
Phone: 647-291-1558
Fax: 416-674-7280
Email: franklin.chan@bndinc.com
Website: www.bndinc.com

Bio-Rad Laboratories Canada

BOOTH # 229

Bio-Rad Laboratories is one of the biggest leading diagnostics companies worldwide. It is recognized for its leadership position in quality control, diabetes monitoring, autoimmune diseases and microbiology.

Louis Beaudoin
National Sales Manager
2403 Guénette
Montréal, Québec H4R 2E9
Phone: 514-334-4372
Fax: 514-334-4415
Email: louis.beaudoin@bio-rad.com
Website: www.bio-rad.com

Bruker Corporation

BOOTH # 221

Bruker Corporation supplies analytical mass spectrometry for diagnostic applications. The industry leading MALDI Biotyper System produces identifications in minutes with minimal reagents from primary culture.

Angela Abraham
Customer Support Specialist
555 Steeles Avenue East
Milton, Ontario L9T 1Y6
Direct: 905-876-4641, ext. 107
Office: 978-663-3660
Fax: 978-667-5993
Email: ms.sales.bdal@bruker.com
Website: www.bruker.com

Canadian Foundation for Infectious Diseases (CFID)

BOOTH # 212

CFID is a charitable organization committed to improving the health of Canadians through the support of research and dissemination of knowledge pertaining to infectious diseases. CFID’s vision is to achieve effective research outcomes, strong and extensive stakeholder connections, successful advocacy and a positive impact on public policy.

Dr. Susan Richardson
President, CFID
c/o The Hospital for Sick Children
Department of Paediatric Laboratory Medicine
Room 3227, Burton Wing
555 University Avenue
Toronto, Ontario M5G 1X8
Phone: 416-813-5992
Email: cfid@researchid.com
Website: www.cfidresearchid.com

CEDARLANE

BOOTH # 215

CEDARLANE® provides ATCC bacterial/viral controls, Millipore’s DFA kits,SSI’s Strep. Pneumo kit, Altona Diagnostics’ PCR kits, Biomed Diagnostics’ media system and AdvanDx’s rapid pathogen detection platform.

Eddie Johnson
General Manager
4410 Paletta Court
Burlington, Ontario L7L 5R2
Phone: 289-288-0001
Toll-free: 800-268-5058
Fax: 289-288-0020
Email: eddie.johnson@cedarlanelabs.com
Website: www.cedarlanelabs.com

CIHR Institute of Infection and Immunity (III)

BOOTH # 239

CIHR is the federal agency responsible for funding health research in Canada, and III supports research and builds capacity in the areas of infectious diseases and the immune system.

Édith Brochu
Associate, Strategic Initiatives
2705 Laurier Boulevard, TR62
Québec, Québec G1V 4G2
Phone: 418-577-4688
Fax: 418-577-4689
Email: edith.brochu@crchudequebec.ulaval.ca
Website: www.cihr-irsc.gc.ca/e/13533.html

COPAN Diagnostics, Inc.

BOOTH # 207

With a reputation for innovation in preanalytics, Copan is the leading manufacturer of collection and transport systems. Copan’s collaborative approach has resulted in Flocked Swabs, ESwab, Universal Transport Medium and laboratory automation, WASP® and WASP® lab.

Jane Lukashevsky
Business Development Manager, Canada
26055 Jefferson Avenue
Murrieta, California 92562 USA
Phone: 800-216-4016
Fax: 800-600-1832
Email: marketing@copanusa.net
Website: www.copanusa.com

DiaSorin Canada Inc.

BOOTH # 208

DiaSorin, the Diagnostic Specialist, provides specialized reagents and automated diagnostic instrumentation for laboratories. DiaSorin offers immunodiagnostics assays for infectious diseases, autoimmune, bone and endocrine diseases, as well as automated nucleic acid purification from clinical samples.

Jeff Kormos
Vice President, US National Accounts & Canada Commercial
Units 3 & 4, 2nd Floor, 205 Export Boulevard
Mississauga, Ontario L5S 1Y4
Phone: 905-677-1630
Fax: 905-677-1630
Email: jeff.kormos@diasoninc.com
Website: www.diasoninc.com
EUROIMMUN Medical Diagnostics
Canada
BOOTH # 228
EUROIMMUN is one of the leading manufacturers for laboratory diagnostics worldwide. Laboratories in more than 150 countries use EUROIMMUN products for the diagnosis of infectious diseases, autoimmune diseases and allergies and for genetic analyses.

Dr. Donglai Ma
Director
2566 Meadowpine Boulevard
Mississauga, Ontario  L5N 6P9
Phone: 905-542-8828
Fax: 905-542-8988
Email: info@euroimmun.ca
Website: www.euroimmun.ca

Fusion Genomics
BOOTH # 204
Fusion Genomics offers massively multiplex pathogen sequencing panels and analytics. Our ONETest MDx platform offers 1000X the sensitivity (than PCR-based assays) and 99% accuracy.

Dr. Mohammad Qadir
CSO
8888 University Drive, Discovery 1, Room 1450
Burnaby, British Columbia  V5A 1S6
Phone: 604-428-7701
Fax: 604-428-7702
Email: info@fusiongenomics.com
Website: www.fusiongenomics.com

Gold Standard Diagnostics Corp.
BOOTH # 217
Gold Standard Diagnostics provides comprehensive diagnostic solutions that improve efficiency and minimize costs. Through an extensive product menu and outstanding customer service, we solve real laboratory problems.

Tyler Cann
Canadian Sales Consultant
2851 Spafford Street
Davis, California 95618 USA
Phone: 530-759-8000
Fax: 530-759-8012
Email: tccann@gsdx.us
Website: www.gsdx.us

Hologic Canada Limited
BOOTH # 241
As a leader in molecular diagnostic solutions, Hologic thoughtfully blends engineering and science. Our innovative Aptima assays and advanced automation platforms work together to give laboratories the power to quickly and accurately detect and monitor infectious diseases. Our proven solutions help promote early detection, appropriate treatment and better outcomes—both clinical and financial.

Kayla Shea
Regional Business Manager
401-130 Spadina Avenue
Toronto, Ontario  M5V 2L4
Phone: 416-449-8261
Email: kayla.shea@hologic.com
Website: www.hologic.ca

Infectious Diseases Society of America and IDWeek
BOOTH # 222
IDWeek is the premier international meeting in infectious diseases - October 4-8 in San Diego. Now accepting abstracts, travel awards available, visit www.idweek.org.

John Buckley
Director, Convention Operations and Corporate Relations
300-1300 Wilson Boulevard
Arlington, Virginia 22209 USA
Phone: 703-740-4961
Email: info@idweek.org
Website: www.idweek.org

Innovatek Medical
BOOTH # 220
A Canadian company selling rapid diagnostic kits in the areas of drugs of abuse, women’s health and infectious diseases. Our primary focus is on innovation for clinical laboratory technology.

Marcus Titian Parsad
National Sales Manager
3-1600 Derwent Way
Delta, British Columbia  V3M 6M5
Phone: 604-522-8303
Fax: 604-522-8318
Email: marcus@innovatekmed.com
Website: www.innovatekmed.com

Inter Medico
BOOTH # 106
Inter Medico provides automated solutions for rapid PCR molecular testing including MRSA, VRE, C. difficile, MTB, Carba-R and Flu, plus other general microbiology reagents and consumables.

Carrie Ebenhardt
Vice-President, Sales & Marketing
1-50 Valleywood Drive
Markham, Ontario  L3R 6E9
Phone: 800-387-9643
Fax: 905-470-2381
Email: cebenhardt@inter-medico.com
Website: www.inter-medico.com

Lumed
BOOTH # 211
We improve patient care through the delivery of an antimicrobial stewardship software that produces automated alerts based on a knowledge base of published and local guidelines.

Vincent Nault
CEO
168 rue Boisé
Canton Hatley, Québec  J0B 2C0
Phone: 819-574-2471
Email: vnault@lumed.ca
Website: www.lumed.ca
Merck Canada Inc.  
**BOOTH # 230**

For over a century, Merck has been a global healthcare leader working to help the world be well. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers to deliver innovative health solutions. Visit [www.merck.ca](http://www.merck.ca) and connect with us on YouTube and Twitter @MerckCanada.

**Debra Manning**  
*Exhibits and Conventions Manager*

16750 Trans-Canada Highway  
Kirkland, Québec  H9H 4M7  
Phone: 514-428-3477  
Cell: 514-795-5127  
Email: debra.manning@merck.com  
Website: [www.merck.ca](http://www.merck.ca)

MiraVista Diagnostics, LLC  
**BOOTH # 210**

MiraVista Diagnostics is a specialty reference laboratory committed to providing accurate, high-quality testing to aid in the diagnosis and treatment of serious fungal infections.

**Janet Raymond**  
*Sales Director*

4705 Decatur Boulevard  
Indianapolis, Indiana  46241  USA  
Phone: 866-647-2847  
Fax: 371-856-3685  
Email: info@miraquistalabs.com  
Website: [www.miraquistalabs.com](http://www.miraquistalabs.com)

Nosotech  
**BOOTH # 243**

Nosotech provides the most complete and efficient software solutions for antimicrobial stewardship and infection control combining user-friendly solutions, top clinical expertise and best-in-class customer support.

**Laurent Bellavance**  
*General Manager*

215-133 Julien-Réhel  
Rimouski, Québec  G5L 9B1  
Phone: 418-723-0862  
Email: laurent.bellavance@nosotech.com  
Website: [www.nosotech.com](http://www.nosotech.com)

Pfizer Canada Inc.  
**BOOTH # 247**

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., the world’s leading biopharmaceutical company. Pfizer discovers, develops, manufactures and markets prescription medicines and vaccines for humans.

**Nathalie Labonté**  
*CHE Manager*

17300 Trans-Canada Highway  
Kirkland, Québec  H9J 2M5  
Phone: 418-580-1073  
Fax: 418-877-6174  
Email: nathalie.labonte@pfizer.com  
Website: [www.pfizer.com](http://www.pfizer.com)

Phoenix AirMid Biomedical Corp.  
**BOOTH # 248**

PAB provides Canadian laboratories with high performance results and flexibility across multiple automated platforms through our comprehensive menu of molecular diagnostic kits and controls for infectious diseases, gastroenteritis and transplant monitoring.

**Amir Memon**  
*National Sales Manager*

1166 South Service Road West  
Oakville, Ontario  L6L 5T7  
Phone: 905-469-4253  
Fax: 905-825-9795  
Email: info@phoenixairmid.com  
Website: [www.phoenixairmid.com](http://www.phoenixairmid.com)

Pro-Lab Diagnostics Inc.  
**BOOTH # 214**

Pro-Lab Diagnostics is an industry leader in the development of diagnostic test kits. A new division called Canadian Molecular Diagnostics is developing new molecular technologies and primer sets for use with the Genie Instrument.

**Karen Moffatt**  
*Sales and Marketing Manager*

4-120 Mural Street  
Richmond Hill, Ontario  L4B 1K3  
Phone: 905-762-3580  
Fax: 905-731-0206  
Email: kmoffatt@pro-lab.com  
Website: [www.pro-lab.com](http://www.pro-lab.com)

Quidel Corporation  
**BOOTH # 226**

Quidel is a leading brand in molecular, immunoassay and point-of-care diagnostic technologies such as QuickVue®, AmpliVue®, D3 Direct Detection™, Thyretain®, Sofia®, Solana® and Lyra®.

**Kevin Orr**  
*Senior Sales Manager - Canada*

200-12544 High Bluff Drive  
San Diego, California  92130  USA  
Phone: 647-289-3717  
Email: kevin.orr@quidel.com  
Website: [www.quidel.com](http://www.quidel.com)

Roche Diagnostics Canada  
**BOOTH # 234**

Roche Diagnostics is a world leader in in vitro diagnostics that offers a wide range of rapid, reliable instruments and tests for disease screening and diagnosis in laboratories, at the point of care, and for patient self-management.

201 Armand-Frappier Boulevard  
Laval, Québec  H7V 4A2  
Phone: 450-686-7050  
Email: laval.marketing_diagnostics@roche.com  
Website: [www.rochecanada.com](http://www.rochecanada.com)
Seegen Canada Inc.
BOOTH # 102
Seegen is the world’s leading developer of multiplex molecular technologies and multiplexed clinical molecular diagnostics. Seegen’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labour and cost.

JAMES YANTZI
President
800-661 University Avenue
Toronto, Ontario  M5G 1M1
Phone: 416-995-9849
Fax: 888-950-9004
Email: jyanzi@seegen.com
Website: www.seegen.com

Somagen Diagnostics Inc.
BOOTH # 244
As Canada’s leading laboratory diagnostics distribution company, we represent an expanding portfolio of innovative products and technologies for microbiology and infectious disease.

JAYLENE LAVOIE
Director of Business Development
9220-25 Avenue
Edmonton, Alberta  T6N 1E1
Phone: 800-661-9993
Fax: 780-438-6595
Email: info@somagen.com
Website: www.somagen.com

Starplex Scientific Inc.
BOOTH # 101
Starplex Scientific Inc. specializes in premium quality collection and transportation devices including Leakbuster™ containers and Starswab II™ transport swabs.

FRED TURCO
Phone: 800-665-0954
Email: info@starplexscientific.com
Website: www.starplexscientific.com

Sunovion Pharmaceuticals
Canada Inc.
BOOTH # 237
Sunovion Pharmaceuticals Canada Inc. is focused on the commercialization of prescription products in Canada. Our strategy is to license pharmaceuticals products that meet the needs of patients and the Canadian health care system. We are focused in the areas of neurology, central nervous system and infectious disease.

PAUL PETERS
Associate Director, Hospital and Specialty
100-6790 Century Avenue
Mississauga, Ontario L5N 2V8
Phone: 905-814-9145
Email: paul.peters@sunovion.com
Website: www.sunovion.ca

The University of Toronto Press
Journals Division
BOOTH # 202
Founded in 1901, University of Toronto Press (UTP) is Canada’s leading scholarly publisher and one of the largest university presses in North America. The official publisher of the Journal of the Association of Medical Microbiology and Infectious Disease Canada (JAMMI), UTP Journals is a leader in its field with a long-standing reputation for excellence in journal management and support.

ANTONIA POP
Senior Manager, Journals
5201 Dufferin Street
Toronto, Ontario M3H 5T8
Phone: 416-667-7838
Fax: 416-667-7881
Email: apop@utpress.utoronto.ca
Website: www.utpjournals.com

Thermo Fisher Scientific – Microbiology
BOOTH # 224
The industry-leading Thermo Scientific product portfolio features Oxoid prepared media, VersaTREK™ automated blood culture and Sensititre™ AST/MIC solutions. Our products are renowned for quality, accuracy and reliability.

100-1926 Merivale Road
Nepean, Ontario K2G 1E8
Phone: 800-267-6391
Email: oxoid.ca.webinfo@thermofisher.com
Website: www.thermoscientific.com/microbiology

VidaShield Canada
BOOTH # 105
VidaShield is a patented environmental purification system that provides 24/7 shielded UV-C technology with proven results of cleaner air and surfaces. Come visit us!

NANCY WILSON
Canadian Distributor
203-14419 Downton Avenue
Summerland, British Columbia V0H 1Z1
Phone: 250-809-1955
Fax: 250-494-3024
Email: nwilson@cnjlightingsolutions.com
Website: www.VidaShield.ca

Thermo Scientific
BOOTH # 340
Thermo Fisher Scientific is the world leader in serving science. Our Applied Biosystems and Invitrogen brands help customers accelerate innovation and enhance productivity.

5250 Mainway
Burlington, Ontario L7L 5Z1
Phone: 800-955-6288
Email: customercare@thermofisher.com
Website: www.thermofisher.com

Sheraton Centre Toronto
May 3–6 mai | Sheraton Centre Toronto
Square (large) Square (small) Horizontal (long) Horizontal (short) Landscape rectangle Portrait rectangle
GENERAL INFORMATION
Conference Secretariat
192 Bank Street
Ottawa, ON K2P 1W8, Canada
Tel.: (613) 260-3233 ext. 103
Toll-free: 1 (888) 467-1215 ext. 103
meetings@ammi.ca

REGISTRATION INFORMATION
Unconventional Planning
32 Colonnade Road, Unit 100
Ottawa, ON K2E 7J6, Canada
Tel.: (613) 721-7061
Toll-free: 1 (888) 625-8455
registration@unconventionalplanning.com